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Abstract 
A strategy is described for method evaluation to manage the influence of endogenous compounds to 
induce bias in pharmaceutical quantification from blood samples of different animal species 
resulting from ionisation matrix effects.  The approach introduces the possibility of simultaneous 
cross animal species calibration for ethical reasons using a simple indicative test, which also rapidly 
demonstrates the utility of a test assay in other matrices. 
 
A quantitative Turboflow LC-MS/MS assay was evaluated using samples prepared in species matched 
controlled matrices with deuterated internal standardisation.  The method was subsequently tested 
to assess the analysis of samples from multiple animal species using calibration samples from a 
single matrix origin.  The object of this was to enable the substitution of analytical control samples in 
rodent plasma, reducing the plasma volume required, therefore the number of rodents used 
indirectly to support development studies.  The method was unsuccessful due to concentration bias 
in identically prepared test samples.  The bias origin was investigated using a fixed ratio solution of 
the analyte and its deuterated analogue with matrix test aliquots.  The investigation identified non 
equivalent relative ionisation efficiency between compounds.  The ratio method is proposed as an 
evaluation strategy for matrix effects causing non-equivalent response ratios. 
 
The origin of this deviation was identified using a post column standard infusion test highlighting a 
region of ionisation suppression co-eluting with the analyte.  Full scan acquisition analysis revealed 
co-elution of endogenous glycerophospholipids.  The relative expression of these compounds 
between species was investigated, employing a precursor ion scanning method of a common 
product ion indicative of phosphotidyl choline compounds; the human diversity was also 
investigated.  Distribution was found to differ between animal species, which was further tested by 
construction of a model using partial least squares regression which correctly identified the species 
origin of all non-primate species tested.  The mechanism of differentiation between compound and 
deuterated analogue by endogenous phosphotidyl choline was proposed as micellar phase 
equilibrium following elution from the HPLC column. 
 
A new Turboflow LC-MS/MS assay was optimised with attention to the resolution of 
glycerophospholipid interferences and retested for applicability between species.  It was 
simultaneously applied to the analysis of small volume whole blood samples via dried blood spots on 
filter paper.  Precision and bias were acceptable for the analysis of rat and mouse samples using 
human control plasma.  Analysis of incurred ex-vivo samples from rats was successful in 
demonstrating equivalence between calibration sources.  
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Glossary of Terms 
Descriptive Statistics 
Mean Percent Difference (M%D) is used to describe the mean bias of a group of values as 
their deviation from a nominal or expected value.  It is calculated by subtracting the mean 
experimental value from the expected value and expressing the difference as a percentage 
of the expected value. 
     
                                                      
                      
       
Percent Coefficient of Variation (%CV) is used to describe the imprecision in a group of 
values, calculated by expressing the standard deviation as a percentage of the mean. 
     
                       
    
 
Inter-run Coefficient of Variation is used to describe run to run variability following multiple 
determinations of the same sample on multiple occasions.  It is calculated as the %CV of 
mean calculated concentration results from several runs containing multiple determinations 
of samples of the same nominal concentration. 
Intra-run Coefficient of Variation is used to describe the variability which exists within 
individual runs following multiple determinations of the same sample on multiple occasions.  
It is calculated as the mean of %CV values calculated from several runs containing multiple 
determinations of samples of the same nominal concentration. 
Total Coefficient of Variation is used to describe the variability in a large dataset 
independently of individual runs and is calculated as the %CV of every individual 
concentration value of the same nominal concentration. 
Physicochemical Parameters 
Log P (or log Poct/wat) is the logarithmic expression of the octanol-water partition coefficient 
(P) and is used as a measure of the hydrophobicity (or lipophilicity) of a compound by 
describing the partitioning of the compound at equilibrium between water and an 
 17 
immiscible non-polar solvent.  The partition coefficient is calculated for the neutral molecule 
therefore to determine the coefficient experimentally requires adjustment of pH ensure the 
compound was predominantly unionised. 
          
               
             
  
Log D (or log Doct/wat) is the logarithmic expression of what is often described as the 
distribution coefficient (D).  It is equivalent to log P as a function of pH and describes the 
hydrophobicity of a compound under test pH conditions. 
OECD is the Organisation for Economic Cooperation and Development, an 
intergovernmental organisation in which representatives of industrialised countries in North 
America, Europe and the Pacific, as well as the European Commission, meet to co-ordinate 
and harmonize policies, discuss issues of mutual concern, and work together to respond to 
international problems.   The work of the OECD related to chemical safety is carried out in 
the Environmental Health and Safety Division. A key document published by the OECD 
governing the conduct of pharmaceutical laboratory and analysis is ‘Testing and 
Assessment; Principles on Good Laboratory Practice and Compliance Monitoring’. 
Selected Reaction Monitoring (SRM) is the method of generating a selective ion signal on a 
triple quadrupole mass spectrometer by selecting a precursor ion using the first quadrupole, 
which is transmitted to the second quadrupole where fragmentation is induced.  The 
product ion is transmitted to the third quadrupole where the major product ion is selected 
for detection.  
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1 Pharmaceutical Development 
1.1 Overview of Pharmaceutical Development 
Pharmaceutical development is a lengthy, extensive and expensive process.  Of the 
hundreds of thousands of new chemical entities entering discovery research, typically one 
will reach the pharmacist.  This follows a development programme lasting up to 15 years, 
involving hundreds of multidisciplinary teams of scientific and medical professionals and 
following a research and development budget approaching 1 billion US dollars. 1, 2 
 
The first stage in the development lifecycle is ‘drug discovery research’.  The process is 
devoted to identifying new compounds which have the potential to induce a 
pharmacological effect which may be applied to the improvement or prevention of disease.  
Methodologies in the research stage are high throughput; where hundreds of analyses are 
performed each day using techniques to facilitate automated sample preparation and rapid 
analysis. 3  Therapeutic targets are identified by bioinformatic technologies which use 
powerful computational resources to characterise endogenous chemical changes during the 
progression of a disease state by comparing diseased subjects with the healthy population. 4  
Chemical entities with the potential to effect a change in the disease state are synthesised 
and tested in-vitro before evaluation of safety and efficacy by screening studies in animal 
models.  Chemical compounds with the potential to be developed as drug candidates are 
taken forward into ‘preclinical development’. 
 
Preclinical development progresses the drug as a raw material into a preliminary 
pharmaceutical preparation suitable to conduct clinical trials.  The physicochemical 
properties of the compound are studied and characterised while it is formulated by 
pharmaceutical scientists into a dosage form to accurately deliver the compound into the 
body appropriate to the intended clinical use.  Drug disposition studies are conducted to 
model the effect of the body on the concentration distribution or metabolic transformation 
of the drug, while pharmacodynamic studies relate these to the observed effects on the 
body.  Toxicologists determine the safety of the drug in nonclinical in-vivo models prior to 
administration in clinical trials.  Preclinical development is a very selective process further 
refining the compounds nominated from discovery research.  If the drug candidate 
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compound demonstrates promising potential for efficacy in therapeutic use with an 
appropriate margin for safety, it will progress in to the clinical development programme. 
 
Clinical development is divided into 3 distinct stages as represented in Figure 1-1.  During 
Phase I, the compound is dosed to a small number of healthy volunteers, initially at doses 
significantly below therapeutic levels and considerably below those associated with any 
toxic effect.  The trials correlate the activity of the drug in the body with that seen in animal 
models at clinically relevant doses so tolerability can be assessed before the dose is 
increased towards the target range.  Following completion of phase I studies, the drug can 
be dosed to a small population of patients to refine and develop the dose formulation in 
phase II and then enter phase II trials on a much larger population.  In phase III, population 
effects may be studied and the efficacy of the drug is compared with alternative marketed 
products for the condition in blinded clinical trials.  Following successful completion of the 
clinical trials the company will file the drug for registration with international regulatory 
agencies and obtain approval to market the drug.  At this point, the drug is available to 
clinicians to prescribe to patients as a marketed product and the company have exclusive 
rights to sell it, although the research groups continue to study the drug for new indications 
and effects on the larger population. 
 
 
Figure 1-1; Stages of drug development 
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1.2 Disposition Science in Pharmaceutical Development 
1.2.1 Pharmacokinetics 
The study of pharmacokinetics models the concentration distribution of pharmaceutical 
compounds in the body to determine key parameters which are related to studies into 
safety and efficacy of the new compound.  Pharmacokinetic studies are conducted 
throughout preclinical and clinical development. 5 
 
The pharmacokinetic profile is represented by Figure 1-2.  In this simulation, following oral 
administration of the drug, concentration in plasma increases as the drug is absorbed into 
the blood compartment until it reaches a maximum concentration, when drug metabolism 
and elimination exceeds absorption to facilitate excretion via renal or hepatic clearance and 
removal from the body predominantly in urine or faeces.  Drug may also be partitioned into 
body tissues.  Pharmacological effects are proportional to circulating blood concentrations, 
often analysed and defined by plasma concentration therefore the therapeutic effect occurs 
at a given concentration range, above which toxicity may occur.  Duration of therapeutic 
effect is consequently proportional to the period that the therapeutic concentration is 
maintained.  The key pharmacokinetic parameters monitored in accordance with safety and 
efficacy studies are; 
Bioavailability:  This is the proportion of the administered dose which reaches the blood 
stream and plasma compartment to induce exposure to the body.  It is affected by the 
physicochemical properties of the compound and characteristics of the product delivery 
route and formulation. 6 
Exposure (AUC0 to ):  The area under the plasma concentration time profile from 
administration of the dose modelled to infinity.  This is the characteristic measure of the 
exposure of the body to the dose administered and is proportional to the pharmacological 
effect. 7 
Maximum concentration (Cmax):  The maximum concentration achieved in the plasma 
compartment from a single dose.  This is proportional to the intensity of the 
pharmacological effect. 8 
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Time to maximum concentration (Tmax):  The time taken to achieve maximum 
concentration.  This relates to the time delay between dose administration and the 
pharmacological effect. 8 
Half life (T½):  This measures the persistence of the drug in the body.  It is proportionate to 
exposure. 6 
Clearance (Cl):  This is the efficiency of the body in metabolism of the compound and 
elimination, principally by excretion into the urine or faeces.  It is inversely proportionate to 
the half life. 6 
 
The study of pharmacodynamics relates the exposure to the pharmacological effect of the 
compound.  The way that exposure parameters might relate to safety and efficacy are 
represented in Figure 1-3, where the therapeutic window defines the exposure at which the 
desired pharmacological outcome is achieved.  If insufficient dose is administered, then no 
effect of the drug will be observed; however, if the dose level is too high and the 
therapeutic window is exceeded then toxicity may occur. 9   
 
 
Figure 1-2; Oral pharmacokinetic profile and parameters 
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There are many factors which may influence the exposure of the body to the drug. 10  It is 
therefore necessary to not only model these pharmacokinetically but to control them via 
the ultimate pharmaceutical formulation and dose regime to ensure reproducible safety and 
efficacy of the product. 
 
Figure 1-3; Relationship between exposure and therapeutic window 
Other key pharmacokinetic factors which are evaluated are the effects of biological factors 
on the linearity of dose response and the impact of multiple dosing on accumulation and the 
induction of steady state when a constant concentration in the body is achieved in the 
therapeutic window without accumulating to the point where toxicity may occur 7, 11, 12 
(Figure 1-4). 
 
Figure 1-4; Effect of accumulation on exposure 
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1.3 Analysis of Pharmacokinetic Samples 
1.3.1 Bioanalysis 
Drug pharmacokinetic parameters are calculated from circulating concentrations of the 
compound in plasma or blood.  Much of the drug compound circulating in the plasma 
component may be bound to circulating plasma proteins. 13, 14  It is the unbound drug in 
circulation which is pharmacologically active; however, the total drug in plasma is the 
concentration taken to represent pharmacokinetics and pharmacodynamics, so with the 
exception of specific studies concerned with protein binding, this is the concentration 
measured.  The plasma constitutes 55% of blood volume and is derived experimentally from 
the supernatant following centrifugation of whole blood in the presence of anticoagulants in 
the region of 3000 rpm.  The plasma contains 90% water, the remainder being composed of 
proteins, hormones and salts listed in Table 1-1 as well as co-administered xenobiotic 
compounds. 8 
 
In the pharmaceutical industry, pharmacokinetic bioanalysis is performed extensively by 
HPLC-MS/MS following extraction from biological fluid. 15 The first analytical problem in the 
development of bioanalytical methods is the removal or macromolecular interferences to 
prevent blockage of the analytical column.  Historically, many methods followed crude 
protein precipitation sample preparation techniques, involving de-proteination of the 
samples using 2 to 4 volume equivalents of acetonitrile or methanol to cause protein 
denaturation. 16, 17  The enhanced signal specificity of triple quadrupole mass spectrometry 
reduced the necessity to resolve interferences to prevent direct chromatographic 
interferences.  Protein precipitation protocols were also extremely generic since they were 
largely independent of analyte physicochemistry.  However, problems were encountered 
due to unmonitored components in the precipitated sample co-eluting with the analyte and 
giving rise to significant matrix effects. 18  Liquid-liquid extraction into an immiscible solvent 
is a more selective therefore cleaner extraction technique less prone to matrix effects, but 
less generic and more difficult to automate so practically producing lower throughput of 
samples.  The first stage of a reliable bioanalytical method is therefore optimally a more 
selective extraction of the analyte group of interest from matrix components. 
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Component Function 
Serum albumin 
The most abundant plasma protein, binds 
calcium 
Serum Globulins  
      α-globulin Binds thyroxin and bilirubin 
      β-globulin Binds iron, cholesterol, vitamin A, D and K 
      γ-globulin 
Immunological antibody, also binds 
histamine 
Prothrombin Promotes blood clotting 
Fibrinogen Blood clotting protein 
Enzymes  
Mineral ions; Na+,  K+, Ca2+, Mg2+,HnPO4
n-, 
SO4
2-, HCO3
- 
 
Table 1-1; Major regulated components of blood plasma 
1.3.2 Solid Phase Extraction 
A potentially selective extraction technique is solid phase extraction. 19, 20 This employs the 
loading of the plasma sample onto alkyl modified silica or polymer based stationary phase 
packed into a disposable polypropylene column to achieve complete adsorption of the 
analyte onto the sorbent material.  The column is then washed to remove interferences 
with the analyte attached to the stationary phase in-situ to selectively remove small 
molecule chemical interferences while macromolecules are filtered at the top of the sorbent 
bed.  The analyte is later eluted by passing an appropriate solvent through the column and 
the eluent further processed for transfer to the HPLC analytical system.  This technique is 
extensively commercialised, with a range of sorbent chemistries available through alkyl 
ligands to ion exchange media and mixed mode chemistries 19, 21 both off-line (Figure 1-5) 
and in-line (1.3.3).   
 
A summary of solid phase extraction chemistries and the mode of extraction used for the 
recovery of small molecule pharmaceuticals from plasma for analysis by LC-MS obtained 
from articles published in between 2009 and September 2010 (obtained referencing plasma, 
solid phase extraction and chromatography) is summarised in Table 1-2.  Reversed phase 
polymeric sorbents were most widely used in both on-line and off-line modes, owing partly 
to the more generic application of such a widely retentive media.  Reversed phase polymers 
were also widely used in mixed mode extraction chemistry. 
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 Chemistry Mode Material Refs Count 
P
o
ly
m
er
ic
 
Reversed Phase Polymer ON-LINE Oasis HLB 22, 23 5 
Supelco HiSep  24 
Hysphere resin GP 25 
Turboflow Cyclone 26 
OFF-LINE Oasis HLB 27-45 21 
Varian Plexa 46 
HyperSep 47 
M
ix
ed
 M
o
d
e 
Mixed Mode Reversed 
Phase Polymer- Anion 
Exchanger 
ON-LINE Oasis MAX 48 1 
OFF-LINE Oasis MAX 49 2 
Oasis WAX 50 
Mixed Mode Reversed 
Phase Polymer- Cation 
Exchanger 
OFF-LINE CleanScreen DAU 51 7 
Oasis MCX 52-56 
Strata XCW 57 
Io
n
 E
xc
h
an
ge
 Cation Exchanger ON-LINE Monolith 58 2 
Spherisorb SCX 59 
OFF-LINE Argonaut SCX 60, 61 4 
Bondelut PBA 62 
Isolute PRS 63 
A
lk
yl
 b
o
n
d
ed
 p
h
as
e 
C2 OFF-LINE Isolute 64 1 
C1 ON-LINE Kromasil 59 1 
C8 OFF-LINE BondElut certify 65 2 
Isolute 66 
C18 ON-LINE Lichrospher 67 6 
Zorbax 68 
Kromasil 69 
Turboflow 70 
Biotrap 500 71 
Hysphere 72 
OFF-LINE Bond Elut 73 4 
AccuBond 74 
Bakerbond 75 
SepPak 76 
(CH2)3CN ON-LINE Isolute 77 1 
OFF-LINE Supelco 78 
Table 1-2; Literature review of SPE modes and chemistries for small molecule pharmaceutical recovery from plasma for 
LC-MS 2009 to August 2010 
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Figure 1-5; Schematic of off-line solid phase extraction 
The large range of SPE chemistries commercially available enable a high degree of 
specificity, while microtitre plate formatting and robotic liquid handling platforms increased 
throughput and automation of SPE protocols.  Interaction of the analyte with the stationary 
phase proceeds via polarity interactions on reversed phase alkyl modified silica or ion 
exchange on ionic surfaces, or in mixed mode sorbents (those containing both alkyl 
modified silica together with an ion pairing reagent).  In addition to alkylated silica, 
polymeric sorbents with similar reversed phase properties are also used. 
1.3.3 In-line Solid Phase Extraction 
The solid phase extraction principal was modified to enable the repeated use of sorbent to 
extract multiple samples by formatting them into packed columns, with the aim of 
combining extraction and analysis into a single process. 79, 80  This is done by enabling 
extraction and retention of the analyte on the SPE pre-column and elution and transfer onto 
a second analytical HPLC column for separation and quantification.  Modification of the 
sorbent particles sterically or geometrically prevents fouling by macromolecular species in 
the analysis mixture enabling reconditioning of the column between injections.  These 
packed columns are generally referred to as restricted access media (RAM) columns. 81   
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The first restricted access column was developed by Pinkerton et al. 82 in 1986 featuring 
standard chromatographic particles packed into a steel column, where access restriction to 
the sorbent was achieved either by replacing the external surface of the particle with an 
inert coating of the tripeptide Gly-Phe-Phe (internal surface reversed phase; GFF ISRP, 
Figure 1-6).  Using the same principle a later modification was developed by Regnier and 
Dessiliets by bonding an inert polymeric ‘mesh’ of polyethylene glycol over the surface of 
the particle (semi permeable surface; SPS, Figure 1-7). 83, 84  
 
    
 
Figure 1-6; ISRP particle 
 
Figure 1-7; SPS particle 
In both columns, the analyte is injected directly as a plasma sample towards the detector 
while the macromolecules flow over the surface and elute in the void volume of the column, 
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analytical gradients could then be applied to chromatograph the analyte as a standard HPLC 
injection.   In practice, blockage of the column was found to be problematic, making analysis 
costly while the analyte retentive chemistry for single column injection was limited. 85  The 
columns were also used as pre-columns for multidimensional column switching methods 
enabling the injection and removal of macromolecules while the analyte was later eluted or 
further chromatographic separation done by liquid chromatography. 86 
 
The multidimensional approach was further optimised by the production of short, robust 
pre-columns dedicated to sample cleanup for column switching to analytical HPLC columns.  
An advantage of the coupled column approach for bioanalysis was that sample enrichment 
on the second column was enabled to support achievement of low limits of quantification, 
in addition to a higher loading capacity while column lifetime was extended.  The 
simultaneous removal of macromolecules and analyte separation on the same column 
became a sequential process; however, since cleanup of the extraction column could be 
performed simultaneously with chromatographic separation on the second, there was no 
significant loss of throughput efficiency.  The columns were prepared using the technique of 
enzymatic cleavage of the alkyl ligand from a bonded silica chromatographic particle and 
replacement by a biochemically inert barrier first demonstrated by Pinkerton. 82  Alkyl diol 
groups (Merck ADS) 85  or α1 -acid glycoprotein (Biotrap 500)
 87 were bonded to the cleaved 
silica of the external surface of the particle, leaving a reversed phase surface within the 
particle accessible only to analytes small enough to permeate the particle (15 kDa cut off).     
 
An extensive range of chromatographic sorbent chemistries are available with the 
introduction of mixed mode particles. 88  Boos and Grimm categorised the available 
restricted access media columns into 4 types, 85 depending on exclusion barrier or surface 
topochemistry (Table 1-3).  ISRP GRR (II) is an example of the physical exclusion where the 
reversed phase sorbent has been removed from the outer surface of the particle while 
BioTrap 500 is excluded chemically by steric restriction caused by α1 -acid glycoprotein 
surface coverage.  In each of these examples, the surface topochemistry is dual, the particle 
surface being functionally different to the inner pore surface. 
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TYPE Exclusion 
Barrier 
Surface 
Topochemistry 
Commercial Products 
A PHYSICAL UNIFORM ChromSpher 5 Biomatrix 
(Chrompack) 
B PHYSICAL DUAL ISRP GFF (II) (Regis) 
LiChrospher ADS (Merck KGaA) 
C CHEMICAL UNIFORM Hisep (Supelco) 
Capcell Pak MF (Shiseido) 
D CHEMICAL DUAL Ultrabiosep (Shanon) 
BioTrap 500 (ChromTech) 
SPS (Regis) 
MAYI-ODS (Shimadzu) 
Table 1-3; Boos classification of restricted access materials 
A modification of RAM columns was the development of large particle support 
chromatography (LPS) columns 83, 89 where macromolecules are excluded by size using 
hydrodynamic properties of the mobile phase rather than steric restriction.  The columns 
are constructed with a 30 - 50 µm particle size packed into 0.5 to 1.0 mm i.d. columns.  The 
most prominent example of these columns is Turboflow (Thermo). 90, 91 LPS columns use a 
range of column chemistries in 50 µm particle sizes packed into steel columns.  For a 1.0 mm 
i.d. column operating at a flow rate of 5 mL/min, the combination of flow rate and particle 
size enables the establishment of ‘turbulent flow’ characteristics, as defined by Quinn and 
Takarewski. 92  Eddy formation between stationary phase particles promotes radial diffusion 
across the column to reduce the effects of frictional drag against the column walls.  This 
contributes to the band broadening observed as flow rate increases in the laminar flow 
region according to the Van Deemter relationship.  Back pressure across the column is also 
reduced.  The resulting flat fronted fluid profile is represented in Figure 1-8 in comparison 
with the less uniform flow profile observed in the laminar flow region; in consequence band 
broadening is relatively low and the sample is transferred to the front of the HPLC column in 
a tight band. 
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Figure 1-8; Flow profiles in laminar and turbulent flow 
In the reduced equation of the Van Deemter relationship (Figure 1-9) within the laminar 
flow region, the C term is dependant on axial diffusion.    The optimum (minimum) value of 
height equivalent of theoretical plates (H) in the laminar flow region is observed at relatively 
low flow rate, but increases with band broadening as flow velocity is increased since slow 
axial diffusion means that frictional drag to the tube walls (or particle surface) distorting the 
moving band.  As flow rate increases, beyond the laminar zone, diffusion and mass transfer 
occurs more rapidly and the significance of the C term diminishes.   Characteristically, the 
flow in the turbulent region takes on a more parabolic profile as frictional interactions with 
the vessel walls are less significant (Figure 1-8). 
 
Figure 1-9; Illustrative representation of the Van Deemter relationship between linear velocity and height equivalent of 
theoretical plates 
The advantage of this flow profile for extraction of small analytes from macromolecules is 
that while mass transfer of small molecules into the stationary phase is efficient, the eddies 
generated prevent macromolecules from accessing the pores so they are channelled to 
waste via the larger interstitial spaces.  The profile restricts the access of macromolecules to 
the stationary phase since the spatial restriction close to the particle surface reduces the 
eddy formation so that mass transfer is limited by molecular diffusion, the rate of which is 
• Laminar flow : Frictional 
drag on the column walls 
gives rise to differing rates 
of flow across the column 
diameter.
• Turbulent Flow : Rapid 
movement of the liquid 
evens out the rate at which 
different molecules travel 
through the column.
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proportional to molecular mass. 92  A practical advantage of extraction at high flow rate is 
that the separation occurs rapidly so speed of analysis is high which is favourable to sample 
throughput and relatively large volumes can be injected onto the column.  As with other 
direct injection methods discussed, elimination of additional transfer steps aids sample 
conservation, especially where small sample sizes are available so that the maximum 
recovery of mass on the analytical column is attainable from the analytical aliquot taken. 
1.3.4 Chromatographic Separation 
The functionality of chromatographic separation is to provide a physical method of 
separation in which two components to be separated are distributed between two phases, 
one of which is stationary, while the other moves in a definite direction. This forms part of 
the definition accepted by IUPAC. 93 In the case of liquid bioanalytical separations, the 
chemical diversity and complexity of the sample mixture necessitates the separation of the 
analyte of interest from a very large number of defined and undefined co-eluents, for 
example drug metabolites, impurities, endogenous molecules, xenobiotic compounds, 
concomitant medications or contaminants resulting from sampling such as anticoagulants or 
plasticising agents.   
 
As described in 2.1, the chromatographic separation in many bioanalytical methods typically 
involves two stages of liquid chromatographic separation.  The first, during initial extraction 
where analytes that are large are excluded from chromatographic retention by some form 
of steric or dynamic restriction, or unretentive components are eluted to waste while the 
analyte and compounds with broadly similar structural and polar characteristics are 
retained.  This has been described as ‘digital’ chromatography since upon contact with the 
chromatographic sorbent, analytes are either retained with total affinity or unretained and 
there is no migration through the column.  The second chromatographic separation involves 
more specific separation across very pure sorbents under high pressure (typically 80 to 350 
bar).  Due to the aqueous nature of the samples injected, and primary extraction, this 
separation is reversed phase, either under isocratic conditions, or following application of an 
elution gradient, to ensure that the analyte migrates through the column at a rate which 
infers sufficient specificity from other compounds in the mixture injected (or switched from 
the primary extraction column). 
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Specificity and selectivity 
Since quantitative analysis is achieved using mass spectrometers with a high degree of 
specificity,  chromatographic selectivity has been considered less important than that 
required for less selective detection techniques such as HPLC-UV,23 since there is far less 
incidence of chromatographic visible interference or baseline disturbance.   The main 
function of the HPLC separation in this case is to concentrate the analyte into a narrow band 
during migration through the column which will elute as a sharp peak enabling efficient 
integration and maximising signal sensitivity.  A rapid cycle time from sample injection to 
peak elution is important in the context of pharmacokinetic bioanalysis particularly in 
clinical studies as high sample throughput is necessary.  However, co-elution of unseen 
components can give rise to less visible but equally undesirable effects of ionisation 
suppression (or enhancement) as described in section 2.1.  It is therefore necessary that the 
HPLC separation achieves an adequate capacity factor (k’>5, so chromatographic retention 
infers sufficient separation from the solvent front and co-injected species) without losing 
the efficiency benefits of rapid separation. 
 
Choice of mobile phase 
There are a number of restrictions on selection of mobile phase chemistry due to the nature 
of the wider analytical system.  The mobile phase in reversed phase HPLC consists of two 
components, the organic and aqueous solvents.  In combination, the mobile phase should 
be compatible with the analyte, the analysis mixture, the stationary phase and the mass 
spectrometer as well as exhibiting more polar nature than the alkylated stationary phase. 
 
The solvent must be relatively non-polar but water miscible, with a sufficiently high boiling 
point and suitable viscosity.  Chlorinated solvents are unfavourable due to safety and 
environmental concerns and more highly flammable solvents are also avoided.  Typically, 
methanol or acetonitrile are used as the solvent of choice.  Buffer species is important not 
just in respect of buffering capacity but also in other chemical characteristics.  Primarily, it 
must be volatile for compatibility with the mass spectrometer; therefore, salts of organic 
acids are favoured as formate or acetate.   
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The pH of the buffer influences not only the analyte but also the stationary phase.  Since the 
stationary phase is alkyl modified silica, incomplete alkylation leaves free silanol groups on 
the surface of the stationary phase which, being acidic in nature dissociate under neutral or 
basic conditions, leaving an exposed anionic surface.  There is therefore the potential for 
secondary interaction of analytes by cation exchange mechanisms with uncapped silica 
under basic conditions.   This may give rise to loss of chromatographic peak shape by tailing.  
The use of buffers with pH values greater than pH 7 also tends to degrade the column by 
stripping the alkyl ligand.   
 
A review of mobile phase components and their concentrations published in the Journal of 
Chromatography B volume 878 issues 1 to 26 (2010) is summarised in Figure 1-10 to Figure 
1-12 and tabulated in Appendix 1.  This review revealed that although pure water was 
occasionally used as aqueous mobile phase, the most frequent salts were ammonium salts 
of formic or acetic acid or acidification using the free acids only with the most frequent 
composition containing formic acid only (between 0.001 and to 2 % v/v).  The only organic 
mobile phases reported during this period were methanol or acetonitrile or a mixed 
composition of the two with acetonitrile used most frequently. 
 
 
Figure 1-10; Journal of Chromatography B 878 Volumes 1 to 26: aqueous mobile phase composition 
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Figure 1-11; Journal of Chromatography B 878 volumes 1 to 26: aqueous mobile phase salt molar concentration 
 
Figure 1-12; Journal of Chromatography B 878 volumes 1 to 26: organic mobile phase composition 
1.3.5 Mass Spectrometric Quantification 
Mass spectrometry as a quantitative detection device enables the derivation of a signal 
from compounds with the same mass to charge properties of the analyte of interest.  It is 
therefore a very selective detection tool and enables the achievement of very low limits of 
quantification and removes the extent of chromatographic resolution from co-eluents 
necessary to define a clearly integratable chromatographic peak.  Common constituents of 
the mass spectrometer are an inlet and ionisation device where analytes eluting from the 
chromatography column are transformed into gas phase ions at atmospheric pressure and 
then diverted via a series of lenses into a mass separation device.  Here, ions are selected by 
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mass to separate ions with the mass of the target molecule and further fragmented in a 
collision cell before selection of a product ion, and transfer to an electron or photomultiplier 
tube to generate a signal proportional to the amount of ions present. 
 
Ionisation source 
The function of the ionisation source is to efficiently transfer the analyte in the liquid phase 
at atmospheric pressure to its ionised form in the gas phase.  There are a number of 
ionisation source types available, but the ones used for pharmaceutical bioanalysis are 
those generally considered as the ‘soft’ ionisation techniques of atmospheric pressure 
chemical ionisation (APCI), electrospray ionisation (ESI) and occasionally, atmospheric 
pressure photo-ionisation (APPI).  The ‘soft’ terminology describes the fact that they can be 
optimised to ionise compounds without causing further fragmentation in the ionisation 
source which may be induced by higher energy techniques such as electron bombardment. 
This ensures that the maximum mass of analyte is transferred to the mass analyser to 
maintain sensitivity. 94  The ionisation sources are suited to the typical mass range of small 
molecule pharmaceuticals 200 to 800 Da, and to labile metabolite compounds which may 
degrade in source. 
 
In APCI, the eluent enters the source and is dried rapidly to remove residual solvent vapour 
by a heated nebuliser containing a carrier gas.   The stream of volatilised solvent containing 
the analyte molecules are exposed to electrons generated by a corona discharge needle.  
The electrons cause the ionisation of solvent vapour molecules which transfer charge to the 
neutral analyte via proton transfer reactions.  In APPI, the corona discharge needle emitting 
electrons is replaced by a photon source and the transfer reactions are promoted by the 
addition of additional dopant solvents, eg toluene.  In both cases, ionisation is achieved 
while the analyte molecules are in the gas phase.  A schematic representation of the APCI 
source is illustrated in Figure 1-13. 
 
In ESI, before entering a desolvation chamber, the eluent passes through a capillary where a 
high electric potential is applied.  The applied potential infers a charged surface and spreads 
out the droplets which form as they are nebulised in the presence of a desolvation gas and 
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increased temperature.  The ionisation of analyte molecules occurs by the process of ion 
evaporation where as the charged droplets reduce in size due to desolvation, the charge 
density increases to the point where the field gradient is so large that ‘coulombic explosion’ 
occurs and charged analyte molecules are ejected into the gas phase.   A schematic 
representation of the ESI source is illustrated in Figure 1-14. 
 
Figure 1-13; Schematic atmospheric pressure chemical ionisation source 
 
Figure 1-14; Schematic electrospray ionisation source 
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Mass selection 
Of the many mass analysers available, the most frequently applied to quantitative LC-MS 
contain at least one quadrupole for the selection of the base peak.  This quadrupole may be 
in-line with a second quadrupole where collision reactions may take place to induce 
fragmentation and a further quadrupole to select a fragment ion which can be used to 
generate a quantitative signal.  Hybrid instruments containing a quadrupole and an 
alternative mass analyser such as an ion-trap or time-of-flight may be used to infer greater 
mass accuracy or structural information, by respectively allowing multiple fragmentation 
and mass selection reactions, or using an extended ion flight tube to increase mass 
resolution.  The majority of reported methods for quantitative pharmaceutical bioanalysis in 
recent years; however, have been achieved using triple quadrupole mass analysers.  In all 
cases, separation of ions by mass is achieved by generating an ion beam in a vacuum and 
adjusting the applied field to affect the stability of ions in the beam using direct current or 
radio frequency in a way which is proportional to their mass to charge ratio.  The 
quadrupole is constructed with four symmetrical parallel rods through which oscillating 
radiofrequency (RF) fields are applied through diagonally opposing rods together with direct 
current (DC).  The construction of the quadrupole is shown in Figure 1-15 showing the stable 
trajectory of an ion travelling through the quadrupole. 
 
Figure 1-15; Diagrammatic representation the quadrupole showing opposing (oscillating) RF values linked diagonally.   
The orange line represents an ion travelling through the quadrupole in direction z, accelerated by DC and stabilised in 
the x-y axis by the oscillating RF frequencies 
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For each mass and charge, an ion with a trajectory in the z axis is stable in the x-y plane at a 
specific combination of RF potential and DC amplitude. 
 
Detection device 
The signal is generated when the filtered ion arrives at an electron multiplier.  This consists 
of a horn shaped open tubular continuous dynode under vacuum coated with a 
semiconducting material such as lead oxide with a high negative potential at the entrance 
and ground state at the collector at the end of the horn. 95  Positively charged ions collide 
with the surface to release electrons which in turn are converted to secondary electrons 
during multiple collisions as the electrons are draw towards the ground state collector 
providing signal amplification.  In some instruments, photo multipliers are used in place of 
electron multiplier tubes.  
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2 Bioanalytical Matrix Effects 
2.1 Ionisation Enhancement and Suppression 
Suppression (or inversely enhancement) of ionisation occurs when the efficiency of the 
ionisation process is either reduced or augmented by the presence of co-eluting species  
which either facilitate or inhibit charge transfer to the target analyte.  As such, suppression 
and enhancement of ionisation processes are relative phenomena and it is generally 
accepted that some degree of suppression or enhancement are inevitable.  The effects 
become critical when ionisation efficiency of the target analyte differs significantly between 
the test sample and calibrant samples giving rise to quantitative assay bias which is 
attributed to such ‘matrix effects’. 96  The effect of uncontrolled ionisation suppression can 
therefore give rise to a greater signal response from unknown samples causing deviations in 
precision and accuracy not just loss of absolute sensitivity. 97 
 
From a regulatory perspective, matrix effects must be evaluated and controlled so that 
appropriate steps are taken to ensure the lack of matrix effects throughout the application 
of the method. 98 Routinely, this means that in validation, multiple different batches of 
control samples from the target matrix are analysed to verify that quantitative bias remains 
within defined limits.  While these phenomena can occur in all atmospheric pressure 
ionisation sources, their impact is greatest during the electrospray process. 99  
Pharmaceutical bioanalytical assays are generally standardised by using stable isotope 
labelled internal standards so within matrix ionisation effects are compensated. 
 
Although matrix effects are defined relatively as suppression or enhancement, 
mechanistically, the phenomena are simply defined in terms of suppression of a 
theoretically complete ionisation process.  In this case, suppression is caused by the action 
of species co-eluting with the analyte to prevent the analyte from forming ions in the gas 
phase.  The mechanism of ionisation suppression is not clearly defined, a number of models 
have been proposed, and these may potentially influence the system simultaneously. 100, 101 
Mechanisms of ionisation suppression were reviewed by Jessome and Volmer 100 and 
discussed by van Eeckhaut et al. 101  In electrospray ionisation sources, the net effect is that 
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analytes are prevented from transforming to gas phase ions in the condensed phase where 
electrospray droplets form.  The following effects are presented as proposed mechanisms. 
  
1. Limitation of charge: competition effects where co-eluting species ionise more 
efficiently, therefore preferentially to the target analyte which remains partly 
unionised.  This is analogous to simply overloading the source with analytes to be 
ionised, leading to a loss of linearity at high concentration, biased towards more 
efficiently ionised analytes. 100, 102 
2. Droplet surface properties: co-eluents reduce the volatility of the electrospray 
droplet and increase its viscosity preventing ions from overcoming surface tension to 
enter the gas phase. 100, 103 
3. Ion pairing effects: cause neutralisation and co-precipitation of the charged analyte. 
104 
 
Suppression effects have been identified as greatest when ionic species are present, 105 
correlation was also made by King et al. 99 between the effectiveness of the extraction 
technique in eliminating non-volatile components with the relative reduction in matrix 
effects caused by ionisation suppression.  Simple deproteinisation which results in the 
greatest proportion of non-volatile components remaining in the sample yielded a greater 
tendency to ionisation suppression than liquid-liquid extraction which optimally retains the 
more non-polar and volatile components.  In general terms, liquid-liquid extraction is not 
universally applicable to small molecule bioanalysis due to the varying physicochemical 
properties of the target analytes.  In the context of high throughput bioanalysis, throughput 
may be reduced by the requirements to carry out multiple solvent transfer steps increasing 
sample preparation time as well as resulting in an incompatible injection solvent for RP-
HPLC.  Extraction via SPE encompasses a broader range of analyte polarities and can readily 
be automated as earlier described (section 1.3.2).  Karst and Liesener determined that 
effective separation on-line extraction columns such as Turboflow could be used to 
minimise ionisation suppression while maintaining sample throughput. 106 
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2.2 Assessment of Matrix Effect 
A quantitative assessment of ionisation efficiency and its contribution to process efficiency 
can be made by comparing the peak area responses of (A) the drug and its internal standard 
in post extracted samples, (B) samples prepared by addition of standards to extracted blank 
matrix, and  (C) samples of the same concentration in unextracted solvents injected directly 
into the LC-MS instrument. 104  Extraction efficiency is determined by comparing A with B, 
ionisation efficiency, B with C, and process efficiency, A with C.  The limitations of this 
method in in-line analysis methods are that (i), plasma samples are injected into aqueous 
extraction buffers where solubilisation is achieved by plasma protein binding whereas 
injection of drug standards in solvents may cause loss of solubilisation, non-specific binding 
or solvent mediated effects on chromatographic retention on the extraction sorbent.  
Furthermore (ii), due to the composition of the analytical system, it is not possible to add 
drug standards to an extracted control sample without influencing the extraction.  As a 
consequence, the ionisation efficiency and degree of suppression determined by this 
protocol applied to in-line extraction methods is only achievable as a gross process 
efficiency result including extraction efficiency. 
A second and more versatile method of assessing relative ionisation efficiency in the 
presence of all co-eluents as a function of chromatographic retention time may be achieved 
by continuous post column infusion 107 as represented by Figure 2-1.  In this method, a 
syringe pump is used to deliver a constant infusion of drug standard in an appropriate 
solvent into the mobile phase via a tee piece after the column while the mass spectrometer 
monitors the selected transition for the drug to generate a chromatographic baseline with a 
relatively high background caused by the constant ionisation and detection of the target 
analyte.  Injection of a sample of blank matrix prepared by the test method under 
investigation is then acquired, and the potential of eluting species to enhance or suppress 
the ionisation mechanism of the target analyte are presented as peaks or troughs, 
respectively in the baseline.  Repeating the same experiment but without the post column 
infusion and monitoring using full scan can then assist in identifying the compounds 
responsible for inducing suppression. 
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Figure 2-1; Schematic diagram of post column infusion 
In bioanalytical assays, the complexity of the sample analysed means that suppressing 
species may arise by salts, 108 plasticisers, 109 mobile phase components, 103, 110 formulation 
components, 111- 113 concomitant medications, 114 and most critically endogenous 
components. 107, 115, 116  Importantly, while mutual ionisation enhancement/suppression of 
analyte and internal standard have been reported, 117, 118 the potential of co-eluting species 
to induce ionisation suppression is not necessarily related to structural or mass similarities 
to the analyte other than those which behave with similar chromatographic properties. 
2.3 Phospholipid Biochemistry 
A major endogenous source of ionisation suppression arises from phospholipids present in 
plasma samples.  These polar lipids are diverse and abundant in plasma samples. 
2.3.1 Mammalian Lipid Distribution 
Lipids form the most diverse and abundant chemical class in biological organisms.  The 
general chemistry encompasses fats, oils, some vitamins and hormones and form most of 
the non-protein components of cell membranes.  They are formed by condensation of 
glycerol and fatty acids (Figure 2-2). 119 
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Figure 2-2; Formation of triglyceride lipids 
Biologically abundant fatty acids are predominantly C16 and C18, almost half of biological 
fatty acids in animal lipids are unsaturated or polyunsaturated containing up to 3 double 
bonds. 119  The simple triglyceride represented by Figure 2-2 (tristearoylglycerol), the 
constituents of adipose tissue is the most abundant lipid type in the body, used primarily as 
an energy store.  The normal human fat content is 21% in males and 28% in females. 119  
Some abundant fatty acids are shown in Figure 2-3.  The first double bond occurs between 
the C9 and C10 position from the carboxylic acid group in a fatty acid and in 
polyunsaturated fatty acids; double bonds occur every third carbon atom, always taking up 
the cis conformation. 119  The chain bending this infers on the fatty acid when substituted 
into lipids increases fluidity with polyunsaturation which is an important physicochemical 
property in biological membrane function.  There are over 1000 known naturally occurring 
fatty acids although less than 50 are common. 120 
2.1 Membrane Lipids 
Membrane lipids take the form of glycerophospholipids with the general chemistry 
indicated in Figure 2-4.  Here R’ and R’’ are fatty acids which infer the diversity of molecular 
species and functionality to the biological membrane.  Substituent X is the functional group 
which classifies the glycerophospholipid (Table 2-1). 
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Figure 2-3; Some C18 fatty acids showing effect of degree of unsaturation on conformation 
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Figure 2-4; General chemistry of phospholipids 
The highly surfactant nature of these compounds containing phosphodiester headgroup in 
place of one of the triglyceride fatty acid groups (with polar phosphoryl ‘heads’ and long 
nonpolar aliphatic ‘tails’) facilitate the aggregation into bilayers and micelles at low critical 
micellar concentrations of nano- or micromolar rather than millimolar concentrations 
observed in domestic surfactants such as sodium dodecyl sulphate. 121 
 
The nature of glycerophospholipids is highly diverse with 300 species existing in the human 
erythrocyte membrane alone.  Biologically, in addition to barrier functions, phospholipids 
within membranes are responsible for solvation and modulation of membrane proteins, and 
their composition and location throughout the cell membrane is bioactively driven to be 
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complex and asymmetric across the membranes, altering in response to biological factors.  
They can also be involved in biosynthetic mechanisms and cell signalling. 122, 123  The field of 
lipidomics has arisen to associate the distribution and regulation of lipid species to 
determine functional biomarkers of disease state. 124, 125  Phospholipids have been identified 
as varying with changes in conditional states for example renal failure, 126 cancer 127 or 
leukaemia 128 and may serve as biomarkers of disease.  It is clear that phospholipids are 
highly diverse and variable so their variable distribution between animal species and 
potentially between human groups is feasible.  While these lipids form cell membranes, they 
are transported in plasma as excretory products. 
2.2 Phospholipid Classes and Nomenclature 
Substitution of the X group in the general glycerophospholipid chemistry in Figure 2-4 
identifies the major phospholipid classes in mammalian cell membranes summarised in 
Table 2-1. While the phospholipid groups and their fatty acid residues can be described with 
both IUPAC and trivial nomenclature, they are most commonly described in the literature 
for simplicity by the carbon and bond number of each bonded fatty acid and a fatty acid 
nomenclature which identifies the position of the first double bond with respect to the 
terminal methyl group. 123, 120 For example, linoleic acid (Figure 2-3) may systematically be 
named as 9,12-octadecadienoic acid or alternatively as 18:2 (n-6) fatty acid.  
Lipid Phosphodiester functional 
group 
Percentage found in 
Human Erythrocyte
 129
 
Percentage found in 
Human Myelin
 129
 
Phosphatidic acid -H 1.5 0.5 
Phosphotidyl choline* -CH2CH2N(CH3)3
+
 19 10 
Phosphotidyl 
ethanolamine* 
-CH2CH2NH3
+
 18 20 
Phosphotidyl inositol*  1 1 
Phosphotidyl serine -CH2CH(NH3
+
)COO
-
 8.5 8.5 
Phosphotidyl glycerol -CH2CH(OH)CH2OH 0 0 
Sphingelomyelin -CH2CH2N(CH3)3
+ 
Additionally, sn2 is 
substituted with
 
 -NH(C=O)-(CH2)nCH3 
17.5 8.5 
Cholesterol  10 26 
Glycolipids  25 26 
* Lyso-phosphatidyl~ species are also identified where the acyl residue on one of the 2 available glycol groups is replaced 
by hydrogen so that the lipid has only one non-polar tail.  
Table 2-1; Cell membrane phospholipid classes found in mammals 
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2.3 Mass Spectrometric Analysis of Phospholipids 
Mass spectrometric determination of the major membrane phospholipid groups has been 
described by Millne et al. 122  The species that can be ionised in either positive or negative 
ion electrospray ionisation are identified in Table 2-2.  The method used to identify the 
phosphotidylcholine species is by monitoring precursors of m/z = 184.  The characteristic 
detection of each phospholipid species are summarised in Table 2-2 
 
Analysis of the LC-MS chromatograph obtained by the above scanning mode allows the 
speciation of each group of phospholipids while the mass of each compound can be 
determined. 
Species Ionisation 
mode
 121
 
Scanning mode Headgroup 
specific ion
 122
 
Origin 
Phosphotidyl 
choline* 
+ Precursor ion scan 184 Common fragment of 
H2PO4CH2CH2N
+
(CH3)3 
Phosphotidyl 
ethanolamine* 
+ Neutral loss scan 141  
 
Loss of 
H2PO4CH2CH2NH3 
Phosphotidyl 
serine* 
+ Neutral loss scan 185 Loss of 
H2PO4CH2CH(NH3
+
)COO
-
 
Sphingelomyelin + Precursor ion scan 184 Common fragment of 
H2PO4CH2CH2N
+
(CH3)3 
Phosphotidyl 
inositol 
- Precursor ion scan 241 Loss of H2PO4C6H11O5 
loss of H and loss of H2O 
* Lyso-phosphatidyl~ species are also identified where the acyl residue on one of the 2 available glycol groups is replaced 
by hydrogen so that the lipid has only one non-polar tail. 
Table 2-2; Ionisation and common fragmentation of major mammalian phospholipid classes 
  
 47 
3 Analysis of Samples from Dry Blood Spots 
3.1 Principal and Applications 
Collection of blood samples on filter paper was first described by Dr Robert Guthrie who 
demonstrated a technique of sampling from neonates to enable early screening for 
phenylketonuria (PKU) by measuring phenylalanine in dried blood spots (DBS). 130, 131  The 
procedure known as the Guthrie test is routinely carried out on newborns in hospitals 
globally where blood is drawn from a puncture in the heel within the first week of birth and 
taken on to screen against indicators of an array of congenital disorders such as congenital 
hyperthyroidism (CHD), sickle cell disorders (SCD), cystic fibrosis (CF), medium chain acyl-
coA dehydrogenase deficiency (MCADD). 132 
The samples first taken using Dr Guthrie’s method were analysed by bacterial inhibition 
assays, where the presence of phenylalanine leached from the paper into an agar disk 
mediated bacterial cell growth that had been chemically inhibited.  With the initiation of 
mass screening which followed the introduction of the neonatal heel prick, an array of 
additional diseases screened shortly after birth were added to the tests.  The main 
biochemical disease groups tested were organic acidemias and fatty acid oxidation 
disorders. 133  The presence of multiple screened conditions each with threshold limits 
identified for multiple diagnostic fatty or amino acids meant that specific bacterial inhibition 
assays were unable to meet the throughput requirements.  GC-MS and LC-MS assays 
enabled the direct monitoring of markers such as arginosuccinic acid, while phenylalanine 
could be measured simultaneously with tyrosine indicatively as a ratio.  Quantitative/semi 
quantitative HPLC-ESI-MS detection of DBS samples was able to facilitate sensitive, robust 
and high throughput neonatal screening analysis amounting to six 96-well plates per day. 134  
A strategy for the comprehensive analysis of a battery of amino acids using a multiple 
gradient approach to adequately analyse all relevant acids without the need for 
derivatisation was described using HPLC-MS/MS. 134 
The application of DBS-LC-MS analysis was logically applied to therapeutic monitoring of 
exogenous compounds where drug concentrations in blood are analysed to verify 
therapeutic exposure to the drug substance.  This is critically important where patient 
specific dosage is optimised based on drug exposure to achieve therapeutic concentrations 
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in the body while minimising side effects where the therapeutic index is narrow. 135, 136  It is 
also important in aggressive therapies where unwanted side effects are unavoidable and 
increase the tendency towards non-compliance. 137, 138 
A key advantage of dried blood spot sampling over analysis from whole blood or plasma 
liquid samples is that samples may be drawn outside of a laboratory or clinic and ideally in a 
home setting.  For patients using the immunosuppressive drug tacrolimus this reduces 
return visits to hospital following transplant surgery since capillary blood samples can be 
taken onto a sampling card following finger puncture using a disposable lancet and without 
the presence of an expert phlebotomist then mailed back to the clinic for analysis. 139  This is 
important for patient convenience and therefore increases compliance with sampling; 
however the technique is also important in hospital settings which lack the equipment such 
as centrifuges, freezers and frozen transport which would be necessary to take plasma 
samples.  This is the case for many studies taking place in remote locations or developing 
countries where epidemiological studies are conducted.  Drug development studies 
involving anti-malarial treatments are typically monitored by DBS for this reason. 140- 143 
Significantly, the volumes of blood required for DBS analysis are far lower than those 
required for plasma sampling.  Firstly since the total volume of blood drawn is taken into the 
sample for DBS while the red blood cell portion is removed by centrifugation to yield plasma 
meaning that the blood sample volume required per unit plasma volume is almost double.  
Sampling into appropriate volume blood collection tubes and transferring to plasma tubes 
limits the lower volume of blood to hundreds of microlitres while spotting onto filter paper 
can be completed in a single drop of tens of microlitres.  This factor meant that DBS could 
be applied to rudimentary pharmacokinetic evaluation in discovery studies in rodents as 
described by Bateman and Beaudette. 144  The total volume involved meant that serial 
bleeding of rodent specials could be used instead of destructive, or stratified serial bleeding  
145 (see Chapter 4) reducing total animal number and also improving data by reducing inter-
animal variability. 
The use of DBS for fully quantitative pharmacokinetic studies was first described by Spooner 
et al. in 2008 146 following a pilot study which monitored paracetamol in dogs by HPLC-
MS/MS using samples of blood dried onto paper.  A method was demonstrated where 
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samples were cut from a dried blood spot and reconstituted into a methanolic solution of 
deuterated analogue internal standard.  The resulting extract was analysed by HPLC-MS/MS 
with a lower limit of quantification of 100 ng/mL.  The published assay validation data and 
application to analyse ex-vivo samples from an exploratory pharmacokinetic study 
demonstrated that the technique could be applied to support studies with GLP regulatory 
compliance.   The method was later applied to analyse samples from a clinical study. 147  The 
validation methodology was subsequently applied to a number of further analytes and 
incorporated into a drug development study strategy. 148, 149 
3.2 Paper Media 
Traditionally, for neonatal screening, diagnostic and analytical applications, blood samples 
were spotted onto uniform untreated cellulose based paper, often described as ‘filter paper’ 
although the specification of the paper media has been dedicated to blood sample storage 
for many years.   The application of dried samples to paper was importantly utilised in 
nucleic acid analytical applications to collect samples for DNA fingerprinting, genetic analysis 
or epidemiological analysis by RNA/DNA analysis of microbiological or parasitic infection.  
 
While dried blood spot sampling is used for the collection of epidemiological nucleic acid 
analysis of blood borne pathogens and DNA fingerprinting, the most common and least 
invasive technique of sample matrix application to the paper for forensic identification 
purposes is buccal swab sampling.  Here, small amounts of tissue are brushed from the 
inner cheek membrane of the subject and applied to the paper.  Although blood cells lyse on 
drying to release cell contents, additional workup is required to release nucleic acids from 
other tissue cells.  A modified paper type was designed to facilitate the extraction of DNA 
from cells applied to paper media by impregnation with chemicals to promote rapid cell lysis 
to release nucleic acids which are then immobilised within the fibres of the cellulose paper 
for storage and transport, while further impregnated chemicals promoted virus and enzyme 
activation and nucleic acid stabilisation.  As well as availability for immediate downstream 
Polymerase Chain Reaction (PCR ) analysis, the stability inferred to the sample by this 
process enables storage of archive samples for many years. 150  FTA® paper is now routinely 
used for forensic and epidemiological nucleic acid sampling. 151-153  This impregnated media 
was further modified to produce a second generation paper type which enabled nucleic 
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acids to be simply desorbed with an aqueous wash, considerably simplifying the nucleic acid 
extraction process and is marketed as FTA elute®. 154 
 
Currently, FTA® and FTA elute® supplied by Whatman are the only 2 chemically modified 
paper types available while a number of untreated paper types have been used for DBS 
applications with grade 31ETF and grade 903 papers supplied by Whatman (GE medical)A 
and Ahlstrom 226 supplied by ID BiologicalB are the predominant papers with sufficient 
uniformity for quantitative analysis.  Recently, blood collection for pharmacokinetic analysis 
has used impregnated FTA®/FTA elute® papers to combine the advantages of rapid virus and 
enzyme inactivation with the alternative elution characteristics of 2 different modified 
paper types with the alternative elution selectivity from pure cellulose paper. 146- 148  The 
chemically modified papers are not without limitations since loading volumes are limited by 
the capacity of the impregnated chemicals.  The advantages and disadvantages to the use of 
modified and pure cellulose DBS paper are summarised in Table 3-1. 
 
3.3 Extraction Methodology for Small Molecules 
Solvents 
The first step for all analyses involving extraction from the sampling paper is to remove an 
aliquot of the paper by punching out a circle of paper containing sample into an extraction 
tube or microtitre plate.  In the literature these vary from 3 to 8 mm diameter and can be 
cut by hand using a Harris unicore punch or equivalent or dedicated robotic punching 
equipment.  The method used to extract pharmaceutical molecules from paper varies and is 
compound specific.  Tawa et al. utilised  0.5 M Na2HPO4  (pH 8.7) for the elution of 
aminoglycoside antibiotics. 136  Allanson et al. used acidic buffering of rifampicin dried blood 
samples on paper with 0.02 M ammonium acetate (pH 4.0) followed by extraction into 
methanol and subsequent evaporation and reconstitution in injection solvent. 155  Liquid-
liquid extraction of buffered punches into larger volumes of aqueous immiscible solvents 
such as methyl tert-butyl ether were reported prior to evaporation and reconstitution 148 
with the ability to selectively extract and separate steroids and their glucuronide 
                                                          
A 
www.gehealthcare.com 
  
B
 www.id-biological.com 
 51 
metabolites between basic organic and aqueous layers prior to derivatisation. 156  Ideally, if 
sufficiently rapid extraction mass transfer is possible, the punched paper extract may simply 
be vortex mixed with an aqueous solvent mixture containing internal standard with removal 
of the paper punch to form the HPLC injection solvent. 138 , 146, 157 
Paper type Advantages Disadvantages 
1. Pre-treated; cellulose based, 
impregnated with patented 
chemicals to lyse cells, fix DNA, 
and enable DNA recovery. 
(FTA®, FTA elute®)C 
 
 Documented to 
inactivate viruses 
 Demonstrated to 
rapidly inactivate 
plasma enzymes 
 Provides alternative 
recovery selectivity 
 Long term physical 
stability determined for 
the storage of genetic 
samples 
 
 Currently 1 vendor. 
 Volume (spot size) 
limitations 
 Moisture sensitive 
 Distribution effects 
attributed to loading 
chemical treatments 
 May be difficult to 
store and handle,  
 May be light and 
temperature sensitive 
 
2. Non treated paper; cellulose 
based, high purity paper.  
(Whatman 903, Whatman 
31ETFD, IDB226) 
 
 Less expensive with 
multiple vendors  
 Large spots possible, 
evenly distributed 
 May be heated to 
accelerate drying (to be 
tested) 
 No additional chemicals 
present. 
 No distribution effects 
or volume limitations 
caused by chemical 
overloading or 
moisture sensitivity (to 
be verified) 
 
 Does not rapidly 
inactivate enzymes 
 Data on virus 
inactivation unavailable 
- historical evidence of 
regular mail shipment 
(US CDC permitted) 
 Less scope for 
alternative recovery 
selectivity 
 Some grades may not 
give equivalent 
uniformity 
 
Table 3-1; Summary of DBS sampling paper properties 
In instances where low extraction recoveries from the paper were limiting to assay 
sensitivity, novel methods of pre-treatment of filter papers have been reported. 158, 143  Van 
der Hijeden et al. 158 described impregnating Whatman 903 paper with acidic ammonium 
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D
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acetate buffered pasteurised plasma protein solution which was applied to the paper and 
dried prior to blood sampling for analysis of the antimalarial everlimus.  Blessborn et al. 143 
pre-treated paper with tartaric acid for the collection of blood samples to analyse another 
antimalarial, lumefantrine.  This was necessary for the large acidic molecule to disrupt the 
gradual ionic binding to the paper which had been observed to give rise to the phenomenon 
of reduced recovery following several days’ storage. 143 
Extraction Protocol 
Samples extracted from the paper matrix into solvents may be either injected directly for 
separation on an HPLC column, or cleaned up by solid phase extraction, either off-line 142,143, 
159 or on-line. 158, 139  Sonication time was investigated by Damen et al. 160 in the extraction of 
vincristine and actinomycin-D from paper into acetonitrile:methanol:water solvent; they 
found a standard 15 minute sonication step was adequate for this transfer 160 while longer 
sonication times and centrifugal filtration of the paper were required for the everolimus 
assay of van der Heijeden et al. 158  Beaudette and Bateman 144 employed a 2 hour 
incubation step of the paper in the extraction medium at 37°C with shaking. The duration of 
exposure to the extraction medium for dry blood spots was investigated by Koal et al. 137 
who found that for extraction recovery increased with time between 20 seconds and 75 
minutes of contact with the extraction reagent following vortex mixing with 1 of the 9 
antiretrovirals tested amounting to a 50% increase in recovery. 137 Clearly, to optimise 
recovery from the punched blood spot when sensitivity is likely to be a limiting factor, the 
method utilised in the extraction process– shaking, sonication, heat must be optimised in 
addition to extraction medium chemistry.  Liu et al. Introduced the term ‘elution efficiency’ 
to describe this. 161 
Factors Influencing Distribution and Recovery 
One factor which may be significant in the recovery of analyte from the spot is water 
content.  Water may arise from drying time of the spot following sampling or the ambient 
humidity of the card or dried spot storage.  It is particularly significant for the chemically 
modified media of FTA® and FTA elute® which contain hygroscopic components in 
formulations and FTA elute® is designed to facilitate easy nucleic acid elution in aqueous 
reagents.  As a result, it is imperative that samples are stored under desiccation prior to 
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extraction.   Hoogstanders et al. 139 investigated the time to dry a typical 30 µL spot by 
weighing papers after timed ambient drying, and found that up to 18 hours, the mass of the 
spot was still falling due to sample drying, 139 however; Koal et al. 137 related drying time to 
extraction recovery and found there to be no significant difference after 2 hours for up to 5 
days, 137 although it is notable that both work was done using untreated paper which is less 
sensitive to moisture. 
An aspect with the potential to affect the distribution in paper is the blood sample rheology, 
particularly the effect of shear viscosity on the percolation through the paper matrix.  The 
more viscous a blood sample is upon application to the paper, the more slowly it will 
percolate through the paper and therefore dry to form spots with smaller radii than spots of 
the same volume from a less viscous matrix.  In consequence, the unit area of sample cut 
from the spot for analysis potentially contains a differing proportion of the applied blood 
sample.  The significance of the extent of this affect on the analytical bias of the assay is 
subject to validation.  The influence on anticoagulant 162 and clinical condition of the donor 
163 on the shear viscosity of blood is well studied; Reinhart et al. investigated a range of 
commonly used blood anticoagulants and showed EDTA to result in the lowest blood 
viscosity. 164 Rosenblum 162 showed that elevation in the relative viscosity of blood samples 
taken from animals using citrate anticoagulant was initiated by red cell shrinkage caused by 
the anticoagulant.  He related the action of each anticoagulant as those which induced 
shrinking of the erythrocyte (citrate and oxalate) and those with no effect on shape or size 
(heparin, EDTA) to the effect of the anticoagulant on the viscosity of blood. 
Rosenblum also related alternative anticoagulants to changes in hematocrit; the proportion 
of blood volume occupied by red blood cells. 162  The hematocrit is known to have a 
proportional relationship to blood viscosity. 165  Mei et al. 166 related hematocrit volume with 
the amount of serum extracted from 6.0 mm punches cut from 100 µL blood spot samples 
across a range of hematocrit values between 30 and 70%.  An increase in hematocrit 
corresponded to a decrease in serum content of the punched spot for 2 sources of unnamed 
untreated filter paper. 166 Holub et al. 167 studied the effect of hematocrit on recovery of 
acylcarnitines and amino acids from neonatal samples and found recoveries to increase 
proportionally to hematocrit.   
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The potential exists for distribution differences as the blood sample percolates through the 
paper media which have been compared to chromatographic effects. 166  In untreated paper 
it has been shown from neonatal samples that punches cut from the centre of the blood 
spot may give rise to differing recoveries to those cut from peripheral positions. 167  In 
treated papers the additional complexity of impregnated chemicals which may overload 
causing changes in the paper medium with volume spotted limit the spot size, while 
differing migration rates of components of the blood following contact lysis give rise to 
visibly unevenly distributed samples with serum rings forming around the lysed erythrocyte 
centre. 147 Ren et al. demonstrated the potential for deviation from homogeneity using 
autoradiography to image the distribution of 14C labelled compounds added to blood and 
spotted to different paper types. 168  They also related storage environmental conditions to 
the extent of the effect in treated papers. 
3.4 Safety Implications 
The most significant hazard when handling biological fluids, particularly from human or 
primates is exposure to etiologic agents infecting the blood.  Viruses such as HIV and 
particularly hepatitis B and C present a hazard in handling known positive or unscreened 
blood and plasma samples and have been transmitted as laboratory associated infections. 
169  In the pharmaceutical industry, liquid samples are routinely handled in biosafety 
containment cabinets 170 in conjunction with appropriate personal protective equipment and 
following risk assessment. 
Transportation of plasma is by frozen shipment, 171 packaged into polystyrene boxes 
containing dry ice which maintains the sample at -78°C to prevent purification and analyte 
instability.  Since many etiologic agents are still active under these conditions, the samples 
are subject to the International Air Transport Association (IATA) Dangerous Goods 
Regulations.  Transport and handling of samples as dried blood spots however, presents a 
lower biological risk since many viruses such as HIV are rapidly inactivated on drying 172 
while others such as Hepatitis B reduce in activity with time. 173  Where no data exists on 
viral inactivation on drying, the reduced sample volume and reduced possibility of ingestion 
into the bloodstream of material immobilised onto paper presents a lower infection risk, 
viruses loose infectivity due to disruption of their envelope on drying. 174, 175  As a result, the 
 55 
International Air Transport Association (IATA) recommends that dried blood spot samples 
are not subject to the dangerous goods regulations. 176  Indeed, transport of samples from 
epidemiological investigations to study infection rates of Hepatitis C and HIV (generally by 
viral RNA analysis) have been routinely conducted using regular mail transport. 177- 179 
3.5 Ethical Considerations of DBS in Drug Development 
The key advantage of DBS sampling from an ethical perspective is the ability to collect 
samples in very small volumes (a few drops of blood).  For pharmacokinetic bioanalysis, 
developments in HPLC-MS/MS in recent decades have facilitated the achievement of 
analytical methods with sufficient sensitivity to achieve specified lower limits of 
quantification at low sample volumes.  However, the practical volume limitations of blood 
withdrawal, plasma centrifugation and volumetric pipetting and the loss of sample residues 
on multiple surfaces meant that typical sample volumes remained in the order of hundreds 
of microlitres of whole blood.  DBS provided Spooner et al. with a medium to obtain blood 
volumes of typically 15 µL, at least an order of magnitude less than those required for 
plasma analysis of pharmacokinetic study samples. 146- 148  Ethical considerations are at the 
core of the decision of Spooner’s organisation, Glaxo SmithKline to replace plasma analysis 
with DBS for all feasible drug development programmes.   Their approach is to implement 
DBS analysis when drug molecules enter development, since drug exposure will be defined 
as blood concentrations rather than plasma concentrations and differences in kinetics may 
arise from distribution into blood cells.  The immediate contribution to the principals of 3Rs 
(see chapter 4) is the refinement of a less invasive sampling protocol.  Small blood volumes 
withdrawn by sampling capillary via the lateral caudal vein of rats and mice is much easier 
and with less potential to cause stress.  As occasionally practiced in human sample 
withdrawal, for the withdrawal of blood volumes required for plasma analysis, the animal is 
warmed to increase blood flow by gently comfortably increasing the temperature of the 
animal housing for a period of time before the sample is taken.  Lovatt et al. 180 reported 
that this step may be eliminated for rat sampling and reduced for samples from mice.  
Critically, since less of the blood volume of the animal is taken for each sample, more 
sample time points may be taken, meaning that the number of animals used to generate the 
dataset may be reduced.  Limiting inter-subject variability additionally improves data 
quality.   
 56 
Evolution of drug development into clinical trials, the less invasive methodology is 
anticipated to improve patient recruitment since capillary blood sampling by finger prick is 
less objectionable to the patient or volunteer than venopuncture.  As has been 
demonstrated by therapeutic monitoring reports, the method is consistent with late phase 
monitoring where samples may be taken at home without visiting a clinic to see a 
phlebotomist.    This is most important where paediatric studies are conducted to 
adequately study pharmacokinetic characteristics of drug molecules in children.181, 143  Such 
studies and their impact on the safety evaluation of drugs in the target population where 
pharmacokinetics may not have routinely been studied are promoted as a priority by 
pharmaceutical regulatory authorities. 
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4  Ethical use of Animals in Pharmaceutical Research 
4.1 The use of Animals in Preclinical Safety Studies 
Before new drug compounds can enter clinical development, where single low doses are 
administered to healthy human volunteers, extensive data on safety must be compiled by 
conducting essential studies into various elements of the physiological effects of the new 
medicine.  This is not only essential in protecting the safety of volunteers who will be 
exposed to the new pharmaceutical compound before calculating the first dose, but is a 
legal prerequisite of the regulatory authorities before approval to initiate clinical trials and 
define the endpoint of subsequent dose escalation. 182, 183  Safety pharmacology and acute 
toxicity studies from single and repeat dosing supported by pharmacokinetic studies to 
define the dose relationship to adsorption distribution, metabolism and excretion of the 
molecule must be conducted.  Within Sanofi-Aventis, every scientific protocol is reviewed by 
an ethics committee before approval with emphasis on animal welfare. 
4.2 Blood Sampling Volumes and Study Samples 
Blood samples are taken according to strict guidelines by qualified personnel under licence 
in the UK by the home office. 184, 185  For any animal, the maximum permissible non-terminal 
sampling volume is 15% of total blood volume in a 24 hour period.  This is important for 
both animal welfare and the integrity of the study to ensure that any physiological effects of 
blood loss do not contribute to pharmacologic observations.   
The sampling protocol adopted by the study design is dependent on the sampling frequency 
and volume requirements for analysis and the weight of the animal used to calculate blood 
volume.  The protocols are in Table 4-1.  
Serial sampling  Entire pharmacokinetic or toxicokinetic profile is sampled from 
an individual animal 
Composite sampling   A single profile is derived from more than one animal, but each 
animal provides more than one sample 
Terminal sampling   Animal is exsanguinated for a single sample 
Table 4-1; Blood sampling protocols 
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The volume of plasma required for a pharmacokinetic sample analysis therefore influences 
the blood sampling protocols described above.  For a pharmacokinetic study of 3 animals 
per sex per time point, and 6 time points required to define the pharmacokinetic 
parameters, the relationship between sample volume requirements and bleed protocol and 
consequently total animal number are calculated in Table 4-2. 
Species Plasma 
volume 
for 
analysis 
(µL) 
Plasma 
volume 
requested 
(µL) 
Blood 
volume 
required 
(µL) 
Bleed Protocol Blood 
volume 
per 
animal 
(µL) 
Number 
of 
animals 
required 
Rat 500 1500 3000 Terminal (1 
time point per 
animal) 
3000 36 
Rat 200 600 1200 Composite (2 
time points per 
animal) 
2400 18 
Rat 100 300 600 Composite (3 
time points per 
animal) 
1800 12 
Rat 50 150 300 Serial (6 time 
points per 
animal)  
1800 6 
Table 4-2; Relationship between sampling volume, blood sampling protocol and animal number 
From the data above, smaller analytical sample aliquots may facilitate more serial study 
design; reducing animal numbers used which additionally improves data quality by reducing 
inter-animal variability. 
4.3 Blood Sampling and Control Matrix 
To support the analysis of study specimens, analytical samples are routinely prepared from 
control plasma to construct calibration curves and quality control samples and frequently 
for the preparation of internal standard sample solutions.  Due to the large dynamic range 
of concentrations analysed, from maximum post dosing concentrations to days after dosing 
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and across large dose ranges, it is often necessary to dilute the samples into the validated 
calibration concentration range using control plasma taken from untreated animals.  The 
use of control plasma is matched by species, such that, for analysis of samples from a dog 
study, calibration and quality control samples, together with the working internal standard 
and dilutions must be prepared using dog plasma.  This is the practice for analysis of 
samples subject to inspection for good laboratory practice 186  by the Food and Drug 
Administration (FDA) or Medicines and Health Regulatory Authority (MHRA) for US or UK 
markets, respectively. 
In small rodent species, blood samples are removed under general anaesthesia to achieve 
total exsanguination of an anaesthetised animal which is therefore a destructive process 
and animals are necessarily destroyed to supply control plasma. Typical maximum blood 
volumes and estimated plasma attainable are shown in Table 4-3. 
Species Blood 
Volume (mL) 
Rabbit 224 
Rat (male) 25 
Mouse 1.8 
Table 4-3; Typical maximum blood volumes of laboratory rodents 
Samples are usually diluted by adding 50 µL of sample to 500 µL of control plasma to enable 
sufficient pipetting precision and accuracy. For a typical rat toxicokinetic study, this might 
amount to 100 to 200 mL of control plasma. 
4.4 Reduction Refinement and Replacement 
Following recommendations of the House of Lords select committee on animals in scientific 
procedures 2001 report, the National Centre for the Reduction, Refinement and 
Replacement of Animals in Medical Experiments (NC3Rs) was formed to provide an ethical 
framework to experimentation using animals. 187  The mission of the centre is to reduce, 
refine and replace the use of animals in experimentation by working with scientific 
institutions and regulatory authorities and fostering innovative approaches to providing 
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scientifically valid alternatives to animal use without compromising protection of human 
health. 
The principals of the 3R are supported by the major pharmaceutical companies and the 
Association of the British Pharmaceutical Industry.  Sanofi-Aventis subscribe clearly to the 
3Rs strategy and the fundamental importance of animal welfare and culture of animal care 
is central to the charter for the humane care and use of laboratory animals. 188 
4.5 Research Aims and Objectives  
The aim of this project was to optimise an LC-MS/MS bioanalytical assay method to focus on 
ethical objectives of minimising blood volume requirement for sample analysis.  It was 
proposed to investigate the substitution of animal plasma control matrix for plasma 
withdrawn from a larger, non-destructively bled species primarily to replace rodent plasma 
as control matrix for dilutions and calibrant sample preparation.  While the use of surrogate 
matrices has been reported where matched matrices are unobtainable or frequently 
contaminated by the test item, 189, 190  extensive cross validation for ethical purposes has not 
been reported.  Previous obstacles to cross calibration between species were investigated 
to identify the effects of endogenous biochemical components on the integrity of cross 
calibrated assay methodology.  The main objective was therefore to demonstrate valid and 
unbiased analysis of a pharmaceutical sample in rodent plasma by extrapolation against 
control samples prepared in human plasma relative to matrix matched analysis. 
The recently adopted technique of dried blood spot analysis of pharmaceuticals using blood 
as an exposure medium instead of plasma following extraction of the sample from paper 
matrix was also to be investigated with the object of facilitating volume reduction of sample 
requirements for analysis.  This could then be translated into smaller animal sample 
volumes, leading to refined sampling of fewer animals. 
The principal is also supported by regulatory agencies responsible for scrutinising the 
validity of methodology used in the conduct of analysis used to generate data for 
pharmaceutical safety studies.  This was expressed by Beharry who stated her opinion that 
the UK Medicines and Healthcare Regulatory Agency (MHRA) are fully committed to 
encouraging the development of alternative methods and actively seek to influence 
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international harmonization initiatives to ensure the protection and welfare of animals and 
to minimise the numbers of animals used. 191  
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5 Experimental 
5.1 Reagents and Materials 
5.1.1 Chemicals 
All drug standards and stable isotope labelled internal standards were obtained from Sanofi-
Aventis.   Acetonitrile, methanol, propan-2-ol (HPLC grade) and dimethyl sulphoxide 
(reagent grade) were obtained from Fisher Scientific (Loughborough, UK).  Formic acid (free 
acid 95% and ammonium salt, both ACS grade) and ammonium hydroxide were obtained 
from Sigma Aldrich (Dorset, UK).  Ultra-pure water was generated using an Elga maxima 
water purifier (Marlow, UK) and verified as having maximum conductivity of 18.2 MΩ.cm-1 
prior to use. 
5.1.2 Biological Material 
Pooled control human plasma screened and free from antibodies to HIV and Hepatitis B and 
C from blood drawn into lithium heparin, sodium citrate, sodium heparin and potassium 
EDTA tubes were obtained from Biochemed (Winchester, USA).  Individual control plasma 
samples from Japanese volunteers drawn in EDTA anticoagulant were obtained from Sanofi-
Aventis (Kawagoe, Japan); control plasma samples from individual human volunteers 
specially screened from Caucasian, Hispanic and African American origin fasted or lipemic 
were obtained from Biochemed (Winchester, USA).  Fresh human whole blood was obtained 
from volunteers from Sanofi-Aventis (Alnwick, UK) drawn into potassium EDTA or lithium 
heparin vacutainers (Beckton and Dickson, UK).  Whole rat blood was obtained from Sanofi-
Aventis (Alnwick, UK).  
Plasma samples obtained from individual animals were obtained by pooling intra-individual 
sample aliquots remaining from study samples taken from drug development programmes 
of other drug candidates following authorisation for sample disposal.  Pooled blank plasma 
from rat, mouse, guinea pig, rabbit, dog and Cynamologous monkeys (Macaques) used to 
prepare control samples was obtained from Biochemed (Winchester USA).  All liquid 
biological materials were handled in a class I biosafety cabinet (Astec-Microflow, Hants, UK).  
All plasma samples were stored frozen at -20°C in walk-in freezers (Thermo Scientific, 
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Basingstoke, UK) all liquid blood samples were stored under refrigeration at 4°C in 
refrigerators (Labcold, Basingstoke, UK). 
5.1.3 Laboratory Consumable Equipment 
Polypropylene microtitre injection plates (96-well) and injectable square sealing mat 
manufactured by Porvair were obtained from Fisher Scientific (Basingstoke, UK).  Dried 
Blood Spot analysis paper Ahlstrom 226 was obtained from ID Biological (South Carolina, 
USA); Whatman FTA® and FTA Elute® DBS cards were obtained from GE Life Sciences 
(Amersham, UK).  
5.1.4 Extraction and Analytical Columns 
Large particle support columns were Turboflow® columns, C2, C8, C18 and Cyclone 
(reversed phase chromatography polymer), supplied by Thermo (Hemel Hempstead, UK).  
HPLC columns used were BetaBasic C8 50 x 3.0, 3 µm, supplied by Thermo (Hemel 
Hempstead, UK) and Gemini C18 50 x 3.0, 3 µm, supplied by Phenomenex (Macclesfield, 
UK). 
5.2 Analytical Equipment 
5.2.1 Sample Preparation and HPLC Separation 
The HPLC-MS equipment (Figure 5-1) used was composed of an Agilent 1100 quaternary 
pump delivering mobile phase to the extraction column with an Agilent 1100 binary pump 
delivering mobile phase to the analytical column.  Mobile phase flow paths were controlled 
to enable column switching using a valve interface module (VIM) unit, containing twin 6 port 
valves fitted with valco rotor seals, obtained from Thermo (Hemel Hempstead, UK).  The 
two pumps were connected with the autosampler, VIM unit, extraction and analytical 
columns and the mass spectrometer using PEEK tubing as represented in Figure 5-2. 
Mobile phase was degassed by in-line vacuum degasser (Agilent, Stockport, UK).  Samples 
were injected using a PAL CTC autosampling microtitre plate injector fitted with a PEEK loop 
and Hamilton gastight syringe appropriate to the injection volume (Jaytee Biosciences, Kent, 
UK).  Turboflow extraction columns were maintained at ambient temperature, while HPLC 
columns were thermostatically controlled using Phenomenex column ovens (Phenomenex, 
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Macclesfield, UK).  HPLC autosampler sequences and HPLC gradient sequences and VIM 
were coordinated and data using Aria software (Thermo, Hemel Hempstead, UK). 
5.2.2 Dried Blood Spot Cutting 
Dried blood spot samples were stored in a Secador automatic desiccator supplied by Fisher 
Scientific (Loughborough, UK).  Aliquots were punched for analysis using a BSD 6000 duet 
spot cuter (BSD Robotics, Queensland, Australia). 
5.2.3 Mass Spectrometry 
Mass spectrometry detection was using either a Waters Micromass Quattro Ultima or 
Waters Micromass Quattro Premier (Waters, Manchester, UK) triple Quadrupole mass 
spectrometer operating with an electrospray ionisation interface. 
 
Figure 5-1; Turboflow HPLC-ESI-MS photograph 
Autosampling 
Injector Port
Valve Interface Module
Containing Turboflow 
Extraction Column
Column Oven 
Containing 
HPLC Column
Quaternary HPLC Pump
(Extraction Column 
Loading)
Vacuum Degasser
Binary HPLC Pump
(HPLC Analysis)
Mass Spectrometer 
Electrospray Interface
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Figure 5-2; Tubing and valve interface 
5.2.4 Computer Software 
LC-MS data was acquired using Micromass Masslynx v1.4.1 (Waters, Manchester, UK).  Peak 
integration was performed using Quanlynx v1.4.1 (Waters, Manchester, UK) and linear 
regression to obtain concentration data was performed using either Quanlynx or Watson 
LIMS (Thermo, Altrincham, UK). 
Descriptive statistical analysis was carried out using either Microsoft Excel or Prism 
statistical software (GraphPad, La Jolla, CA, USA).  Statistical design of experiments (DOE) 
analysis was done using MODDE 9 (Umetrics, Umea, Sweden), LC-MS data alignment was 
done using XCMS (Scripps Research Institute, La Jolla, CA, USA), multivariate analysis by 
principal component analysis (PCA) and partial least squares regression discriminative 
analysis (PLS-DA) was carried out using SIMCA P 11+ (Umetrics, Umea, Sweden).  
Physicochemical properties were calculated using log D suite software suite (ACD labs, 
Bracknell, UK). 
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6 Results and Discussion – SARX; Initial Work 
6.1 Introduction 
4-Chloro-3-[(3R)-5-chloro-1-(2,4-dimethyoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-
yl]-N-ethyl-N-(3-pyridinylmethyl) benzamide (subsequently referred to as SARX; Figure 6-1) 
is a potent, selective oxytocin receptor antagonist which has been shown to reduce 
contractions induced by oxytocin. 192  The nonapeptide oxytocin is the most potent of the 
endogenous stimulants of uterine contractions and is expressed during the onset of preterm 
labour.  Administration of the drug at the onset of labour has the potential to induce uterine 
quiescence and delay the gestational age of delivery to improve the neonatal outcome.   The 
compound was in development by Sanofi-Aventis and at the start of this project, undergoing 
preclinical development studies while preparing to commence phase 1 (first in man) clinical 
trials. 
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Figure 6-1; Structure of SARX 
SARX is weakly basic with a molecular weight of 604.5 and a pKa of 4.72.  The calculated Log 
P is 3.54 +/- 0.9 while the log D increases from approximately 1.5 at pH 2.5 to 3.5 at pH 6 
and is unchanged at higher pH (Figure 6-2). 
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Figure 6-2; Effect of pH on Log D values for SARX 
A deuterated stable isotope analogue was available for use prepared by substitution of the 
1H hydrogen atoms for 2H on both methyl groups in the dimethoxy benzyl group.  This 
resulted in a heavy labelled compound with a molecular mass of 610.6.  The difference of 6 
mass units from the unlabelled analyte was sufficient to prevent cross-talk in mass 
spectrometer response as a result of the isotopic distribution of the two chlorine atoms in 
the structure.  The hexadeuterated analogue was therefore sufficiently discriminative for 
use as an internal standard for discriminative mass chromatogram quantification. 
6.2 Method Optimisation/Validation  
 Preparation of standard solutions 
Stock standard solutions (100 µg/mL) were prepared in DMSO from SARX hydrochloride salt 
and stored under ambient conditions.  The stock standards were further diluted with DMSO 
to yield standard solutions of 0.01, 0.02, 0.05, 0.10, 0.50, 1.00, 2.00 and 3.00 µg/mL.  
Internal standard solution of 4-Chloro-3-[(3R)-5-chloro-1-(2,4-bis-
trideuteromethyoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-
pyridinylmethyl)benzamide (0.100 µg/mL) was prepared in DMSO. 
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Preparation of human plasma analytical samples 
Plasma calibration samples were prepared by mixing control human plasma (4.95 mL) with 
an aliquot (50 L) of the SARX standard solutions to give concentrations of 1, 2, 5, 10, 50, 
100, 200 and 300 ng/mL.  Analytical samples were processed immediately or stored frozen 
at -20  10C.  A second set of validation test standard samples were prepared in control 
human plasma at 1, 2, 10, 300 ng/mL.  Working internal standard sample (10 ng/mL) was 
prepared by mixing internal standard solution with K2EDTA derived control human plasma. 
Preparation of samples for analysis 
Each plasma sample (50 L) was added to a 96 deep well polypropylene microtitre plate and 
mixed with 50 L of working internal standard ([2H6]-SARX in plasma).  The plate was sealed 
with a pierceable square well polypropylene sealing cap and the plate centrifuged (4000 
rpm; ambient temperature) for 10 minutes to enable maximum contact between small 
volume components.  The samples were mixed for 10 minutes on a vortex plate mixer and 
then centrifuged for a further 10 minutes (4000 rpm; ambient temperature) to remove 
suspended particulates from the plasma sample and also to ensure that the small volume of 
plasma was collected at the bottom of the microtitre plate following mixing to ensure 
aspiration of the complete aliquot volume by the autosampling injector.  An aliquot of the 
plasma (40 µL) was then analysed by Turboflow LC-MS/MS using the method described 
below. 
Chromatographic procedure 
50 L plasma samples were injected onto the Turboflow (C2; 50 x 1.0 mm i.d., 50 µm) 
column in pH 3 20 mM ammonium formate at 5 mL/min for 30 seconds allowing plasma 
proteins and macromolecules to elute to waste while SARX is retained.  The analyte was 
then eluted from the turboflow column by pumping pH 3, 20 mM ammonium 
formate/acetonitrile (60:40 v/v) through the column at 0.5 mL/min in the reverse direction 
of loading by means of the valve interface module (Table 6-1).  The eluent flow was split 
using a flow splitter and 250 µL/min diverted to the mass spectrometer. 
 
The chromatographic separation was achieved by diverting the eluent of the Turboflow 
column through the analytical BetaBasic column (C8; 50 x 1.0 mm, 50 µm) and applying a 
gradient of 40 to 75% acetonitrile over 2.0 minutes (Table 6-1). 
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Loading Mobile Phase 
Pump (Pump A) 
Analytical Mobile Phase  Pump 
(Pump B) 
Valve positions and flow path 
Time 
(min) 
Flow  
(mL/
min) 
% B Valve 
1* 
Flow 
(mL/
min) 
% B  Valve 
2* 
 
0.00 5.0 0 LOAD 0.5 40 Step LOAD 
 
0.75 5.0 0 LOAD 0.5 40 Step ELUTE 
 
1.00 5.0 0 ELUTE 0.5 40 Step ELUTE 
 
 
 
1.75 5.0 100 ELUTE 0.5 75 Ramp ELUTE 
3.75 5.0 100 LOAD 0.5 75 Step ELUTE 
 
 
 
4.08 5.0 100 LOAD 0.5 75 Step ELUTE 
4.67 5.0 0 LOAD 0.5 40 Step LOAD 
 
Table 6-1; Chromatographic sequence 
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Mass spectrometry 
The mass spectrometer was operated using electrospray ionization under the conditions 
described in Table 6-2: 
Experimental Method 
Parameters 
MS Acquire time  
Type Multiple Reaction Monitoring 
Ion Mode ESI +ve 
Channel 1 Precursor m/z 604.1 Da 
Product m/z 151.0 Da 
Span 0 
Dwell (sec) 0.3 
Delay (sec) 0.03 
Channel 2 Precursor m/z 610.1 Da 
Product m/z 157.0 Da 
Span 0 
Dwell (sec) 0.3 
Delay (sec) 0.03 
ESI Source Parameters Source Temperature (ºC) 130 
Desolvation Temperature (ºC) 375 
Collision Gas Pressure (MBar) 1 x 10
-3
 
Cone Gas Flow (L/h) 55 
Desolvation Gas (L/h) 900 
Cone Voltage (V) 40 
Capiliary Voltage (kV) 1 
RF Lens 1 (V) 5 
Aperture (V) 1 
RF Lens 2 (V) 0 
Typical Analyser 
Parameters 
LM1 Resolution  14 
LM2 Resolution 14 
Ion Energy 1 1 
Entrance -1 
Collision 25 
Exit 2 
LM1 Resolution 14 
LM2 Resolution 14 
Ion Energy 1 2 
Multiplier 650 
Table 6-2; Mass spectrometer operating parameters 
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Results and discussion 
An LC-MS/MS mass chromatogram was generated from the selected reaction monitoring 
trace of 604.1 Da  151 Da for SARX and 610.1 Da  157 Da for [2H6]-SARX.  A 
representative precursor and product ion scan for 4-chloro-3-[(3r)-5-chloro-1-(2,4-
dimethyoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1h-indol-3-yl]-n-ethyl-n-(3-pyridinylmethyl) 
benzamide is shown in Figure 6-3 together with the proposed fragmentation and the SRM 
LC-MS/MS chromatogram of the compound and its 6-deuterated internal standard at the 
lower limit of quantification is shown in Figure 6-4. 
 
Figure 6-3; Mass spectrum (top) of 4-Chloro-3-[(3R)-5-chloro-1-(2,4-dimethyoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-
indol-3-yl]-N-ethyl-N-(3-pyridinylmethyl)benzamide and product ion spectrum (bottom) showing proposed 
fragmentation of the most abundant product ion 
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Figure 6-4; Representative product ion chromatogram of control human plasma spiked with (a) SARX (1 ng/mL) and  (b) 
[2H6]-SARX 
Calibration linearity, lower limit of quantification and absolute dynamic range.  
The absolute sensitivity of the assay was determined as at least 20 pg on column from 
plasma.  This originates from a 40 µL injection of an aliquot of test sample (1 ng/mL) diluted 
50% with internal standard.  The resulting chromatogram produced a peak for SARX which 
gave a signal to noise significantly greater than 5-fold when compared to the amplified 
baseline shown in Figure 6-5.  The calibration response was found to be linear between 1 
ng/mL and 300 ng/mL in plasma (y = 0.1086x – 0.02101; R2 = 0.9999).  The inter-run and 
intra-run precision and bias was assessed at 4 concentrations across the calibration range by 
preparing 3 replicate groups of control samples and analysing them on 6 separate occasions 
(6 separate calibration lines).  The suitability of the assay for the determination of test 
samples was determined since each measure of precision and bias were within regulatory 
limitations of ± 15% (± 20% at lower limit) of expected (Table 6-3). 
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Figure 6-5; Representative SRM chromatogram of control human plasma spiked with SARX (1 ng/mL) 
 Plasma Concentration (ng/mL) 
Nominal Concentration (ng/mL) 1.00 2.00 10.0 300 
Mean 0.982 1.91 10.3 303 
Bias (M%D) 
(95% Confidence Interval) 
-1.85 
(-5.25, 1.55) 
-4.28 
(-7.52, -1.03) 
2.82 
(-3.45, 9.09) 
0.944 
(-0.216, 2.11) 
intra-run Precision (%CV) 
(95% Confidence Interval) 
4.25 
(3.04, 7.01) 
7.10 
(5.09, 11.7) 
9.00 
(6.45, 14.9) 
6.67 
(4.78, 11.0) 
inter-run Precision (%CV) 
(95% Confidence Interval) 
2.21 
(0.00, 7.69) 
0.00 
(*, *) 
2.60 
(0.00, 13.2) 
0.00 
(*, *) 
Total Precision (%CV) 
(95% Confidence Interval) 
4.79 
(3.75, 9.02) 
7.10 
(5.09, 11.7) 
9.37 
(7.38, 16.8) 
6.67 
(4.78, 11.0) 
*, confidence interval not calculated 
Table 6-3; Inter- and intra-run precision and bias for the assay in human plasma 
The impact of plasma matrix batch was also reviewed by analysing replicate samples in 
plasma obtained from 3 human volunteers of either sex.  Acceptable precision and bias data 
within ± 15% nominal showed that the assay could be successfully applied without 
significant bias from subject or sex related variability (Table 6-4). 
Matrix 
Variability 
Plasma Concentration (ng/mL) 
1 ng/mL 
Plasma Lot Number Male 1
 
(n = 6) 
Male 2
 
(n = 6) 
Male 3
 
(n = 6) 
Female 1 
(n = 6) 
Female 2 
(n = 6) 
Female 3 
(n = 6) 
All lots 
(n = 36) 
Mean 1.09 1.09 1.14 1.02 1.01 1.01 1.06 
Precision (%CV) 8.27 7.15 7.94 8.21 6.96 8.75 8.70 
Bias (M%D) 9.00 9.00 14.0 2.00 1.00 1.00 6.00 
Table 6-4; The impact of subject variability and gender on assay precision and bias 
Time
0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00 1.10 1.20 1.30 1.40 1.50 1.60 1.70 1.80 1.90 2.00
%
0
100
3
%
1.38
0.74
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Biological stability and solution robustness. 
The long term robustness of a pharmaceutical compound in solution is determined by the 
physicochemical stability of the compound in the dissolution media or solvent, its 
predisposition to undergo oxidative or reductive reactions which gradually degrade the 
compound into alternative products.  Loss of solution robustness may also be caused by 
instability of the solvent to chemical degradation or evaporation and gradual precipitation 
or non specific binding of the compound to storage vessel surfaces.  The net result of these 
changes over time is a (negative) change in compound concentration in solution.  
Pharmaceutical and exogenous molecules contained in blood plasma may also undergo 
concentration changes as a result of both chemical and biological factors 193 where even 
under frozen conditions, metabolic degradation reactions may be enzyme catalysed.  
Therefore, solution robustness of the compound was evaluated in DMSO solvent used in the 
preparation of analytical control samples for up to 12 weeks and biological stability was 
evaluated in the plasma matrix for the same period of time under frozen conditions.   
An aliquot of SARX in DMSO was added to control human plasma to result in nominal 
concentrations of 2.00 and 300 ng/mL which were analysed immediately or stored under 
frozen condition at -20°C in aliquots for analysis after 2, 4 and 12 weeks.  Simultaneously 
solutions of SARX in DMSO were stored under ambient conditions and after 2, 4 and 12 
weeks, an aliquot of each was mixed with control human plasma to result in sample 
concentrations with nominal concentrations of 2.00 and 300 ng/mL.   At each timepoint, 
plasma samples were analysed by the method described in section 6.2 and quantified by 
comparison with a freshly prepared set of calibration samples in human plasma.  The results 
presented in Figure 6-6 show that there was no significant chemical instability during the 3 
month period since at both concentration levels investigated, negative trend is not observed 
and the concentration at 3 months is within 15% of nominal concentration and also within 
15% of the detected concentration of the sample at time zero.   The data demonstrates the 
absence of significant biological instability since the detected concentrations after 12 weeks 
are also within 15% of nominal calculated starting concentration.  An apparent slightly 
negative bias at both levels of the plasma calculated concentrations with respect to those 
calculated from DMSO are attributed to preparation bias in the sample pool prepared for 
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frozen stability storage, in addition to the freeze/thaw cycle incurred when the frozen 
plasma sample is removed from the freezer. 79  It is proposed that Cryoprecipitation of 
plasma proteins on freezing induce a loss of compound mass in addition to reducing volume.  
Since calculated concentrations remain within the acceptable window of ± 15% and the 
difference is very small, this factor is not considered to have a significant effect on 
quantification.  Additionally, the effect is further compensated by the use of calibration 
samples to construct a calibration curve for the extrapolation of sample data ensuring 
homogeneity of sample handling. 
 
 
Figure 6-6; Calculated concentrations (± sd) indicating stability of SARX in DMSO under ambient and plasma under frozen 
conditions at (upper) 300 ng/mL and (lower) 2.00 ng/mL 
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The absence of degradation or ex-vivo metabolism under the test conditions to greater than 
15% deviation from expected concentration indicates that the assay is suitable for use 
following storage under the test conditions for the period tested (Figure 6-6). 
Factors influencing specificity of the assay. 
Co-elution of interfering components present in variable concentrations in the test mixture 
has the potential to disrupt the assay.  Chromatographic interference is less significant due 
to the signal selectivity of precursor to product ion transition although co-elution can cause 
deterioration of peak shape and ionisation suppression in the mass spectrometer source. 194, 
117 The plasma sample aliquot is a complex mixture with a number of variable factors.  The 
origins of compounds present in the mixture may be endogenous biomolecules, xenobiotic 
compounds such as concomitant medications, or compounds added to the test sample as a 
result of sample removal, such as blood tube anticoagulant or agents used in the 
manufacture of the sampling vessels or analytical equipment.  The impact of variability in 
endogenous compounds on the assay was assessed by the analysis of control samples from 
different individuals by performing matrix variability studies as detailed above.  Red blood 
cell haemolysis to contaminate the plasma sample with cell debris was investigated and 
found to have no significant effect, as was the effect of collection of blood samples using 
sodium and lithium heparin and sodium citrate as anticoagulants which may alter the 
protein distribution in the plasma sample. 
The most likely concomitant medications; non steroidal anti-inflammatory drugs, caffeine 
and nicotine, female pharmaceutical hormones and enzyme inhibition study substrates 
were all added to plasma at therapeutic concentrations used to prepare test samples of 
SARX which was analysed to demonstrate specificity.  The assay evaluated was validated in 
accordance with regulatory requirements and used to support preclinical development 
studies and phase 1 (first into man) clinical trials. 
6.3 Surrogate Matrix Evaluation 
Control mouse, rat, rabbit, guinea pig and dog plasma were used to prepare test samples in 
each plasma type to support method validation within each species to comply with 
regulatory compliant sample analysis conducted in accordance with the OECD principles of 
Good Laboratory Practice 195 and adhering to the guidelines for bioanalytical method 
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validation issued by the US FDA 98 such that the validated assay was suitable for use in 
generating data to support non-clinical safety studies.  Samples were analysed at 4 levels, in 
replicates of 6, across the assay concentration range against a calibration curve prepared 
separately in plasma from the same species.  The results summarised graphically in Figure 
6-7 were satisfactory to support the use of the assay for regulatory preclinical studies since 
the precision and bias were within 15% (20% at lower limit of quantification). 
 
Figure 6-7; Plot of percentage recoveries (± %CV) of samples at concentrations across the assay range (n=6) for test 
samples in animal plasma analysed against a calibration curve from matrix matched animal plasma. 
To evaluate cross species calibration, the experiment was repeated by adding internal 
standard to each sample from the same batch of human plasma and using a human 
calibration line in each run to analyse replicates of 6 samples from each species at 4 
concentration levels.  The dataset obtained is summarised in Figure 6-8. 
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Figure 6-8; Plot of percentage recoveries (± %CV) of samples at concentrations across the assay range (n=6) for test 
samples in animal plasma analysed against a calibration curve prepared using human control plasma. 
While results from mouse, rat and rabbit gave concentrations with acceptable (within 
15%/20% at lower limit) precision and bias to support cross-verification, there was 
significant deviation in detected concentration in dog plasma as indicated by the difference 
in the lines above while precision data was <15% as expected.  A similar observation was 
made for the analysis of samples in guinea pig plasma.  This was due to a suspected species 
specific matrix effect where endogenous components more abundant in guinea pig and dog 
plasma co-elute with the analyte and either suppress or induce ionisation efficiency in the 
mass spectrometer giving rise to non-equivalence of the detector response. 
6.4 Ionisation Suppression Investigation 
To investigate the effect, the mass spectrometer was configured to operate under post 
column infusion conditions where a syringe pump was incorporated between the analytical 
column and the mass spectrometer to deliver a constant infusion of SARX in acetonitrile 
(100 ng/mL) at 5 µL/min(Figure 6-9).  LC-MS chromatograms were acquired at the SRM 
transition for SARX (604.2 Da  151.1 Da) so that induction or suppression is observed as 
broad peaks or troughs, respectively (Figure 6-10). 
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Figure 6-9; Schematic diagram of post column infusion experimental setup 
 
Figure 6-10; Identification of ionisation suppression trough originating from plasma matrix and proximity to analyte 
retention time. 
The post infusion chromatogram of blank plasma in Figure 6-11 shows a suppression zone at 
approximately 4.25 minutes which is not present in the blank chromatogram.  Injection of a 
sample containing SARX shows that this is close to the retention time of the analyte.  In an 
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attempt to identify the species responsible for the matrix effect, an aliquot of EDTA derived 
control human plasma was injected onto the system using the post column infusion method 
to obtain a suppression chromatogram.  The infusion pump was removed and the mass 
spectrometer was set to operate in full scan mode in quadrupole 1 with the collision cell and 
quadrupole 3 not operating.  The resulting chromatogram acquired mass spectra for all 
species eluting from the chromatography column with the aim of predicting the most 
abundant species present when zones of suppression are observed. 
 
Figure 6-11; Injections of control human plasma (a) post column infusion of SARX monitoring m/z = 604.2  151.1 Da (b) 
full scan mass spectrum.   
The experiment identified glycerophosphocholine species present at close to the retention 
time of the analyte (Figure 6-11).  These are endogenous compounds that form a 
component of cell membranes and are known to give rise to ionisation suppression in 
bioanalytical assays. 116  Another evident compound class present abundantly although 
separated from the analyte is polyethylene glycol.  A number of compounds containing 
ethylene glycol polymers may be found in bioanalytical samples residually from the 
manufacture of sampling equipment but also frequently present in study samples absorbed 
from intravenous formulations. 112, 196 
Additional full scan chromatograms were obtained for plasma from all test species and 
found to contain glycerophosphocholine species in a similar profile to those in human 
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plasma.  However, since subject variability has been demonstrated not to have a 
detrimental effect on quantification, it was postulated that the differential effect on 
ionisation was due to inter species variations in glycerophosphocholine distribution. 
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Figure 6-12; General chemistry of glycerophosphocholine species showing common fragmentation 
A method to identify glycerophosphocholine species was reported by Little et al. 116 to select 
species based upon the general fragmentation of the trimethylammonium-ethyl phosphate 
ion functional group represented in Figure 6-12.  The first quadropole of the triple 
quadropole mass spectrometer was set to full scan, with potential applied to the collision 
cell and the third quadropole set to m/z 184 Da.  The chromatogram was then acquired, 
generating a precursor ion scan of all species fragmenting to the indicative product of 184 
Da.  This methodology was applied and a blank plasma sample from each of the test species, 
together with 3 batches of control human plasma.  The precursor ion spectra were obtained 
at the analyte retention time for each animal species to predict variability in 
glycerophosphocholine species present.  The sum of spectra obtained from 4 to 5 minutes 
from each chromatogram is presented in Figure 6-13. 
These results suggest that the distribution of glycerophosphocholine species is variable 
between animal species but a more quantitative analysis with selected reaction monitoring 
for the individual glycerophosphocholines would be necessary to identify the extent of the 
variation.  While it is clear why ionisation suppression occurs to different extents due to the 
endogenous chemical diversity of different test species, non-equivalence of assay regression 
was due to variability in the peak area ratio response since these effects effect SARX and its 
6-deuterated internal standard to differing degrees. 189, 197  The variability was significant 
between human, dog and guinea pig and not significant between individuals within the 
same species. 
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Figure 6-13; Precursor ion spectra of all precursors of product ion mass 184 extracted from 4 to 5 minutes in 
chromatograms obtained by injection of aliquots of control plasma from animal test species (a) mouse (b) sheep (c) rat 
(d) dog (e) rabbit 
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6.5 Differential Ionisation Suppression of Drug and Stable Isotope Labelled 
Standard 
To quantitatively compare the impact of response non-equivalence between animal species 
without the  contribution of variability caused by preparation error variability, a fixed ratio 
spiking solution was prepared in DMSO containing SARX and [2H6]-SARX.  This method was 
described by Avery for the characterisation of suppression differences applied to analogue 
internal standards that were chromatographically resolved from the target analyte. 198  This 
was added to control plasma from human and animal test species to result in a plasma 
concentration of 1 and 10 ng/mL for SARX and [2H6]-SARX respectively.  These 
concentrations represent the lower limit of quantification of the assay where the bias 
caused by differential ionisation suppression is anticipated to be greatest.  A sample from 
each animal species together with human plasma from 5 different individuals were analysed 
in triplicate using the SRM method since preparation of a fixed ratio standard eliminated the 
contribution of preparation error to bias in peak area ratio.  Variation in peak area ratio 
using this test can only be effected by differences in signal response therefore comparative 
differences between samples are indicative of non equivalent calibration response. 
 
 
 
 
 
 
 
Figure 6-14; The detected peak area ratios (± SD; n=3) of SARX/[2H6]SARX obtained by analysing replicate plasma 
samples from animal species and 5 different human volunteers prepared using a fixed ratio solution of SARX/[2H6]SARX 
added to control 
The results in Figure 6-14 agree with observations made during cross-calibration 
experiments that the SARX/[2H6]-SARX ratio response differs due to species specific matrix 
effect.   
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6.6 Proposed Mechanisms for Differential Matrix Effects 
The mechanism by which lipid distribution may cause discriminative bias to absolute 
recovery of an analyte relative to isotopic composition may arise from factors affecting 
either of chromatographic or ionisation efficiency.  The species specific nature of 
phospholipid composition may consequently infer species specific bias. 
6.6.1 Chromatographic effects 
Substitution of protons for deuterium atoms are known to affect pKa and therefore 
chromatographic retention characteristics of the analyte. 202 Transient modification of 
stationary phase chemistry by association of lipophilic compounds which affect the 
retentive properties of the phase may consequently affect chromatographic retention of 
analytes.  The extent of this affect may differ between isotopologues with differing pKa 
values.  Since neither difference in chromatographic peak shape nor retention time was 
observed with respect to the observations shown in Figure 6-14, it is concluded that the 
influence does not arise from modification of the analytical separation. 
The chromatographic mechanism operating on the extraction column may also potentially 
be affected by stationary phase modification.  Here, the differential affect would influence 
the potential of the stationary phase to overcome association of the analyte with plasma 
proteins, its absolute retention and subsequent transfer to the analytical column.  If the 
affect was realised, a change in extraction column surface chemistry might bias the recovery 
ratio of analyte and deuterated standard. 
6.6.2 Mass spectrometer ionisation efficiency 
Differential ionisation suppression of an analyte and deuterated internal standard have 
been described,  101, 117, 197, 199, 200 with the explanations i) there is some chromatographic 
resolution between peaks so the two components co elute with slightly different 
suppressing species 197, 201 or ii) different bond lengths of the carbon-hydrogen/carbon-
deuterium bond give rise to different pKa values therefore extraction efficiency. 202  In this 
assay, the chromatographic resolution explanation is unlikely since there is complete 
overlap between peaks (Figure 6-4), and the differing extraction efficiencies may not 
completely explain the lack of proportionality giving rise for the relative difference of up to 
30% between some matrices with exactly the same proportions of standard added. 198  Co-
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eluting phospholipids are present in plasma at concentrations of approximately 300-400 µM 
for lysophosphotidylcholines, 128, 127 while the reported range of reported Critical Micellar 
Concentrations (CMCs) of lysophosphatidyl cholines (the point at which surfactant 
molecules are able to aggregate independently in water to form bilayers or spherical 
micelles) is between 7 µM to 7 mM.  The degree of hydrophobicity of the non polar aliphatic 
fatty acid chains is inversely proportionate to CMC since micelle formation is favoured, the 
wide range of physicochemical properties is biochemically important and also explains the 
broad region of chromatographic interference. 
 
Following plasma extraction and chromatographic retention, it is likely that many coeluting 
phospholipid species will exceed their CMCs and aggregate into micelles or mixed micelles 
on elution.  Following electrospray ionisation of the column eluent, it has been shown that 
micelles may enter the gas phase intact, 203 and that glycerophospholipid aggregates may 
enter the gas phase. 204  In the analytical technique of capillary electrophoresis, 205 the 
presence of micelles induced by adding surfactants such as sodium dodecyl sulphate to the 
capillary buffer at greater than CMC have been shown to act as a pseudo-stationary phase. 
This enables the retention and separation of lipophilic analytes or those insufficiently polar 
to achieve separation in capillary zone electrophoresis (Micellar ElectroKinetic Capillary 
Chromatography; MEKC). 206  The incorporation of naturally occurring micelles and co-
micelles of bile salts has been demonstrated to provide sufficient selectivity to achieve 
chiral separation. 207  Furthermore, recent work has incorporated phosphotidyl 
ethanolamine with polyethylene glycol to form the pseudostationary phase for MEKC. 208, 209 
 
It is proposed that the animal species differences in phospholipid molecular species gives 
rise to different compositions of glycerophospholipids co eluting with the analyte which 
form characteristic micelles.  Following column elution, an equilibrium exists between 
partitioning of the analyte and its deuterated analogue in and out of the micelle.  The 
micellar composition is complex and characteristic of animal species and influences the 
equilibrium of analyte/deuterated analyte in the micelle, resulting in differences 
in efficiency of ion ejection into the gas phase for mass spectrometry of each analyte ion.   
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6.7 SARX; Initial Work Conclusions 
The assay method described was evaluated and validated sufficiently to support regulated 
preclinical and clinical pharmacokinetic studies.  The potential to cross validate between 
calibration curves from different species was studied and failure of the process was 
investigated.  While the intra-species calibration was sufficient to support regulated 
analytical studies, the inter species calibration was not possible in all test species due to the 
effects of co-eluting endogenous species.  A fixed ratio standard spiking protocol was 
utilised as a comparative predictor of non equivalent ionisation of drug molecules and their 
stable isotope internal standards in samples of different matrix origins.  This is introduced 
for future application early in method development as a new tool to assess the potential of 
the assay to cross calibrate between matrices.   
Alternative mechanisms of differential extraction chemistry and discriminative pseudo-
stationary phase equilibrium biasing relative ionisation efficiency of a compound and its 
deuterium labelled analogue, each involving co-eluting species specific endogenous 
glycerophosphocholines are proposed to explain animal species specific differences in 
matrix effect.  Elucidation of the actual mechanism would require the repetition of the fixed 
ratio test derived from a common control plasma source and conducted in the presence of a 
continuous infusion of mixtures alternative specific probe choline phospholipids pre-
extraction column and post analytical column. 
To achieve the objective of interspecies calibration would require re-development of the 
method to increase extraction selectivity or chromatographic separation.  For the assay in 
question, this would be impractical to avoid impacting on the continuity of ongoing studies. 
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7      Phospholipid Distribution Investigation 
7.1 Introduction 
It was proposed that variation in ionisation efficiency between isotopically labelled drug 
molecules could be effected by differing phospholipid expression between animal species.  
Initial phospholipid profile screening described in section 6.4 suggested that expressed 
phospholipid species might differ between animal species.  Factors which may affect the 
distribution of phospholipids are complex and contradictory.  Phosphotidyl choline species 
in plasma are endogenous, being synthesised in the body while dietary phospholipids are 
metabolised by pancreatic phospholipase enzymes.  The compounds have been identified as 
effective biomarkers of disease, 126, 128 being expressed in response to biochemical stimulus, 
and contributing to biochemical pathways.  However, nutritional biomarker studies have 
also found that the proportion of unsaturated phosphotidyl choline and other phospholipid 
species correlate to the intake of dietary polyunsaturated fatty acids, 210-212 most abundantly 
-linolenic acid (Figure 7-1) so while phospholipids do not enter the blood stream directly 
from the diet, dietary influences may also contribute to this variability in expression. 
 
 
Figure 7-1; -linolenic acid (octadeca -9, 12, 15-trienoic acid) 
The dietary sensitivity of some phosphotidylcholines would suggest observed variability may 
be attributed to diet while validation of other molecular species as biomarkers of disease 
state suggests independence from dietary effects.  Since membranes can contain a 
thousand distinct molecular species of phospholipid 213 with diverse structural or 
biochemical functions, such apparently contradictory behaviour within a class may be 
understandable. 
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7.2 Distribution between Animal Species 
To characterise the distribution of phospholipids between animal species using an 
extraction method appropriate to the drug bioanalytical assays under investigation, an 
HPLC-ESI-MS/MS method using Turboflow extraction (described later in section 8.5) was 
applied monitoring all precursors of m/z = 184 Da.  Lithium heparinised plasma from 
individual animals across a variety of species obtained as pre-dose (ie, not drug exposed) 
samples from study animals following completion of study analysis and scheduled for 
disposal were analysed.  Overlaid phospholipid profiles on normalised scales from individual 
animals of dog, macaque and rat (12, 4 and 18 individual animals, respectively) are 
presented in Figure 7-2 against an equivalently scaled x axis of time in minutes. 
Comparison of these overlaid mass chromatograms support the observation of variability in 
distribution between species.  Since mass chromatograms have been presented on a 
normalised scale, the largest peak originating from the most abundantly expressed 
phospholipid is scaled to 100%.  Other peaks are plotted rationally which means that the 
proportionality of the expression of phospholipid peaks within a species group may be 
compared between species.  Peaks evident at 2.25 and 3.75 minutes are expressed 
proportionately strongly in samples from dog plasma and less in the other species, while in 
rat plasma, a peak with a retention time of 2.75 minutes is most predominant and in 
macaque, there is a large peak at 2.8 minutes.     Total extracted spectra from 120 to 240 
seconds of individual representative animals also support this as represented in Figure 7-3.  
In each spectrum, the major component is m/z = 497 Da, while in dog plasma, an ion is 
evident with almost equal intensity at m/z = 525 Da.  In rat and macaque plasma, the ion 
with second greatest intensity is at m/z = 521 Da although in rat plasma this ion is 
approximately 70% while in macaque plasma it is less than 50%.  A peak with m/z = 544 Da 
is present in each spectrum but with variable intensity while later in the spectra, a peak with 
m/z = 759 Da is present in dog and rat but close to the limit of detection in macaque. 
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Figure 7-2; Phospholipid profile (total ion count precursors of m/z 184 Da) of 3 different species of overlaid individual 
animals 
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Figure 7-3; Summed ions (precursors of m/z = 184 Da) from 120 to 240 seconds from a) dog b) rat c) macaque 
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1.78e7496.994
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468.834
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568.886
570.844
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571.941 758.460
760.888809.026
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m/z
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%
0
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DMD0214_64_032 156 (2.709) Cm (113:230) Parents of 184ES+ 
1.63e7496.963
496.378
482.853
520.898
526.007
544.852
570.712
776.974759.073
632.666 803.085
(a)                                                                                  (b)                                                                                   (c) 
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The total ion count mass chromatograms of these samples were used to populate m/z, and 
time versus ion intensity tables which was imported in to SIMCA P+ software (Umetrics, 
Umea, Sweden) and used to achieve multidimensional separation by multivariate statistical 
analysis.  The analysis is used to summarise a complex dataset with multiple variables by 
simplifying and summarising the key data from background noise and recognising 
differences between variables by mathematical projection.  The techniques used were 
principal component analysis (PCA), where the large number of possibly correlated variables 
described as eigenvectors in a data matrix is reduced to a small number of uncorrelated 
variables defined as the principal components of the dataset.  This is done by representing 
each sample together in a mathematically calculated multidimensional space (containing 
variables of retention time, mass and peak intensity) then calculating a new coordinate axis 
through which the data represented most variability in the model.  This coordinate axis is 
defined as the first principal component which describes the maximum variability in the 
dataset, a second axis orthogonal to the first is defined as the second principal component 
and representing the largest proportion of the remaining variability.  Multidimensional data 
can then be transformed and plotted on a 2 dimensional axis showing the maximum 
variability in the dataset and used to achieve pattern recognition to gain an overview of the 
variability features of the dataset.  In this case, the patterns may reveal differences between 
the phospholipid chemical species used to compile the eigenvector for each sample in 
multidimensional space.  Since many phospholipids are present in the sample which may 
not differ between species, these will not contribute to the calculation of the axes of the 
first principal components.  PCA analysis of the dataset is presented in Figure 7-4. 
The data shows separation between groups with one apparent outlier from both the 
macaque and rat group and while the range of each group on the graph was large, the 
separation between groups was clear; indicating discernable differences between 
endogenous phospholipids.  Representation by multivariate analysis is more able to 
elucidate differences between data than visual comparison of spectra as shown in Figure 7-2 
since non normalised peak intensities contribute to the differentiation as do minor 
components and those which may not be chromatographically resolved. 
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Figure 7-4; Separation of species classes by principal component analysis of phospholipid profile 
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The second method used is partial least squares regression (PLS), interchangeably called 
projections to latent structures used as discriminative analysis (PLS-DA).  It establishes 
principal components in the same way as PCA but projects the variables by linear regression 
into a new space where more of the variability of the dataset are represented (latent 
variables), therefore separations may be more discriminative and are used to construct 
predictive models that can be used to classify unknown samples.  PLS-DA analysis of the 
dataset in Figure 7-5 demonstrates greater separation between each group with fewer 
outliers. 
To further test the principal that differences occur between species specific phospholipid 
profiles, the method was further modified to extend and flatten the analytical gradient 
allowing greater time separation between molecular species and to achieve elution of more 
retentive less polar lipids.  To reduce the potential for accumulation of persistent 
phospholipid species and elution in later injections 107 an additional wash solvent cycle of 
propan-2-ol was incorporated on the quaternary loading pump, which necessitated a 
reduced flow rate to compensate for the higher back pressure of the more viscous solvent 
composition while the possibility of biasing the model by any accumulation was reduced by 
randomisation of samples.  A summary of the method is contained in Table 7-1. 
To investigate the predictive nature of the separation observed, further lithium heparinised 
plasma samples from monkey, dog, guinea pig and rat individual animals or separate pools 
were analysed by this method together with human lithium heparinised plasma samples 
from healthy volunteers from 2 different ethnic groups (African American and Caucasian 
origin).  A notable observation in the analysis is the low recovery detected from all guinea 
pig samples (Figure 7-6).   
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Figure 7-5; Separation of species classes by partial least squares regression discriminative analysis of phospholipid profile 
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Figure 7-6; Representative Total Ion Count (TIC) mass chromatograms from zero to five minutes of precursors of m/z = 184 Da showing (a) monkey, (b) guinea pig, (c) rat and (d) dog 
samples 
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This is consistent with previous research which found that while the most abundant 
mammalian phospholipids were phosphotidyl choline species, rodents and particularly 
guinea pigs express greater proportions of phosphotidyl ethanolamine. 214 
Modelling the data was automatically performed with SIMCA P+ software, using partial least 
squares regression (PLS) analysis and the key PLS components were extracted to identify 
latent variables represented by the 9 components in Figure 7-7.  Here, the results of internal 
cross validation of the predictive model using each component are used to derive 
cumulative Q2 values (blue bars) which are an estimate of the predictive separating power 
of the component selected in the model.  Cumulative R2Y values (green bars) which are 
plotted on the same scale are a measure of the degree of expression of the component 
within the dataset. 215  The contributions of individual datapoints to the model are 
represented in the loadings plot shown in Figure 7-8; describing the degree of correlation of 
the PLS component (mass transition/ chromatographic retention time) with the original 
variable (species) where positive values of towards (+1) indicate a positive response to the 
separation and negative values towards (-1) indicate no contribution.  The ‘VIP list’ as 
defined by SIMCA software containing the most important variables (precursor ion 
mass/chromatographic retention time) is presented in Table 7-2 (top 50 values).  The values 
are calculated by correlation with X (the other terms) and Y (the projection) and assigned a 
confidence interval using a jacknife method (data is resampled to calculate the statistic 
using subsets where individual observations are sequentially excluded, reducing bias).   
Representation of this dataset on a 2 dimensional eliptical plot (component 1 plotted 
against component 2) shows separate grouping of rat, dog and guinea pig samples, while 
other species show significant overlap. 
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Loading Mobile Phase Pump 
(Pump A) 
Analytical Mobile Phase  Pump 
(Pump B) 
Valve positions and flow path 
Time 
(sec) 
Flow  
(mL/min) 
% B % C Valve 
1* 
Flow 
(mL/min) 
% 
B 
 Valve 
2* 
 
0 1.25 0 0 LOAD 0.75 55 Step LOAD 
 
45 1.25 0 0 ELUTE 0.75 55 Step LOAD 
 
60 1.25 0 0 ELUTE 0.75 55 Step ELUTE 
 
75 1.25 50 0 ELUTE 0.75 95 Ramp ELUTE 
375 1.25 0 50 ELUTE 0.75 95 Step ELUTE 
735 1.25 0 50 LOAD 0.75 95 Step LOAD 
 
750 1.00 0 100 ELUTE 0.75 95 Ramp ELUTE 
 
765 1.00 0 100 ELUTE 0.75 95 Step LOAD 
 
780 1.00 0 100 LOAD 0.75 95 Step LOAD 
 
795 1.00 0 100 ELUTE 0.75 55 Step LOAD 
 
810 1.00 0 100 LOAD 0.75 55 Step LOAD  
840 1.25 0 0 LOAD 0.75 55 Step LOAD 
Table 7-1; Total phospholipid separation chromatographic sequence 
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Component Number 
Figure 7-7; Multiple species phospholipids separation; selection of partial least squares component 
 
Figure 7-8; Multiple species phospholipids separation; contribution of individual data points to the separation model 
(loadings plot) 
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Figure 7-9; 2-dimensional elliptical plot of components 1 and 2 showing all species investigated 
Better visualisation of separation of each group can be achieved in 3 dimensions by 
incorporating a third axis of an alternative PLS component as demonstrated in Figure 7-10 to 
Figure 7-14.  It can be seen that within 3 dimensions, by manipulating the variable plotted 
on the z axis and rotating the plot, separation may be visually achieved for each component 
or for several distinct components from the dataset.  Manipulation of the first, second and 
third PLS component can be used to achieve separation of rat, dog and guinea pig from 
other groups (Figure 7-10 to Figure 7-12) while manipulation of the first and second 
component with the fourth enable separation of macaque monkey group from the rest 
(Figure 7-13) and separation of the first and second with the fifth component (Figure 7-14) 
separate the human groups from animal groups. 
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Figure 7-10; 3-dimensional elliptical plot of components 1, 2 and 3 showing separation of the cluster of guinea pig 
samples 
 
Figure 7-11; 3 dimensional plot of PLS components 1, 2 and 3 showing separation of the cluster of dog samples 
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Figure 7-12; 3 dimensional plot of PLS components 1, 2 and 3 showing separation of the cluster of rat samples 
 
Figure 7-13; 3 dimensional plot of PLS components 1, 2 and 4 showing separation of the cluster of monkey samples 
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Figure 7-14; 3 dimensional plot of PLS components 1, 2 and 5 showing separation of the cluster of individual human 
samples of 2 different ethnic origins 
 
Precursor ion / 
Retention time 
(seconds) 
Variable 
Importance 
Confidence 
Interval  
  
Precursor ion / 
Retention time 
(seconds) 
Variable 
Importance 
Confidence 
Interval 
1 793/376 1.91 1.44 
 
26 571.4/164 1.37 0.595 
2 607.5/345 1.81 1.12 
 
27 823.9/583 1.37 0.632 
3 520.3/133 1.72 0.322 
 
28 777/642 1.37 0.438 
4 753.6/334 1.62 1.05 
 
29 551.5/231 1.36 0.485 
5 793.8/508 1.61 1.32 
 
30 819.8/419 1.35 1.02 
6 759.1/377 1.60 1.15 
 
31 784.5/493 1.34 0.881 
7 510.4/159 1.58 1.09 
 
32 548.8/171 1.34 0.781 
8 601.5/90 1.58 1.17 
 
33 674.7/338 1.33 1.29 
9 512.4/188 1.57 1.33 
 
34 522.7/153 1.33 0.645 
10 765.9/462 1.53 1.05 
 
35 728.9/409 1.32 1.02 
11 787.8/597 1.50 1.20 
 
36 802.1/382 1.32 0.547 
12 538.3/205 1.50 0.758 
 
37 471.5/128 1.31 0.572 
13 690.7/417 1.49 0.914 
 
38 823/529 1.30 1.23 
14 703.9/393 1.49 1.15 
 
39 521.4/153 1.30 0.910 
15 771.7/558 1.47 1.11 
 
40 585.9/101 1.30 1.06 
16 574.4/189 1.45 1.22 
 
41 545.4/154 1.29 0.702 
17 799.8/391 1.45 1.04 
 
42 559.2/91 1.29 0.791 
18 565.5/303 1.44 0.785 
 
43 763.1/578 1.28 0.841 
19 773.8/553 1.42 0.719 
 
44 623.6/257 1.28 0.959 
20 827.1/385 1.42 0.366 
 
45 788.4/608 1.28 0.950 
21 568.3/103 1.41 1.00 
 
46 799/524 1.27 0.822 
22 544.6/133 1.41 0.566 
 
47 855.1/430 1.27 0.969 
23 587.2/106 1.41 1.17 
 
48 609.7/404 1.27 0.912 
24 481.5/183 1.40 1.18 
 
49 702.8/393 1.27 0.915 
25 567.4/102 1.39 0.834 
 
50 807/441 1.26 0.940 
Table 7-2; List of the most important variables (precursor/retention time) 
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7.2.1 Validation of the Separation Model 
To validate the model described by using an external test dataset, a series of plasma 
samples were analysed for predictive comparison with the model dataset containing n = 2 
unique samples from each of the test groups.  These samples were concurrently analysed 
but did not contribute to the separation model.  As the graphs in Figure 7-10 to Figure 7-14 
demonstrate, while each component sample type may be visually separated in 2 or 3 
dimensions from the entire group, a common model would require separation in more than 
3 dimensions.  Figure 7-7 shows that the SIMCA prediction identified 9 PLS components to 
represent separation of the entire dataset.  To demonstrate the separation of 2 plasma 
types (rat and dog) which can be visually separated on a plot of PLS components 1 and 2, 
the test set was compared to the training by plotting each set of data on super imposable 
elliptical plots (Figure 7-15).  Test samples from rat and dog show the same orientation on 
the plot in both training and test datasets.    
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Figure 7-15; Super imposable elliptical plots of PLS component 1 against PLS component 2 showing the same orientation of external test samples 
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Using SIMCA software it was possible to use the entire 9 PLS components to predict the 
identity of the external samples unknown to the PLS model.  This is done by comparing data 
from each test sample to each specified group of variables (species) using the model 
algorithm to present a numerical indication of probability that the test data point belongs to 
each group.  The results of this test are reported in Table 7-3.  The data shows a correct 
prediction of dog, guinea pig and rat samples with scores greater than 0.6 and significantly 
greater than scoring from other groups and indicated as a good fit to the model while for 
the primate samples from two different human ethnic groups and monkey samples, the 
identities are suggested but scores show insufficient magnitude or clear separation from 
other groups.  A species difference in phospholipid distribution is demonstrated while 
accurate prediction would require the construction of a model with fewer variables which 
could be fitted more discriminatively. 
Table 7-3; SIMCA PLS data external dataset prediction 
7.3 Variability in Phospholipids from Human Subjects 
7.3.1 Dietary State 
To investigate the influence of dietary fat state on phospholipid distribution, lithium 
heparinised plasma from n = 18 individual male and female donors from 3 different ethnic 
groups following overnight fasting and n = 18 donors with visibly lipemic plasma were 
analysed by the method described in chapter 8 monitoring precursors of m/z = 184 Da.  
Lipemic plasma is typically milky in colour and turgid due to elevated concentrations of 
ID Actual ID 
Predicted probability 
Predicted ID 
Dog Guinea Pig Human A Human B Monkey Rat 
1 Dog 0.697 0.242 0.0262 0.173 -0.0856 -0.0522 Dog 
2 Dog 0.769 0.116 0.167 0.035 -0.0724 -0.0146 Dog 
3 Guinea Pig -0.0318 0.674 -0.0113 0.124 0.0872 0.158 Guinea Pig 
4 Guinea Pig -0.131 0.759 -0.075 0.0321 0.180 0.235 Guinea Pig 
5 Human A 0.167 0.0981 0.211 0.409 -0.0363 0.152 
 
6 Human A 0.191 -0.0812 0.301 0.421 0.0518 0.117 
 
7 Human B -0.148 0.203 0.264 0.632 -0.0453 0.0942 (Human B) 
8 Human B 0.0170 -0.0578 0.127 0.544 0.250 0.119 (Human B) 
9 Monkey -0.0914 0.184 -0.0898 0.142 0.305 0.550 
 
10 Monkey -0.0484 0.250 -0.123 0.0188 0.538 0.365 (Monkey) 
11 Rat -0.0872 -0.0303 -0.0557 0.131 0.390 0.652 Rat 
12 Rat -0.0917 0.102 0.0113 -0.0197 0.263 0.735 Rat 
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circulating lipids particularly triglycerides at concentrations greater than 800 mg/dL, 216  the 
normal triglyceride concentration range is 40 to 200 mg/dL. 8   Elevation usually occurs 
temporarily following meals (alimentary lipemia) before clearance to unesterified fatty acids 
217 but also occurs chronically as a result of some medical conditions such as diabetes. 
The profiles obtained indicate some visible differences as demonstrated in Figure 7-16.  The 
ion transition selected as the most clearly differing peak at 2.93 minutes (560.8 184 Da) 
was extracted and used to construct an overlaid mass chromatogram and presented in 
Figure 7-17 (constructed using from samples from Caucasian individuals to eliminate ethnic 
differences).  The maximum intensity of the mass chromatogram for this ion transition is 
approximately 50% greater in lipemic than fasted individuals. 
 
Figure 7-16; Overlaid phospholipid profile in plasma samples from fasted and lipemic volunteers of all ethnic groups 
(n=18) 
 
Figure 7-17; Overlaid 560.8>184 transition mass chromatogram in plasma samples from fasted and lipemic Caucasian 
volunteers (n=6) 
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The results of PLS-DA analysis of the derived data are presented in Figure 7-18.  The data 
shows a separation between datasets, which may be an effect of incorporation of dietary 
fatty acids.  Since clinical pharmacokinetic studies are conducted across day long time 
periods incorporating daily food intake and further studies are conducted to compare the 
bioequivalence of drug exposure in fed and fasted volunteers to characterise food effects, 
the potential variability in phospholipid distribution in response to diet is demonstrated. 
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Figure 7-18; Separation of lipemic and fasted groups by PLS regression 
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7.3.2 Variability in Phospholipids from Different Ethnic Groups 
In assessing the effect of diversity in human population, a definable determinant of diversity 
is subject ethnicity.  Reported studies have identified differences in the distribution of 
various lipid molecular species among different populations 218- 220 relating their 
observations to nutritional or epidemiological investigations particularly in relation to 
cardiovascular health.  Previous observations of the effect of dietary lipids on phospholipid 
distribution might indicate that extrinsic cultural or regional factors may influence this; 
however intrinsic genetic factors are also associated with metabolic differences. 221  Ethnic 
differences are additionally associated with predisposition to autoimmune conditions 
effecting endogenous phospholipids. 
The importance of ethnic group as a factor influencing pharmacokinetic parameters is 
acknowledged by the publication of ICH/EMEA regulatory guidance on the evaluation of 
ethnic factors on drug safety and efficacy. 222   Characterisation of pharmacokinetics for new 
drug registration must be conducted in populations appropriate to the geographical region 
when the new drug is to be registered.  This is notably the case for drugs developed in early 
clinical studies in Europe and North America involving Caucasian, Hispanic and African 
American volunteers and registered for use in Japan for prescription to Japanese patients.  
Such pharmacokinetic bridging studies intended to demonstrate the validity of extrapolation 
of clinical study data regarding safety and efficacy will also be conducted reciprocally where 
drugs registered in Europe and North America have been extensively developed in China or 
India.  The guidance describes that intrinsic and extrinsic factors may influence the ethnic 
effect on pharmacokinetics so the ethnicity of the volunteers is as significant as the 
geographical location of the study site.  While the FDA also provides guidance on the 
identification of the ethnic origin of clinical trial subjects, 223 no consideration is yet given to 
the demographics of control matrix donors. 
To investigate the potential ethnic difference between phospholipids, lithium heparinised 
plasma samples from n = 12 male volunteers (fed and fasted) of Caucasian, Hispanic and 
African American origin were analysed using the initial method described in 7.3.1.  The 
typical profiles obtained were indistinguishable by visual comparison as shown in Figure 
7-19.  The summed precursor ion mass spectra of representative individuals represented in  
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Figure 7-20 does not show the distinguishable differences seen in the inter species 
comparisons seen in Figure 7-3.  The data set was subjected to PLS analysis and separation 
observed (Figure 7-21).  
 
Figure 7-19; Phospholipid profile (total ion count precursors of m/z 184 Da) of (a) African American, (b) Hispanic and (c) 
Caucasian individuals (n = 12, overlaid) 
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Figure 7-20; Summed ions approximately 120 to 240 seconds from (a) African American, (b) Hispanic and (c) Caucasian 
individuals 
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759.651 628.492 777.186 
      (b)   
 496.858 
494.836 
468.206 
520.942 
522.894 
544.876 
546.058 
759.121 630.731 735.154 777.060 
      (c)   
 496.957 
496.278 
468.769 
520.978 
522.858 
524.871 
546.788 
776.686 759.458 586.835 809.143 
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Figure 7-21; Separation of phospholipid profiles of individuals from 3 ethnic groups by PLS regression (lipemic samples)
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Following observation of this separation and in consideration of the implementation of the 
EMEA regulatory guidance 222 by Japanese regulatory authorities, it was proposed to repeat 
the analysis incorporating samples from Japanese volunteers.  The experiments were 
performed using the expanded separation method described in Table 7-1 by analysing n = 6 
K2EDTA derived plasma samples obtained from male volunteers of Japanese origin and male 
and female volunteers of African American and Caucasian origin.  The PLS analysis is 
presented in Figure 7-22.  The separation appears to indicate a greater difference between 
Japanese individuals and the remaining groups.  This is attributed in part to geographical 
difference between donors, the Japanese donors living in Kawagoe, Japan while all other 
samples were obtained from Virginia, USA.   
These differences may contribute to extrinsic differences between samples, particularly 
dietary, but as such are illustrative of the additional diversity of sample origins from 
multinational sources.  The investigation into ethnic differences with a limited available 
dataset suggested that it was possible to differentiate between groups using PLS regression; 
however, the model obtained was not predictive. 
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Figure 7-22; Separation of phospholipid profiles of individuals from individuals of Japanese Male, Caucasian Male and Female and African American Male and Female origin by PLS 
regression 
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7.4 Phospholipid Investigation Conclusions 
The distribution of membrane phospholipids in animal and human plasma samples was 
investigated following the development of a Turboflow LC-MS/MS method and application 
together with a mass spectrometric analysis method with selectivity for the detection of the 
most abundant group of membrane phospholipids (phosphotidylcholine and 
sphingomyelin).  Data was analysed using partial least squares regression discriminative 
analysis, and separation was demonstrated between plasma from groups of individual 
animals indicating differences in the distribution of membrane phospholipids between 
species.  The observations were verified by the analysis of ‘unknown’ samples which were 
correctly identified by superimposing plots and by a probability calculation conducted using 
SIMCA software. 
Application of the experiments to plasma samples from individuals of different human 
ethnic groups showed separation but no predictive data verification was obtained.  Samples 
from fasted individuals were compared with lipemic plasma samples and differences noted 
both by mass chromatogram comparison and by PLS-DA analysis.  The differences observed 
in the distribution of phospholipids circulating in sources of test plasma between species 
support the proposal that inter-species differences in phospholipid distribution are 
responsible for the alternative signal responses from analyte and deuterated analogue 
observed in chapter 6.  
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8 Results and Discussion – SARY; Preliminary Work 
8.1 Introduction 
X-tert-butylurea, (subsequently referred to as SARY; Figure 8-1) is new chemical entity in 
pharmaceutical development by Sanofi-Aventis. 224   
O
NH
CH3
CH3 CH3
R
 
Figure 8-1; Partial structure of SARY 
SARY has a molecular weight = 539.4 and a pKa value of 1.2.  The calculated log D of the 
compound (Figure 8-2) shows that its distribution coefficient is largely unaffected by pH 
within the working range of most silica based HPLC columns without loss of robustness 
caused by column damage. 
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Figure 8-2; Relationship between logD and pH for SARY 
A stable isotope analogue was available for use prepared by substitution of the 1H hydrogen 
atoms for 2H deuterium on all three methyl groups in the tert-butyl group.  This resulted in a 
heavy labelled compound with a molecular mass of 548.4.  The difference of 9 mass units 
pH 
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from the unlabelled analyte was sufficient to prevent cross-talk in mass spectrometer 
response as a result of the isotopic distribution of the two chlorine atoms in the structure.  
The nonadeuterated analogue was therefore sufficiently discriminative for use as an internal 
standard for discriminative mass chromatogram quantification. 
8.2 Sample Preparation and Preliminary Analytical Procedure 
To facilitate method optimisation, analytical samples were prepared within the 
concentration range appropriate to the predicted range of study sample concentrations 
calculated by the pharmacokineticist at Sanofi-Aventis.  A preliminary analytical system was 
assembled as described in section 6.2 with chromatographic conditions subjected to 
optimisation. 
Preparation of standard solutions 
Stock standard solutions (500 µg/mL) were prepared in DMSO X-tert-butylurea and stored 
under ambient conditions.  The stock standards were further diluted with DMSO to yield 
standard solutions of 2, 5, 10, 25, 50, 100, 250 µg/mL.  Internal standard solution of X-tert-
nonadeuterobutylurea (20 µg/mL) was prepared in DMSO. 
Preparation of human plasma analytical samples 
Plasma calibration samples were prepared by mixing control human plasma (4.95 mL) with 
an aliquot (50 L) of the SARY standard solutions to give concentrations of 20, 50, 100, 250, 
500, 1000, 2500, 5000 ng/mL.  Analytical samples were processed immediately or stored 
frozen (-20  5C).  A second set of validation test standard samples were prepared in 
control human plasma at 20, 50, 500, 5000 ng/mL.  Working internal standard sample (67 
ng/mL) was prepared by mixing internal standard solution with K+EDTA derived control 
human plasma. 
Preparation of samples for analysis 
Each plasma sample (50 L) was added to a 96 deep well polypropylene microtitre plate and 
mixed with 150 L of internal standard ([2H9]-SARY in plasma).  The plate was sealed with a 
pierceable square well polypropylene sealing cap and the plate mixed for 10 minutes using a 
microtitre plate mixed (Micromix 5, Llanberis, UK) with a frequency alternating between 20 
and 25 Hz set to maximum amplitude, then centrifuged 4000 rpm (2800 rcf) under ambient 
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conditions for 10 minutes on an Eppendorf 5810R centrifuge (Eppendorf, Cambridge) to 
enable maximum contact between small volume components.  The samples were mixed for 
10 minutes on a vortex plate mixer and then centrifuged for a further 10 minutes (4000 
rpm; ambient temperature) to remove suspended particulates from the plasma sample to 
prevent needle blocking on the autosampler or transfer of particulates to the extraction 
column frits.  A mass spectrometry procedure was defined by infusing a standard solution 
prepared in acetonitrile via syringe pump at approximately 5 µL/sec directly into the 
instrument and tuning acquisition parameters to obtain the values listed in the Table 6-2 
operated using electrospray ionisation.  The precursor and product ion mass spectra 
obtained are shown in Figure 8-3 and Figure 8-4.  A precursor ion is shown at m/z = 539 Da.  
Fragmentation of the peak at m/z = 539 Da reveals 4 main product ions.  The greatest 
intensity product ion of m/z = 440 Da was selected as the product ion for use in the MS/MS 
transition to generate a signal for quantitative chromatographic analysis ie, m/z = 539>440 
Da. 
 
Figure 8-3; Mass spectrum of SARY 
 
m/z 
150 200 250 300 350 400 450 500 550 600 650 
% 
0 
100   1.34e8 156.710 
158.883 
539.207 159.139 
224.082 
403.187 
319.068 
541.124 
542.211 
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Figure 8-4; Product ion mass spectrum of SARY 
 
8.3 Extraction Column Recovery 
8.3.1 Drug Recovery 
To maximise the recovery of drug from unmodified plasma using a simplified column 
switching method, recovery was assessed by loading a 0.5 mm i.d. Turboflow column for 30 
seconds at 1.25 ml/min with 20 mM pH 3.0 ammonium formate and injecting an aliquot (50 
µL) of control human plasma into the flow.  Following elution of bulk macromolecules 
through the column, flow was reversed and an elution mobile phase at 0.75 mL/min applied 
containing a variable amount of organic modifier to assess recovery.  The eluent was split 
with a ratio of approximately 1:1 v/v and directed to the mass spectrometer where the 
transition m/z = 539.1 > 440 Da was monitored.  The experimental sequence was repeated 
in replicates of 3 using both methanol and acetonitrile as the organic component and C2, 
C8, C18 and Cyclone (reversed phase polymer) extraction columns were tested.  The results 
of the recovery experiments in each column using methanol and acetonitrile in the elution 
mobile phase are represented in Figure 8-5 and Figure 8-6. 
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Experimental Method 
Parameters 
MS Acquire time 5 minutes 
Type Multiple Reaction Monitoring 
Ion Mode ESI +ve 
Channel 1 Precursor m/z 539.1 Da 
Product m/z 440 Da 
Span 0 
Dwell (sec) 0.3 
Delay (sec) 0.03 
Channel 2 Precursor m/z 548.1 Da 
Product m/z 440 Da 
Span 0 
Dwell (sec) 0.3 
Delay (sec) 0.03 
ESI Source Parameters Source Temperature (ºC) 120 
Desolvation Temperature (ºC) 350 
Collision Gas Pressure (MBar) 1 x 10-3 
Cone Gas Flow (L/h) 55 
Desolvation Gas (L/h) 900 
Cone Voltage (V) 50 
Capiliary Voltage (kV) 1 
RF Lens 1 (V) 20 
Aperture (V) 1 
RF Lens 2 (V) 0 
Typical Analyser 
Parameters 
LM1 Resolution  14 
LM2 Resolution 14 
Ion Energy 1 0.5 
Entrance 0 
Collision 32 
Exit 1.0 
LM1 Resolution 14 
LM2 Resolution 14 
Ion Energy 1 0.8 
Multiplier 650 
Table 8-1; Mass spectrometer operating parameters 
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Figure 8-5; Recovery of SARY from Turboflow columns using variable methanol content; peak area (±sd) 
 
Figure 8-6; Recovery of SARY from Turboflow columns using variable acetonitrile content; peak area (±sd) 
The data shows that recovery increased proportionately with solvent content of the elution 
mobile phase with the exception of the C2 column in the presence of high proportions of 
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accessibility of surface silanol activity induced the contribution of a hydrophilic interaction 
retention mechanism in the presence of a highly organic mobile phase.  While optimum 
recovery via both elution solvents was obtained using a C8 column, peak areas were greater 
by acetonitrile rather than methanol.   
8.3.2 Phospholipid Recovery 
Using the methodology described in 8.3.1, the experiments were repeated to monitor the 
recovery of 4 probe phospholipid species.  The species monitored were m/z= 496>184, 
704>184, 761>184 and 787>184 Da.  These experiments were conducted using acetonitrile 
as the elution mobile phase as selected above and all experiments were conducted in 
replicates of 3.  The results of the experiments are presented in Figure 8-7 to Figure 8-12. 
 
Figure 8-7; Recovery of phospholipid 704>184 from Turboflow columns using variable acetonitrile content 
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Figure 8-8; Recovery of phospholipid 496>184 from Turboflow columns using variable acetonitrile content 
 
 
Figure 8-9; Recovery of phospholipid 761>184 from Turboflow columns using variable acetonitrile content 
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Figure 8-10; Recovery of phospholipid 787>184 from Turboflow columns using variable acetonitrile content 
 
Figure 8-11; Recovery of total phospholipids showing peak area (±sd) from Turboflow columns using variable acetonitrile 
content 
The data shows a variation in the profile of phospholipid recovery of each species on 
different columns with acetonitrile.  Recovery generally increases proportionately with 
acetonitrile content of the elution mobile phase but was frequently found to reach a 
maxima where exceeding acetonitrile content reduced recovery.  This may again be the 
result of a change in retention mechanism under a less polar environment.  Overall, the C2 
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column was shown to recover a greater proportion of phospholipids than other phases with 
the exception of the species m/z = 496>184 Da which showed greater recovery and 
consequently more potential for contamination from the C18 column.  Analysis of recovery 
data in 8.3.1 indicate that C8 columns gave the highest recovery of SARY at elution 
compositions greater than approximately 65% acetonitrile.  The phospholipid recovery data 
was therefore reanalysed looking specifically at C8 column recovery with acetonitrile.  The 
data presented in Figure 8-12 shows that while there is some proportionality with elution 
mobile phase organic composition, recovery of total phospholipid is consistent across the 
profile.  This is reinforced by comparison of total phospholipid recoveries between columns 
in Figure 8-11 which show a relatively flatter profile across the range of elution gradient 
between 10 and 90%. 
 
Figure 8-12; Recovery of individual probe and total phospholipids from C8 Turboflow columns using variable acetonitrile 
content 
8.3.3 Elution Condition Selection 
From the data obtained in 8.3.1 , C8 Turboflow extraction was selected as the optimum 
phase for the extraction and recovery of SARY.  While C18 columns recovered less total 
phospholipid, recovery of SARY was less and required higher proportions of acetonitrile in 
the mobile phase limiting chromatographic retention which would be possible on a second 
analytical column.  The actual recovery behaviour of SARY and total phospholipid from C8 
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column are compared in Figure 8-13 (phospholipid areas were reduced 1000-fold to enable 
representation on the same graph area).  The comparison suggests that an acetonitrile 
composition greater than 70%, SARY recovery will be high while total phospholipid recovery 
will be moderate.  This composition does not demonstrate either total recovery of SARY 
since this would require greater proportion of acetonitrile in the elution phase which would 
inhibit HPLC retention in the secondary column, neither does it demonstrate the absence of 
phospholipid recovery since by consideration of all other phospholipid recovery data shown 
in Figure 8-7 to Figure 8-11, it is not possible to recover zero phospholipids using extraction 
and mobile phase column combinations alone.   The data presented indicates that the 
column and mobile phase selection gives an optimum condition of relatively high SARY 
recovery with relatively low phospholipid recovery from a single column switching 
extraction method. 
 
Figure 8-13; Recovery of SARY and total phospholipids (x 10-5) from C8 Turboflow columns using variable acetonitrile 
content mean of 3 determinations (±sd) 
Examination of Figure 8-13 at low acetonitrile composition identifies the composition of 
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phospholipid recovery is approximately 20% of that at the intended elution composition.  A 
<20% acetonitrile wash may therefore be applied to the Turboflow column after loading to 
further clean up phospholipids without removing extracted SARY.  When SARY is 
subsequently eluted to the analytical column, the proportion of phospholipid eluted may be 
resolved from the peak chromatographically. 
8.4 Chromatographic Separation 
Chromatographic retention of SARY and 5 probe phospholipids was first assessed by eluting 
from the Turboflow column at 0.75 mL/min and chromatographing the eluent under 
isocratic conditions of the elution composition through a Gemini C18 50 x 3.0 mm i.d. 
analytical column (Phenomenex, Macclesfield).  The retention times of the SARY peak and 
the probe phospholipids monitored in 8.3.2 and their peak areas (SARY x 105) are shown in 
Figure 8-14 and Figure 8-15.  At 65% the difference in retention times between SARY and the 
probe phospholipids are sufficient to enable peak resolution of the target analyte from 
phospholipid interferences.  This composition also corresponds to relatively low 
phospholipid recovery.   
 
Figure 8-14; Plot of peak area SARY and 5 probe phospholipids eluted from a C8 Turboflow column to a C18 analytical 
column 
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Figure 8-15; Plot of peak area SARY and 5 probe phospholipids eluted from a C8 Turboflow column to a C18 analytical 
column 
Monitoring the total ion count of probe phospholipids, the mass chromatogram represented 
in Figure 8-16 demonstrates resolution of SARY from phospholipid interferences where in 
trace (a) at the selected transition for SARY, a peak is visible with a retention time of 3.38 
and in the total ion count (TIC) trace of SARY and the probe phospholipids (b) there are no 
other peaks apparent at the SARY retention time.  Furthermore, the mass chromatograms in 
Figure 8-17 obtained by injecting 50 µL of 6 batches of control human plasma which show 
(a) all precursors of m/z 184 and (b) full scan total ion count reveal that there is no 
detectable significant interferences at the same retention time as the drug peak. 
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Figure 8-16; Mass chromatograms showing (a) selected transition for SARY from m/z 539.1>440 (b) total ion 
chromatogram of probe phospholipids and SARY 
 
 
Figure 8-17; Sum of total ion chromatograms (n=6 plasma batches) monitoring (a) SARY and all precursors of m/z 184 Da 
and (b) Full scan mass chromatogram showing all detectable species. 
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8.5 Method Optimisation/Validation  
Chromatographic procedure 
The chromatographic procedure tabulated in Table 6-1 was constructed based upon the 
isocratic elution of SARY from a C8 Turboflow column with 65% acetonitrile and pH3.0 
ammonium formate (20 mM).  The use of a 0.5mm i.d. Turboflow column enabled elution of 
the analyte and transfer onto the analytical column in a smaller volume of mobile phase 
than used previously this was proven during method development to conserve peak shape 
as well as contributing to a reduction in solvent use. 
Results and discussion 
An LC-MS/MS mass chromatogram was generated from the selected reaction monitoring 
trace of 539.1 Da  440 Da for SARY and 548.1 Da  440 Da for [2H9]-SARY as shown in 
Figure 8-18 at the lower limit of quantification of the assay.    
 
Figure 8-18; Representative product ion chromatogram of control human plasma spiked with SARY (20 ng/mL) and [
2
H9]-
SARY (a) 548.1 Da  440 Da (b) 539.1 Da  440 Da 
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Figure 8-19; Representative SRM chromatogram of control human plasma spiked with SARY (20 ng/mL) (a) 539.1 Da  
440 Da (b) 548.1 Da  440 Da 
 
Figure 8-20; Representative SRM chromatogram of control human plasma (a) 539.1 Da  440 Da (b) 548.1 Da  440 Da 
 132 
 
 
Loading Mobile Phase 
(Pump A) 
Analytical Mobile Phase  
(Pump B) 
Valve positions and flow path Description 
Time 
(min) 
Flow  
(mL/min) 
% 
B 
Valve 
1* 
Flow 
(mL/min) 
% B  Valve 2*   
0.00 1.25 0 LOAD 0.75 65 Step LOAD 
 
Sample is injected in to the flow of mobile 
phase from the loading pump (A) and 
pumped through the Turboflow column.  
SARY is retained within by the C8 sorbent and 
unretained macromolecules are flow 
unretained to waste. 
0.75 1.25 0 LOAD 0.75 65 Step ELUTE  
 
 
The direction of flow from the loading pump 
through the Turboflow column is reversed by 
switching valve 1 while retaining aqueous 
100% conditions, flushing proteins and 
particulates trapped on the head of the 
column to waste. 
1.25 1.25 10 LOAD 0.75 65 Step ELUTE 10% acetonitrile is introduced from the 
loading pump to wash lipid material from the 
Turboflow column without elution of SARY. 
1.75 1.25 0 ELUTE 0.75 65 Step ELUTE 
 
The elution pump (B) containing 65% 
acetonitrile is brought in line with the 
Turboflow column which is in turn brought in 
line with the analytical column by switching 
valve 2.  SARY is eluted and transferred from 
the head of the Turboflow column and begins 
chromatographic separation through the 
analytical column. 
2.75 1.25 90 LOAD 0.75 65 Step LOAD 
 
 
HPLC column is isolated from the Turboflow 
column by switching valve 2 while SARY is 
chromatographed through the analytical 
columns and 90% acetonitrile is pumped 
through the Turboflow column to clean up 
retained molecules in preparation for the 
next injection.  
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Loading Mobile Phase 
(Pump A) 
Analytical Mobile Phase  
(Pump B) 
Valve positions and flow path Description 
4.75 1.25 10 LOAD 0.75 90 Ramp LOAD 
 
 
Following elution of SARY a gradient is 
applied to 90% acetonitrile from the elution 
pump (B) to elute any strongly retained 
components from the analytical column to 
prevent late elution during acquisition of the 
next chromatogram. 
5.50 1.25 90 LOAD 0.75 90 Step ELUTE 
 
Valve 2 is switched to clean valve ports with 
90% acetonitrile from the analytical pump. 
6.50 1.25 0 LOAD 0.75 65 Ramp LOAD 
 
 
 Valves are switched sequentially to clear 
valve rotor seals and flow paths.  Mobile 
phase compositions return to starting 
conditions to clear organic solvent from the 
flow path of untreated plasma for the 
following injection to prevent protein 
denaturation. 
6.75 1.25 0 LOAD 0.75 90 Step ELUTE  
7.00 1.25 0 ELUTE 0.75 90 Step LOAD 
7.17 1.25 0 LOAD 0.75 65 Step ELUTE  
 
7.33 1.25 0 LOAD 0.75 65 Step LOAD 
 
Valve positions and mobile phase 
compositions returned to starting conditions 
to allow for re-equilibration. 
Table 8-2; Chromatographic sequence 
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Calibration linearity, lower limit of quantification and absolute dynamic range. 
The absolute sensitivity of the assay was determined to be at least 50 pg on column from 
plasma.  This originates from a 10 µL injection of an aliquot of test sample (20 ng/mL) 
diluted 25% with internal standard in plasma.  The resulting chromatogram produced a peak 
for SARY which gave a signal to noise significantly greater than 5-fold when compared to the 
amplified baseline.  The expanded region of baseline in Figure 8-18 shows that the peak at 
the proposed lower limit of quantification is approximately 54 times baseline noise.  In 
Figure 8-20 and it can be seen that blank control humans plasma did not contain detectable 
peaks with the same retention time as SARY in either the m/z = 539>440 Da transition or 
m/z = 548>440 Da indicating that there is no interfering signal arising from endogenous 
isobaric interferences, or in the m/z = 439>440 Da chromatogram in Figure 8-19 indicating 
that there is no contribution of isotopic cross-talk. 
The calibration response was found to be linear between 20 ng/mL and 5000 ng/mL in 
plasma (y = 0.00739x – 0.00491; R2 = 0.997).  The inter-run and intra-run precision and bias 
was assessed at four concentrations across the calibration range by preparing 3 replicate 
groups of control samples and analysing them on 6 separate occasions (6 separate 
calibration lines; Table 8-3).  The suitability of the assay for the determination of test 
samples was determined since each measure of precision and bias were within regulatory 
limitations of ± 15% (± 20% at lower limit) of expected concentration. 98  Inter-run precision 
was determined by calculating the coefficient of variation of the mean concentration results 
at each level from each of 6 runs, the intra-run precision was determined by calculating the 
mean of the coefficients of variation calculated for each concentration level in each of the 6 
runs.  The total precision of the assay was calculated from the coefficient of variation of all 
36 results from each concentration level. 
The impact of plasma matrix batch was also determined by analysing samples in plasma 
obtained from six human volunteers (three of either gender).  Samples of plasma from each 
donor were analysed in replicates of 6.  Acceptable precision and bias data within ± 15% 
nominal for each batch showed that the assay could be successfully applied without 
significant bias from individual variability (Table 8-4).  A non paired t-test was calculated 
using the mean concentration result calculated from each donor to compare concentrations 
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detected in plasma from male and female volunteers.  A calculated P value of 0.417 
indicated that the difference between groups was not significant so no bias is associated 
with gender of the donors. 
 Plasma Concentration (ng/mL) 
Nominal Concentration 
(ng/mL) 
20 50 500 1000 
Mean 17.0 45.4 493 4980 
Bias (M%D) 
(95% Confidence Interval) 
-15.1 
(-19.5, -10.8) 
-9.20 
(-12.3, -6.12) 
-1.41 
(-4.25, 1.43) 
-0.500 
(-2.55, 1.55) 
intra-run Precision (%CV) 
(95% Confidence Interval) 
5.04 
(3.61, 8.32) 
5.95 
(4.27, 9.82) 
3.45 
(2.48, 5.70) 
4.66 
(3.35, 7.70) 
inter-run Precision (%CV) 
(95% Confidence Interval) 
3.87 
(0.00, 11.5) 
3.45 
(2.48, 5.70) 
1.89 
(0.00, 6.42) 
0.00 
(*,*) 
Total Precision (%CV) 
(95% Confidence Interval) 
6.36 
(4.89, 12.7) 
4.66 
(3.35, 7.70) 
3.94 
(3.08, 7.47) 
4.66 
(3.35, 7.70) 
Table 8-3; Inter- and intra-run precision and bias for the assay in human plasma 
Matrix 
Variability 
Plasma Concentration (ng/mL) 
20 ng/mL 
Plasma Lot 
Number 
Male 1 
(n=6) 
Male 2 
(n=6) 
Male 3 
(n=6) 
Female 
1 (n=6) 
Female 
2 (n=6) 
Female 
3 (n=6) 
P value 
(male-v-
female) 
Mean 17.5 18.2 18.3 18.2 17.1 17.6  
Precision (%CV) 2.88 8.41 5.79 4.74 4.46 6.82 0.417 
Bias (M%D) 87.5 91.0 91.5 91.0 85.5 88.0  
Table 8-4; The impact of subject variability and gender on assay precision and bias 
Biological and chemical stability 
Pharmaceutical and exogenous molecules contained in blood plasma may undergo 
concentration changes as a result of both chemical and biological factors. 193  Therefore, 
chemical stability of the drug was evaluated in DMSO preparation solvent for up to 12 
weeks and biological stability was evaluated in the plasma matrix for the same period of 
time under frozen conditions.  
The absence of degradation or ex-vivo metabolism under the test conditions to greater than 
15% deviation from expected concentration indicates that the assay is suitable for use 
following storage under the test conditions for the period tested (Figure 8-21).  Additional 
stability studies were conducted to assess the stability of SARY in processed samples at 
room temperature for up to 7 days and in control human plasma when stored incubated at 
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37°C for 24 h to replicate approximate physiological conditions.  The potential of instability 
during repeated freeze thaw cycles due to cryoprecipitation of bound proteins 79 was 
assessed by thawing the samples completely for at least 1 hour followed by frozen storage 
for at least 12 hours through 3 cycles.  Under all stability conditions tested, the resulting 
concentrations of SARY remaining demonstrated a bias of less than 15% verifying that the 
integrity of the samples was unaffected by the storage condition. 
 
 
Figure 8-21; Stability of SARY in i) DMSO under ambient and ii) human plasma under frozen conditions 
Stability in whole blood 
The stability in SARY in whole blood was assessed by adding an aliquot of SARY in methanol 
(50:50 v/v) to whole blood at a ratio of 100 µL to 100 mL of whole blood to prepare blood 
samples of concentration 50 and 1000 ng/mL.  The solutions were added at a high ratio of 
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blood to solvent volume to prevent excess haemolysis caused by the organic solvent.  
Immediately following preparation (time 0 hours) and then following 3, 6 and 24 hours 
under ambient conditions in upright tubes, the blood was centrifuged at 2500 rpm (1800 
rcf) for 10 minutes to yield plasma which was immediately frozen and later analysed within 
the same run using the method described previously.  The results of the analysis shown in 
reveal that SARY is stable (degradation/metabolism does not induce bias greater than 15% 
from value at 0 hours) for at least 24h.  The plasma concentrations analysed are greater 
than blood concentrations due to the plasma volume proportionality to the overall blood 
volume.  The actual ratio is a function of blood hematocrit and blood cell partitioning of the 
analyte. 
 
Figure 8-22; Stability of SARY in whole blood under ambient conditions 
Factors influencing specificity of the assay 
Factors with the potential to disrupt the assay as discussed in 6.2 were assessed to 
determine their impact on the determination of SARY.  Inter-subject matrix variability, blood 
haemolysis and anticoagulant used were determined to have no significant effect on the 
assay with M%D and %CV of less than 15%.  A number of concomitant medications and 
xenobiotic compounds anticipated to be present in test samples (paracetomol, asprin, 
ibuprofen, caffeine, levonorgestrel, ethylestradiol, ketoconazole, digoxin, warfarin, 
erythromycin, midazolam and simvastatin) were added to plasma at therapeutic 
concentrations used to prepare test samples of SARY which was analysed to demonstrate 
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specificity.  In each case, precision and bias remained within acceptable limits of within 15% 
coefficient of variation or mean percent difference. 
8.6 Equivalence of Human Ethnic Group and Dietary State 
Since a difference was observed between the phospholipid distribution in lipemic plasma 
samples and those from fasted human volunteers described in chapter 7, a fixed ratio test 
described in chapter 6 was conducted on plasma samples that were visibly lipemic and 
those taken from volunteers who had fasted overnight.  The two groups of samples were 
prepared at the lower limit of quantification in replicates of 18 samples from individual male 
volunteers of African American or Caucasian origin.  The test was performed using just 500 
µL of plasma from each individual sample by spiking 5 µL of a solution in DMSO containing 2 
µg/mL SARY and 20 µg/mL [2H9]-SARY.  The peak area ratio results were compared and 
analysed using an unpaired t-test.  The data presented in Table 8-5 demonstrates that while 
phospholipid distribution has been shown to be separable between fasted and lipemic 
volunteers, the fixed area ratio test has shown quantitative equivalence between both 
groups since the calculated two tailed p-value of 0.189 is greater than 0.05. 
Nominal 
conc 
(ng/mL) 
Container 
SARY/[2H9]-
SARY Ratio 
CV(%) N Mean 
difference 
95% CI of 
mean 
difference 
2 tailed p 
value 
20 FASTED 0.128 2.60 18 0.00200 -0.00103 
to 
0.00503 
0.189 
 
LIPEMIC 0.126 4.27 18 
Table 8-5; Equivalence of fixed ratio spiked SARY and [2H9]-SARY on human plasma from fasted and lipemic volunteers 
The test was repeated next comparing human ethnic groups.  Fixed ratio samples were 
prepared in plasma samples from 12 male Caucasian donors from both lipemic and fasted 
groups equally and compared to samples prepared from plasma from 12 male African 
American or Hispanic volunteers both fed and fasted groups.  The data tabulated in Table 
8-6 and Table 8-7 show that in both cases, the entire 90% confidence interval lies within 
15% of an equivalence ratio of 1. 
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Nominal 
conc 
(ng/mL) 
Container 
SARY/[2H9]-
SARY Ratio 
N Mean 
difference 
95% CI of 
mean 
difference 
2 tailed p 
value 
20 Caucasian 0.129 12 0.00192 -0.00185 
to 
0.00569 
0.3030 
 
Hispanic 0.127 12 
Table 8-6; Equivalence of fixed ratio spiked SARY and [2H9]-SARY on human plasma from Caucasian and Hispanic 
volunteers 
Nominal 
conc 
(ng/mL) 
Container 
SARY/[2H9]-
SARY Ratio 
N Mean 
difference 
95% CI of 
mean 
difference 
2 tailed p 
value 
20 Caucasian 0.129 12 0.00333 -0.00061 
to 
0.00728 
0.0935 
 
African 
American 
0.125 12 
Table 8-7; Equivalence of fixed ratio spiked SARY and [2H9]-SARY on human plasma from Caucasian and African 
American volunteers 
8.7 Validation of the Assay in Non Clinical Species 
To support non clinical development studies, the assay was extensively tested using samples 
prepared in lithium heparinised control rat and dog plasma.  The variability of the assay in 
plasma of each species was determined by analysing 4 concentration levels across the 
calibration range of the assay in replicates of 3 on 6 separate occasions.  The results are 
summarised in Table 8-8 and Table 8-9. 
 Plasma Concentration (ng/mL) 
Nominal Concentration 
(ng/mL) 
20 50 500 5000 
Mean 19.0 47.2 493 5740 
Bias (M%D) 
(95% Confidence Interval) 
-5.15 
(-10.4, 0.101) 
-5.26 
(-9.76, -1.35) 
-1.34 
(-9.30, 6.61) 
-5.26 
(-14.2, 3.66) 
intra-run Precision (%CV) 
(95% Confidence Interval) 
5.00 
(3.54, 8.49) 
2.55 
(1.83, 4.22) 
3.98 
(2.08, 10.3) 
4.73 
(3.34, 10.6) 
inter-run Precision (%CV) 
(95% Confidence Interval) 
4.37 
(0.00, 12.3) 
3.98 
(2.08, 10.3) 
7.29 
(4.01, 18.7) 
8.85 
(5.29, 21.7) 
Total Precision (%CV) 
(95% Confidence Interval) 
6.64 
(4.96, 13.4) 
4.73 
(3.34, 10.6) 
8.41 
(5.85, 19.2) 
9.24 
(5.93, 21.9) 
Table 8-8; Inter- and intra-run precision and bias for the assay in dog plasma 
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 Plasma Concentration (ng/mL) 
Nominal Concentration 
(ng/mL) 
20 50 500 5000 
Mean 18.5 48.4 546 4700 
Bias (M%D) 
(95% Confidence Interval) 
-7.56 
(-10.8, 4.29) 
-3.12 
(-5.46, -0.780) 
9.13 
(6.40, 11.9) 
-6.00 
(7.96, 4.04) 
intra-run Precision (%CV) 
(95% Confidence Interval) 
2.76 
(0.936, 8.11) 
2.12 
(1.52, 3.50) 
1.36 
(0.978, 2.25) 
1.57 
(1.13, 2.59) 
inter-run Precision (%CV) 
(95% Confidence Interval) 
2.98 
(0.936, 8.11) 
1.95 
(0.00, 5.51) 
2.25 
(1.21, 5.80) 
2.63 
(1.85, 5.97) 
Total Precision (%CV) 
(95% Confidence Interval) 
4.04 
(2.99, 8.60) 
2.88 
(2.18, 5.95) 
2.63 
(1.85, 5.97) 
2.36 
(1.75, 5.05) 
Table 8-9; Inter- and intra-run precision and bias for the assay in rat plasma 
In both rat and dog plasma, stability was determined at -20 °C for up to 3 months, following 
at least 3 freeze/thaw cycles and in plasma for 24 hours under ambient conditions. 
8.8 Surrogate Matrix Cross Validation 
To assess the potential for cross validation between species, the fixed ratio test to verify the 
equivalence of ionisation efficiency between plasma sources was described in 6.7.  This test 
was performed using analysis of samples by the assay constructed for SARY using rat, dog, 
guinea pig and monkey plasma and plasma from 2 different groups of human volunteers 
(Figure 8-23).  To ensure inter-individual variability is incorporated, each sample (n = 9) was 
taken from a different individual or separate batch of pooled plasma for guinea pig and rat 
samples.  The individual plasma samples used to prepare the test samples were those 
analysed for phospholipid distribution in chapter 7 where inherent differences in 
phospholipid distribution were demonstrated.  The data shows the mean peak area ratio of 
each sample group with error bars showing ± standard deviation.  The red horizontal lines 
highlighting ± 15% of the mean value of all samples demonstrates that the ratio of ionisation 
efficiency of SARY and [2H9]-SARY are not affected by the presence of endogenous 
components from control plasma from different species to an extent with the potential to 
infer unacceptable bias to cross validation within regulatory limits. 98  Furthermore the red 
dashed lines lying ± 5% of the mean value indicate that the dataset is entirely within 5%.  
The fixed ratio has demonstrated that differential suppression of ionisation should not bias 
cross validation of the assay between any of the groups tested and that the objective to use 
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a human plasma derived calibration line to perform regression for the quantification of 
samples in rodent plasma is possible.  
 
Figure 8-23; Fixed ratio ionisation equivalence test of SARY and [2H9]-SARY prepared in control plasma from several 
species 
The ability to quantify samples in rodent plasma using a calibration line derived from plasma 
from a surrogate species was verified by repeating the assay variability investigation 
described in section 8.7 using control samples from across the calibration range prepared in 
mouse and rat plasma and analysing them using a calibration line prepared in human 
plasma.  The analysis was carried out using 3 replicates at 4 concentrations and performed 
on 6 separate occasions (Table 8-10, Table 8-11).  The test concluded that for both rat and 
mouse plasma samples, precision and bias were within accepted regulatory limits ( ± 15%; 
20% at lower limit of quantification) required to support nonclinical pharmacokinetic 
studies. 98, 225 
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 Plasma Concentration (ng/mL) 
Nominal Concentration 
(ng/mL) 
20 50 500 1000 
Mean 18.9 50.6 521 5360 
Bias (M%D) 
(95% Confidence Interval) 
-5.69  
(-18.2, 6.79) 
1.23  
(-8.25, 10.7) 
4.22  
(-0.00241, 
8.45) 
7.21  
(1.92, 12.5) 
intra-run Precision (%CV) 
(95% Confidence Interval) 
9.23  
(6.62, 15.2) 
8.64  
(6.20, 14.3) 
5.53  
(3.97, 9.13) 
3.05  
(2.19, 5.04) 
inter-run Precision (%CV) 
(95% Confidence Interval) 
11.4  
(4.83, 30.5) 
7.40  
(0.00, 21.3) 
2.17  
(0.00, 8.89) 
4.36  
(2.15, 11.4) 
Total Precision (%CV) 
(95% Confidence Interval) 
14.7  
(10.7, 31.9) 
11.4  
(8.67, 23.2) 
5.94  
(4.68, 10.9) 
5.32  
(3.81, 11.8) 
Table 8-10; Inter- and intra-run precision and bias for the assay in mouse plasma regressed using a calibration curve 
prepared using human plasma 
 Plasma Concentration (ng/mL) 
Nominal Concentration 
(ng/mL) 
20 50 500 5000 
Mean 16.8 47.5 502 5080 
Bias (M%D) 
(95% Confidence Interval) 
-16.0  
(-29.1, -2.90) 
-4.97  
(-8.30, -1.63) 
0.456  
(-8.04, 8.95) 
1.60  
(-2.59, 5.79) 
intra-run Precision (%CV) 
(95% Confidence Interval) 
15.2  
(10.8, 25.8) 
5.89  
(4.22, 9.72) 
12.6  
(9.07, 20.9) 
4.89  
(3.46, 8.30) 
inter-run Precision (%CV) 
(95% Confidence Interval) 
11.8  
(0.00, 34.3) 
0.00 (*, *) 
3.41  
(0.00, 18.3) 
2.65  
(0.00, 8.88) 
Total Precision (%CV) 
(95% Confidence Interval) 
19.2  
(14.5, 38.0) 
5.89  
(4.22, 9.72) 
13.1  
(10.3, 23.4) 
5.56  
(4.26, 10.4) 
Table 8-11; Inter- and intra-run precision and bias for the assay in rat plasma regressed using a calibration curve 
prepared using human plasma 
8.9 Assay Equivalence using Incurred Samples  
The method was applied to the analysis of incurred samples which had been drawn to 
generate exposure data from a pharmacokinetic study in mice.  The animals were dosed 
with two test intravenous formulations of SARY and samples taken at time intervals 
following dosage to calculate the effect of dosage formulation on pharmacokinetic exposure 
to the drug.  Samples were initially analysed using the validated method of analysis 
described previously using an internal standard prepared in mouse plasma and quantified 
using a set of calibration samples prepared in mouse plasma.  The data was reported to the 
drug development project team to support optimisation of the drug target formulation.  In 
total, 38 samples were analysed with calculated concentrations ranging from 37.0 to 24200 
ng/mL.  Where concentrations were found to exceed the upper range of the calibration 
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curve, an aliquot was diluted 10-fold using control mouse plasma by adding 50 µL of mouse 
plasma sample to 450 µL of control mouse plasma. 225 
The samples were subsequently reanalysed using a calibration curve and working internal 
standard prepared in human plasma and a summary of each dataset data compared in Table 
8-12, with extensive data recorded in Appendix 2.  The two-tailed P value of 0.494 
demonstrates that by conventional statistical criteria (p>0.05), there is no significant 
difference between the two sets of data, 226 since the probability that observed differences 
result from random error is greater than 5%.  Therefore the determination of concentration 
of the test samples performed using a surrogate matrix of human plasma based calibration 
curve is equivalent to that obtained using matrix equivalent mouse plasma.  The comparison 
presented in detail in Appendix 2 shows that since the overall percentage bias and 
coefficient of variation are within 20%, and individually, less than 33% of values differ from 
the control value (derived from mouse plasma calibration) by greater than 20% in 
compliance with regulatory requirements 227, 228 of incurred sample reproducibility, the 
assay was therefore presented as being equivalent in the analysis of ex-vivo samples in 
mouse plasma following linear regression using calibration samples prepared in human 
control plasma. 
Group Human Mouse Mean Difference 95% CI Two-tailed P value 
Mean 3303.811 3200.792 103.018 -199.049 to 
405.086 
0.4939 
SD 6860.231 6087.550  
SEM 1112.876 987.531  
N 38 38  
Table 8-12; Incurred sample reproducibility using plasma samples analysed using calibration standards prepared in rat 
and human plasma 
8.10 SARY Method Conclusions 
An assay was developed and optimised for SARY in plasma from human and some non-
clinical species and thoroughly assessed and demonstrated to be suitable for the analysis of 
specimens in support of non-clinical safety studies and clinical trials in compliance with 
criteria required by international regulatory authorities governing study conduct in the 
pharmaceutical industry.  The assay employed on-line Turboflow column extraction from 
plasma macromolecules which enabled efficient inclusion of extraction and analysis steps in 
a single operation while the use of narrow bore Turboflow columns reduced the solvent 
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requirements due to reduced flow rate by comparison with standard bore columns used 
previously.   
With consideration to the reduction of extraction and chromatographic resolution of 
endogenous glycerophosphocholines, a major source of matrix effect was controlled in the 
assay.  A test using fixed ratio solutions of analyte and stable isotope labelled internal 
standard was applied and used to demonstrate that any residual matrix effect between 
plasma of different species did not induce quantitative bias when each was compared.  The 
validity of use of calibration samples prepared in human plasma to analyse control samples 
in rodent plasma was determined in rat and mouse samples demonstrating that the assay 
could be used to quantify rodent plasma samples using human control matrix.  The assay 
was finally applied to the analysis of study samples in mouse plasma using both matrix 
matched calibration samples and surrogate calibration samples prepared using human 
plasma.  Statistical analysis of the data generated showed that there was no significant 
difference between the datasets generated using the species matched and the surrogate 
species plasma control matrix to quantify study samples, therefore the intention to optimise 
the assay to control inter-species matrix effects enabling the use of a surrogate control 
plasma was successful in achieving its objectives. 
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9 Dried Blood Spot Method for SARY 
9.1 Introduction 
To investigate the potential of the assay for SARY evaluated in chapter 8 to quantify samples 
extracted from dried blood spots of human and animal origin as described in chapter 4, 
extraction of SARY was investigated using a number of available paper matrices as listed in 
Table 3-1.  The Turboflow extraction was initially retained to enable injection of the 
anticipated organic extract into a highly aqueous mobile phase in order to retain the analyte 
on the extraction column for transfer to the analytical chromatography column with 
maximum control over chromatographic migration. 
9.2 Preparation and Spotting of Whole Blood Samples 
Samples were prepared in whole blood by adding 50 µL of SARY in DMSO to 4.95 mL of 
human or rat whole blood which was either freshly drawn or stored under refrigerated 
conditions.  After addition of SARY solution, the samples were very quickly vortex mixed to 
minimise haemolysis and rotary mixed for at least 10 minutes.  100 µL spots were spotted 
directly to each test card and allowed to dry at room temperature in a biological safety 
cabinet for at least 3 hours.  Following surface drying, the cards were transferred and 
stored in a desiccator to ensure controlled completion of the drying process for at least 1 
week.  Upon spotting of test samples, visible differences in the formation of blood spots 
were observed as indicated in Figure 9-1.  The ‘halo’ effect of diffusion of the blood serum 
content beyond the bulk blood cell fraction is observed with FTA elute® paper (Table 3.1)  
while rapid and complete red blood cell lysis; breakdown of the cell membrane to release 
the cell contents, gave rise to the rapid change in colour to dark brown/black from red.  To 
prevent bias caused by distribution effects which might be associated with these 
observations, samples were cut from as close to the centre of the blood spot as possible.  
Since blood samples may be spotted at body temperature or following refrigerated 
storage, the effect of blood temperature on the rate of diffusion of the spot into the paper 
was investigated by spotting different paper types with 100 µL of blood (to obtain 
measurable differences) from aliquots of whole blood pooled from the same donor stored 
for 1 hour under refrigeration, at ambient temperature, or following 1 hour incubation at 
37°C.  Spots were added at controlled rate by using an electronic pipette (Rainin EDP 100) 
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and the time measured between completion of the dispense step to the disappearance of 
the final drop of pooled blood below the pipette tip on the paper surface.  Following 
drying, the spots formed were measured by ruler as tabulated in Table 9-1.  The effect of 
temperature on blood viscosity was shown to affect the time taken for blood diffusion into 
the paper matrix; however, this did not affect the size of the spot formed. 
 
 
Figure 9-1; Appearance of fresh human whole blood (30 µL) spotted onto DBS paper media (1) IDB 226, (2) FTA elute, (3) 
FTA 
An additional factor which may affect distribution of blood on paper is temperature since 
samples are drawn at body temperature while drug stability considerations may require 
rapid chilling of blood samples.  As blood cools, changes in viscosity may change the rate of 
distribution through the paper and consequently the size of spots formed per unit volume.  
Any temperature effect on the size of spots formed may induce sampling temperature 
dependant bias on the analytical process.  To assess this, a pool of freshly drawn human 
whole blood in potassium EDTA was aliquotted into identical storage tubes which were 
stored for 10 minutes in an incubator set to 37°C, at room temperature, and on ice (0°C).  
Following thermal equilibration, the blood samples were spotted onto IDB226 paper (25 µL; 
n = 6) using a rate controlled digital pipette.  Following an audible signal at the completion 
of the pipette dispense function; the time was measured until the pool of wet blood formed 
below the tip was observed to diffuse into the paper.  After complete drying and 
desiccation, the diameters of the spots formed were measured.  The results tabulated in 
Table 9-1 indicate that while the temperature of blood on spotting effects the rate of 
distribution through the paper, this has no effect on the diameter of spots formed. 
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Time to spot distribution (seconds) 
37°C 3 3 3 3 3 3 
Room Temp 5 5 4 4 4 4 
0°C 5 6 6 5 6 5 
Spot diameter (mm) 
37°C 16 16 15.5 16 16 16 
Room Temp 16 16 16 16 16 16 
0°C 16 16 16 16 16 16 
Table 9-1; The effect of blood sample temperature on the speed of percolation and size of blood spots in paper 
9.3 SARY Recovery from DBS Paper 
Initial comparison of the recovery of SARY from paper revealed that FTA® paper provided 
the highest recovery of SARY from the paper matrix when compared with FTA elute® and 
untreated Ahlstrom 226 paper.  A simple stepwise method for the recovery of SARY from 
FTA® paper was therefore optimised as follows; 
 A 5.0 mm i.d. spot was cut from the FTA card and transferred to a 2.0 mL Eppendorf 
tube. 
 Internal standard solution (200 µL of [2H9]-SARY; 5 ng/mL in methanol) was added to 
the tube and vortex mixed thoroughly for approximately 10 seconds then allowed to 
stand for at least 2 minutes to extract the punched sample. 
 A further 100 µL of pure water was added to the tube to correct the solvent 
composition and vortex mixed. 
 The entire recoverable volume of extraction solvent (approx 300 µL) was transferred 
into a 96-well plate by pipette, taking care not to pick up solid filter paper. 
 The plate was sealed with a square well pierceable sealing cap and loaded into a deep-
well stack of HTS PAL auto sampler before injection of 100 L of extract using the 
method described in chapter 8.  
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A typical chromatogram obtained by this method is presented in Figure 9-2 showing similar 
retention characteristics to the method described in chapter 8 and a clearly greater than 5-
fold signal to noise ratio satisfactory for the lower limit of quantification. 
 
Figure 9-2; Chromatograms of (a) SARY and (b) [2H9]-SARY extracted from FTA paper dried spots of human blood 
Influence of vortex mixing time on extraction recovery 
To evaluate the effect of time vortex mixing the punched blood spot in methanol has on the 
recovery of extraction of SARY from dried blood on the paper matrix, 4.2 mm punches (n=4) 
were sampled from human blood spotted on FTA paper, and vortex mixed in 200 µL of 
methanol for 10, 20 and 40 seconds before dilution with 100 µL water.  The sample was 
vortex mixed for a further 10 seconds then the liquid was removed to a microtitre plate for 
injection.  Additionally, to assess the effect of standing without vortex mixing, punches were 
mixed with methanol and vortex mixed for 10 seconds followed by standing for a further 50 
seconds, then mixing with water and removal of the liquid. 
 
The results in Figure 9-3 show that extraction recovery increased with time from 10 to 40 
seconds, however, an increase was also observed following a short vortex mix followed by 
standing in the extraction solvent, greater than the recovery attributed to 10 seconds mixing 
alone but not as much as vortex mixing for the entire period since vortex mixing for 40 
seconds achieved greater recovery.  This indicates that following mixing, the compound 
continued to release from the paper into the extraction solvent although at a slower rate.  
For practical reasons, it was decided to mix samples for 10 seconds followed by standing for 
at least 1 minute for later experiments. 
(a) (b) 
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Figure 9-3; The effect of vortex mixing time in the extraction solvent on the recovery of SARY from dried blood spots 
Preparation of human whole blood analytical samples 
Blood calibration samples were prepared by mixing control human whole blood (4.95 mL) 
with an aliquot (50 L) of SARY standard solution in DMSO to give concentrations of 20, 50, 
100, 250, 500, 1000, 2500, 5000 ng/mL.  A second set of validation test standard samples 
were prepared in control human whole blood at 20, 50, 500, 5000 ng/mL.  Blood samples 
were spotted onto FTA® paper and allowed to dry at room temperature for 3 hours then 
transferred to a desiccator for at least 1 week prior to analysis.  A working internal standard 
(5 ng/mL) was prepared in methanol.   
 
The extraction method was evaluated by analysing a full set of calibration samples together 
with 6 replicates of the validation samples across the calibration range in a run bulked out 
to 96 samples with blank samples prepared from the working internal standard.  The 
replicates of quality control samples across the calibration range were to assess the 
precision and bias of the assay which were required to demonstrate compliance with 
acceptable limits of precision and bias (15%; 20% at LLOQ) prescribed by the regulatory 
authorities for the conduct of analysis of samples for drug development studies. 98  
Extending the run size to 96 samples with the inclusion of groups of blank samples prepared 
by addition of aliquots of the reconstitution solvent (300 µL of methanol/water; 2:1) was 
intended to determine that the robustness of the assay across the maximum intended run 
size of 96 samples did not compromise precision and bias of the assay.   The results of the 
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analysis summarised in Table 9-2 show that the method was acceptable for use resulting in 
precision less that 5% coefficient of variation consistently at all levels while bias was less 
that 4% with the exception of the upper level where it was 10%. 
 
Sample Name Nominal Sample 
Concentration (ng/mL) 
Mean Detected 
Concentration (ng/mL). 
Bias 
(M%D) 
Precision 
(%CV) 
Val LLOQ 20 20.6 2.75 4.54 
Val LOW 50 48.9 -2.27 3.94 
Val MID 500 481 -3.87 3.75 
Val HIGH 5000 5510 10.1 3.25 
Table 9-2; SARY dried blood spot validation results 
9.4 Method Optimisation/Validation  
To further optimise the reconstitution of SARY extracted from dried blood spots, a 
multivariate analysis screening experiment was designed using the variables identified 
during preliminary method development as important in influencing recovery.  The 
extraction process was divided into 2 stages, firstly pH adjustment or aqueous control of the 
blood spot on paper followed by controlled mixing and equilibration then extraction into an 
HPLC compatible solvent (methanol, acetonitrile or water).  Whilst it is known that the log D 
values of SARY are constant between pH 2 and pH 10 therefore pH adjustment within this 
range is unlikely to influence analyte ionisation, changes in the pH environment, ionisation 
or polarity of the cellulose paper matrix or associated chemical additives may influence the 
elution of associated SARY from the paper.  Whole blood samples were prepared at 5000 
ng/mL in freshly drawn human blood and as shown in Figure 9-4, 25 µL aliquots were 
spotted onto sample papers of 2 types (FTA® and IDB226) and dried at room temperature 
for at least 3 hours followed by storage in a desiccator for at least 1 week.  Before analysis, a 
4.2 mm sample was punched into each cell of a 96 well microtitre plate using a BSD600 
robot then test extraction solutions applied.  The experimental design for the screening 
experiment followed a factorial design calculated using MODDE9 (Umetrics, Umea, 
Sweden).  Adjustment of pH was done by the addition of 125 µL of either 1 M formic acid or 
1 M ammonium hydroxide while the contribution of pre-wetting with no pH adjustment was 
tested by the addition of pure water.  Following addition of wetting solvent, the samples 
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were mixed for 10 minutes on a MicroMix 5 eliptical shaker (Siemens diagnostics, Deerfield, 
IL, USA).  In the second step, extraction solvent was added (methanol, acetonitrile or pure 
water) as 125 µL aliquots or mixtures prompted by MODDE factorial design totalling 125 µL.  
Where no solvent was added in the first step, 125 µL of extraction solvent was added in step 
2 to ensure approximately equal surface exposure of the blood spot disk to the extraction 
solvent.  After addition of the extraction solvent, the plate containing test samples was 
shaken for a further 10 minutes and left to stand for 1 hour to complete the extraction.  The 
entire supernatant volume was withdrawn by pipette to a second microtitre plate and a 50 
µL aliquot was analysed for SARY using the method described in chapter 8.  
  
  
Figure 9-4; Spotting whole blood, drying in racks and punching using a BSD600 robotic punch 
The difference between extraction conditions were visually evident as shown in Figure 9-5, 
the significance of each condition investigated in the experiments are described by the 
scaled and centred coefficients plot in Figure 9-6.  This is produced by plotting the peak area 
data resulting from the contribution of each test condition and centring the data on an 
average value, resulting in a graphical representation of the contribution of each 
component since centring reveals a positive or negative influence on recovery.  The plots 
are scaled showing residual values of peak area rather than percentage normalised which is 
useful in this instance to compare absolute values between paper types.  It is apparent that 
for each paper type tested, recovery is smallest with acidification of the sample and greatest 
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when the pH is increased.  Extraction with acetonitrile provides the best recovery 
demonstrated by a positive bar on each chart while water provides poor recovery shown by 
a negative bar.  It appears from the coefficients plot that extraction in methanol results in a 
negative value; however, this is a relative result of the centralisation of the coefficients plot 
and reflects the magnitude of the acetonitrile result.  Bars to the right of each plot show 
summed results of both stages in the extraction process.  The first mixed value in both 
charts show that adjustment using formic acid increases the recovery of methanol 
extraction; however, it is interpreted from the left part of each chart that methanol 
extraction is less favourable than acetonitrile extraction.  The combination of ammonium 
hydroxide adjustment with acetonitrile extraction produces a slightly positive trend. 
The contours plot in Figure 9-5 shows more clearly the interaction of each component.  For 
each paper tested, three triangular plots are produced showing the proportion of each of 
the 3 extraction solvents across each axis.  For the conditions in stage 1, adjusting with 
formic acid, ammonium hydroxide, or no adjustment, a graph is populated showing colour 
scaled calculated recovery data with the scale shown to the right of each plot.  It is clear for 
each plot from each paper type that greatest values are observed from acetonitrile 
extraction with highest recovery following pH increase.   The magnitude of peak areas 
recovered under optimum conditions confirms that recovery is greatest from FTA® paper. 
 
Figure 9-5; IDB226 paper punched and extracted in test solvents using the MODDE screening method 
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Figure 9-6; Coefficients plot of dried blood spot recovery screening test 
9.4.1 The Effect of Extraction pH on Recovery of SARY 
To further investigate the relationship between pH modification and the composition of 
acetonitrile in the overall extraction solvent, further experiments were designed using 
MODDE.  A sample of SARY was prepared in human whole blood at 5000 ng/mL and spotted 
in 25 µL aliquots onto FTA® cards, allowed to dry and stored in a dessicator for at least 1 
week.  Analytical samples from 4.2 mm hole cuts were taken into polypropylene deep well 
microtitre plate (Porvair, Fareham, UK) using a BSD robot.  Modification of pH in the first 
stage was done by adding 100 µL aliquots of 1M ammonium hydroxide (pH 11.5) 1 M formic 
acid (pH 2.1) and a neutral solution of 1M ammonium hydroxide adjusted to pH7.  The 
microtitre plate was sealed and samples were mixed for 10 minutes on a MicroMix plate 
mixer.  Following mixing, 100, 200 or 300 µL aliquots of acetonitrile were added and mixed 
on the plate mixer for a further 30 minutes.  After extraction, an aliquot of the extracted 
sample was removed and added to a further microtitre plate and diluted with acetonitrile so 
that the final proportion of acetonitrile in each sample was equivalent.  This was to equate 
total dilution of the extracted sample, to avoid solvent strength influencing injection volume 
or chromatographic extraction, and to prevent non-equivalent evaporation of sample 
volume on the autosampler prior to injection.  The diluted extracted sample was analysed 
using the method described in chapter 8. 
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Figure 9-7; DBS extraction screening 4D contour plot for (a) FTA paper and (b) IDB226 paper 
The contour map of the peak area recovery derived using MODDE software is represented in 
Figure 9-7 and shows the relationship derived from the data available.  As suggested by 
previous screening experiments, extraction is favoured by basic pH modification although 
(a) 
(b) 
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the minima of the recovery surface plot is in the region around pH 5 and adjustment to 
lower pH also enhances recovery.  Increasing the proportion of acetonitrile in the second 
stage of extraction relative to the aqueous solvent volume also increased recovery although 
the improvement is only slight, so not optimal, since large organic solvent proportions are 
unfavourable to avoid solvent composition modification required prior to chromatographic 
sample analysis. 
 
Figure 9-8; Contour plot of the relationship between pre-treatment buffer pH and acetonitrile elution solvent volume 
equivalents on SARY recovery from FTA paper 
9.5 Lipid Recovery from Paper 
9.5.1 Absolute Lipid Recovery 
To investigate the effect of extraction conditions on the recovery of phospholipids, the 
MODDE analysis method relating pH modification and acetonitrile volume to recovery were 
repeated analysing human whole blood spotted onto FTA® paper as described in 9.4.1.  The 
extracts were analysed by the phospholipid screening LC-MS method described in chapter 7.  
While all precursors of m/z = 184 Da were monitored, a chromatographic integration 
method was written to extract five of the most abundant lipid species as probe species.   
Similar to the recovery relationship observed from SARY, neutral pH modification was 
unfavourable to recovery, while in most cases, increasing pH before extraction increased 
yield.  Only in the case of lipid 4 (m/z = 667.5>184 Da) extraction recovery was greater 
under acidic conditions and lowest following increase in pH while in most cases, recovery 
 156 
increased under very acidic conditions.  These results conclude that firstly selective 
extraction of SARY from dried blood spots is unlikely to be achieved using the most optimum 
elution conditions for SARY, while the actual composition of phospholipid molecular species 
eluted from dried blood spots is variable depending on extraction conditions. 
9.6 Lipid Distribution across the Paper 
To evaluate the affinity of lipid recovery from paper and the potential impact of distribution 
effects observed visually in whole blood spotted onto certain paper matrices, a phospholipid 
test method was developed and applied to the analysis of probe phospholipids from blood 
spots.  100 µL of human whole blood was spotted onto various paper types and allowed to 
dry at room temperature before transfer to a desiccator for desiccated storage.  Larger 
blood spots than those anticipated for practical use were employed to enable multiple cuts 
across the spot so that any distribution effects may be detected.  The extraction method 
was as follows: 
 4.2 mm punch was taken using a BSD600 laser aligned robot punching tool and 
transferred to an eppendorf tube 
 50 µL acetonitrile added, sealed and mixed on shaker for 10 minutes 
 75 µL water added to prepare injection solvent, sealed and mixed on shaker for 10 
minutes 
 Tube stood for 5 minutes and extract removed to a microtitre plate for injection. 
 50 µL analysed by the selected lipids analytical method described in chapter 7. 
The blood spots produced together with the position of sampling punch cuts across the spot 
are represented in Figure 9-10 together with the recovery of probe phospholipids 
represented in a chart below each blood spot.  It can be seen that there is variability in the 
recovery of probe phospholipids from different paper types and as anticipated by the 
appearance of spotted blood, the distribution across the spots is greater in treated papers, 
particularly FTA elute® than untreated IDB226 paper.  The practice of punching analytical 
samples directly from the centre of the spot facilitated by using laser alignment on the 
BSD600 robot is expected to standardise some distribution effects. 
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Figure 9-9; Contour plot of the relationship between pre-treatment buffer pH and acetonitrile elution solvent volume 
equivalents on the recovery from FTA paper of five different probe phospholipids. 
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Figure 9-9 (continued); Contour plot of the relationship between pre-treatment buffer pH and acetonitrile elution solvent 
volume equivalents on the recovery from FTA paper of five different probe phospholipids.
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 IDB226                 FTA®   FTA elute® 
                                                
 
Figure 9-10; Probe phospholipids extracted from dried spots of human whole blood on 3 paper types; (left to right) i) 
IDB226, ii) FTA iii) FTA elute 
9.7 Dried Blood Spot Discussion 
A method for the analysis of SARY in whole blood was evaluated, factors influencing the 
recovery of the compound from dried blood spots on paper were investigated and the 
optimum extraction solvent appropriate to generate a sample for analysis by LC-MS was 
found to be acetonitrile.  It was determined that previous pH adjustment to increase the pH 
of the sample enhanced the extraction using acetonitrile.  Alternative paper media were 
investigated and the highest recovery when extracted under identical conditions was 
achieved from FTA® paper.  FTA® paper is a chemically modified paper and while the 
chemistry of the treatment is proprietary, it is known to contain sodium dodecyl sulphate.  
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Since the compound is lipophilic, it is suggested that interaction between the compound 
and the alkyl chain of the dodecyl sulphate group associated with the paper and subsequent 
release into extraction solvent facilitates this.  Alternative chemical modification of 
untreated papers prior to sampling has been shown to influence recovery and storage 
stability in lipophilic drugs. 158, 143  Since the log D of SARY is unchanged between pH 2 and 
pH 10, the variation of recoveries of the analyte from paper between these limits is 
attributed to interaction with the cellulose paper media (Figure 9-11) rather than the 
physicochemical properties of the analyte. 
Analysis of glycerophospholipids revealed that recovery was additionally favoured by high or 
low pH, meaning that optimum conditions observed for recovery of the target analyte were 
also likely to recover phospholipids.  It is also proposed that the affect of high or low pH on 
recovery is in part due to hydrolysis of the glycosidic linkages between saccharide 
monomers. 
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Figure 9-11; Monosaccharide composition of cellulose 
The distribution of phospholipids across the blood spot formed by the addition of human 
whole blood treated and untreated papers was investigated and revealed a more uniform 
distribution across untreated paper than treated papers.  This is attributed to rapid lysis of 
red blood cells on contact with the chemicals coating of the treated papers altering the 
homogeneity of the sample during application.  It was shown that while the temperature of 
blood during application to the paper affected the speed formation of the absorbed spot 
due to changes in viscosity, there was no effect on the size of spot formed; therefore sample 
concentration density depending on blood handling immediately following sampling at body 
temperature. 
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10 Conclusions and Future Work 
Conclusions 
Initial evaluation of cross calibration was unsuccessful giving rise to a degree of bias in 
quantification which indicated that the assay was unsuitable for use with calibration 
samples prepared in a surrogate species.  It was proposed that this effect was a result of 
inequivalent relative ionisation suppression of the drug molecule and its stable isotope 
labelled internal standard between plasma derived from different species.  The phenomena 
was tested by means of a simple test of adding a solution containing a fixed ratio of drug 
and labelled internal standard to test samples of plasma matrix from different sources or 
species.  The samples were prepared to contain the same amount of each component as 
present at the lower limit of quantification where the impact of ionisation suppression 
differences is predicted to be greatest. Following analysis of the prepared samples by the 
LC-MS/MS method, the calculated peak area ratios obtained for each test plasma source 
were compared to quantify the bias associated uniquely with matrix effect.  
The presence of a region of ionisation suppression was identified co eluting with the 
analytes by application of a continuous post column infusion test to evaluate the effect of 
co-eluting compounds on the ionisation efficiency of the target analyte.  Full scan mass 
spectra confirmed that the predominant species co eluting with the analyte were 
phosphotidylcholine species. 
A Turboflow LC method was prepared to investigate the distribution of glycerophospholipids 
analysing precursors of m/z = 184 Da to identify the molecular masses of 
phosphotidylcholine and sphingomyelin membrane phospholipids which are abundant and 
diverse groups and which account for the greatest concentration of circulating plasma 
phospholipids.  Comparison of the profiles obtained by analysing test samples from multiple 
species identified a species difference in phospholipid molecular species distribution.  
Furthermore, separation was observed between the distribution of phospholipids in 
samples taken from human volunteers from different ethnic groups using a partial least 
squared regression discriminative analysis investigation. 
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It is concluded that differences in phospholipid species distributions observed gave rise to 
matrix effect bias.  One proposed mechanism arises from the formation of micelles as 
phospholipids elute from the analytical column containing a different composition of 
constituent molecules.  This infers characteristic surface properties on the micelle which 
interact with the drug and internal standard discriminatively thereby forming an equilibrium 
which continues into the vapour phase within the source and a proportionate quantity of 
each analyte ion are inhibited from entering the gas phase for transferral to the mass 
analyser. 
A second analytical method was investigated for a new compound with attention to 
resolution of the analyte and internal standard from endogenous phospholipids.  On line 
extraction column chemistry and elution conditions and column wash were optimised to 
reduce the amount of lipids transferred onto the analytical column.  The fixed ratio 
standards test at the lower limit of the assay was applied and the distribution of ratio values 
between test species were found to lie within 5% of the mean value. 
Validation tests were applied to the method by using a human plasma derived calibration 
line to analyse samples prepared in rat and mouse plasma in three replicates of four 
concentration levels across the dynamic range of the assay on six separate occasions.  The 
validation results were found to comply with regulatory requirements 98 that the mean 
calculated concentration at each level was within 15% of the nominal value and no more 
than 33% of individual values exceeded this limit.  The method was then used to analyse 
samples taken following dosage to mice as part of a drug development study using human 
plasma calibration and compared with the results obtained from matrix matched 
calibration.  It was demonstrated that the method using matrix matched or human 
surrogate plasma were equivalent for the quantification of SARY in incurred samples in 
mouse plasma.  Furthermore, acceptability of incurred sample reproducibility was 
determined according to regulatory guidelines 227 using human plasma samples as a 
surrogate calibration source by comparison to analysis using calibration samples in mouse 
plasma. 
A method was evaluated for the extraction and analysis of SARY in whole blood dried onto 
filter paper in the form of dried blood spots.  The preliminary method involved cutting a 
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sample from the dried blood spot, extracting the analyte using acetonitrile and modifying 
solvent composition and analysis by the plasma Turboflow LC-MS/MS method.  It 
demonstrated acceptable precision and bias and was shown to be robust for analysis of a 
maximum run size of 96 samples.  Factors influencing the distribution of blood across 
different paper samples and recovery of both analyte molecule and probe phospholipids 
were investigated and discussed, differing distribution of phospholipids across each paper 
were identified by sampling punch position.  Analysis of non-clinical samples in whole blood 
in the form of dried blood spots as an alternative to plasma as an exposure medium has 
been identified to make a significant contribution to the reduction and refinement of the 
use of animals in drug development studies. 180 
Future Work 
To develop the project further, additional investigation into the elimination of phospholipids 
in the context of high throughput bioanalysis for pharmacokinetic studies would be 
recommended either in addition to or in place of solid phase extraction.  One method would 
be liquid-liquid extraction with solid support in the form of diatomaceous earth materials or 
semi permeable membrane.  A further method would be removal of phospholipids by 
aggregation involving the chelation of lanthanide salts. 
The proposed mechanism of involvement of a micellar pseudo stationary phase in 
contribution to discriminative ionisation suppression of analyte by coeluting phospholipids 
would be investigated by the formation of micelles using a synthetic mixture of 
commercially available (lyso)phosphotidylcholine species which could be manipulated to 
coelute with a probe analyte (and isotopically labelled internal standard) and the micellar 
properties adjusted by alteration to the phospholipid composition. 
The effect of storage conditions on the stability of analyte on cellulose filter paper and the 
influence of the stability of cellulose media and chemical paper treatments should be 
investigated in more long term studies.  Recently, a new development in dried blood spot 
analysis involving glass fibre based filter papers for therapeutic monitoring analysis was 
discussed.  Advantages to this method arise from the inert nature of glass fibre paper as 
opposed to contribution of cellulose hydrolysis at extremes of pH.  pH could subsequently 
be more selectively adjusted to influence analyte recovery and furthermore, chemical 
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modification of the glass fibre paper could be investigated to influence binding or stability of 
analyte on glass fibre paper using aliphatic chain surfactants such as sodium dodecyl 
sulphate or proteinaceous material such as bovine serum albumin. 
The use of fixed ratio standard solution approach in the early stages of method evaluation 
should be implemented with other analytes and used to assess the potential of bias caused 
by nonlinear ionisation efficiency in the presence of co eluting molecular species.  This test 
may be used to investigate the effect on human diversity on the precision and accuracy of a 
clinical bioanalytical assay.  Moreover it could be used to rapidly evaluate the potential to 
cross validate an assay for the analysis of animal samples using calibration samples from a 
surrogate source.  
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 Issue Article 
Organic 
Mobile Phase 
Salt Acid/Base 
 
1 26 3 Acetonitrile Ammonium 
acetate 
10 mM - - - 
2 4 Methanol Formic acid 0.1 % - - - 
3 8 Acetonitrile/ 
Methanol 
Formic acid 0.05 % - - - 
4 9 Acetonitrile Ammonium 
acetate 
10 mM - - - 
5 12 Acetonitrile Ammonium 
acetate 
5 mM Formic acid 0.2 % - 
         
6 25 2 Acetonitrile Ammonium 
acetate 
10 mM - - - 
7 5 Acetonitrile - - Formic acid 0.01 %  
8 9 Acetonitrile Ammonium 
formate 
5 mM - -  
9 10 Methanol Ammonium 
formate 
3.5 mM Formic acid - 3.5 
10 12 Acetonitrile - - Formic acid 0.1 % - 
         
11 24 2 Acetonitrile - - Formic acid 0.1 % - 
12 7 Methanol Ammonium 
acetate 
20 mM - - - 
13 13 Methanol Ammonium 
acetate 
10 mM Acetic acid 0.1 % - 
14 15 Acetonitrile - - Formic acid 0.01 % - 
15 16 Acetonitrile Ammonium 
formate 
1 mM Formic acid - 3 
16 17 Acetonitrile - - Formic acid 0.05 % - 
17 18 Acetonitrile - - Formic acid 0.05 % - 
         
18 23 5 Acetonitrile - - - - - 
19 6 Acetonitrile Ammonium 
formate 
20 mM formic acid 0.1 % - 
20 9 Acetonitrile Ammonium 
acetate 
10 mM formic acid 0.1 % - 
21 10 Methanol - - formic acid 0.1 % - 
22 11 Acetonitrile - - formic acid 0.1 % - 
23 16 Acetonitrile - - formic acid 0.5 % - 
24 19 Methanol - - formic acid 1 % - 
         
25 22 5 Methanol - - formic acid 0.05 % - 
26 8 Acetonitrile - - formic acid 0.5 % - 
27 9 Methanol Ammonium 
acetate 
2 mM formic acid 0.15 % - 
28 13 Methanol Ammonium 
bicarbonate 
10 mM - - 9 
29 17 Acetonitrile - - formic acid 0.1 % - 
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 Issue Article 
Organic 
Mobile Phase 
Salt Acid/Base 
 
         
30 21 18 Acetonitrile - - formic acid 0.1 % - 
31 19 Acetonitrile - - formic acid 0.1 % - 
32 24 Acetonitrile - - - - - 
33 26 Methanol - - formic acid 0.05 % - 
34 27 Methanol - - formic acid 0.1 % - 
         
35 20 13 Acetonitrile Ammonium 
formate 
1 mM Formic acid - 3 
         
36 19 5 Acetonitrile - - formic acid 0.05 % - 
37 10 Methanol Ammonium 
acetate 
2 mM - - - 
38 11 Acetonitrile Ammonium 
acetate 
10 mM - - 7.1 
39 26 Acetonitrile Ammonium 
acetate 
10 mM - - - 
40 27 Acetonitrile -  - - - 
41 30A Acetonitrile Ammonium 
acetate 
10 mM - - - 
42 33 Acetonitrile - - Formic acid 0.1 % - 
         
43 15-16 7 Acetonitrile/ 
Methanol 
Ammonium 
acetate 
20 mM   - 
44 8 Acetonitrile - - Acetic acid 
Trifluoroac
etic acid 
1 % 
 
0.05 % 
- 
45 14 Acetonitrile - - Formic acid 0.2 % - 
46 20 Acetonitrile/ 
Methanol 
ammonium 
formate 
10 mM Formic acid 0.2 % - 
47 22 Methanol Ammonium 
acetate 
10 mM Formic acid 2 % - 
48 25 Acetonitrile - - - - - 
49 26 Methanol - - Acetic acid 2 %  
         
50 13-14 6 Acetonitrile/ 
Methanol 
- - - - - 
51 9 Acetonitrile Ammonium 
acetate 
10 mM Acetic acid - 3.7 
52 11 Acetonitrile Ammonium 
acetate 
2 mM - - - 
53 13 Acetonitrile Ammonium 
acetate 
10 mM - - - 
54 15 Acetonitrile/ 
Methanol 
Ammonium 
acetate 
10 mM Formic acid 0.1 % - 
         
55 11-12 4 Acetonitrile/ Ammonium 10 mM - - pH 
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Organic 
Mobile Phase 
Salt Acid/Base 
 
Methanol acetate 6.8 
56 7 Acetonitrile/ 
Methanol 
Ammonium 
acetate 
40 mM - - - 
57 9 Acetonitrile - - Formic acid 0.1 % - 
         
58 9-10 2 Methanol Ammonium 
acetate 
10 mM Formic acid 0.001 
% 
4.7 
59 4 Acetonitrile/ 
Methanol 
- - Formic acid 0.05 % - 
60 10 Acetonitrile - - Formic acid 0.1 % - 
61 13 Acetonitrile - - Formic acid 0.5 % - 
62 15 Methanol - - - - - 
63 16 Methanol Ammonium 
formate 
10 mM - - - 
         
64 7-8 2 Acetonitrile Ammonium 
acetate 
10 mM - - - 
65 7 Acetonitrile - - Formic acid 0.1 % - 
66 9 Methanol Ammonium 
formate 
10 mM Formic acid - 3.5 
67 10 Methanol - - Acetic acid 0.3 % - 
68 11 Methanol Ammonium 
acetate 
10 mM - - - 
69 12 Methanol Ammonium 
acetate 
10 mM Formic acid 0.1 % - 
         
70 5-6 3 Acetonitrile Ammonium 
acetate 
10 mM - - 5 
71 4 Methanol Ammonium 
acetate 
10 mM - - - 
72 8 Methanol Ammonium 
acetate 
1 mM - - - 
73 13 Acetonitrile - - Formic acid 0.25 % - 
         
74 3-4 8 Methanol - - Formic acid 0.45 % - 
75 11 Acetonitrile - - Formic acid 0.1 % - 
76 14 Methanol Ammonium 
formate 
10 mM - - 3 
77 16 Methanol/ 
Acetonitrile 
- - acetic acid 0.1 % - 
78 19 Acetonitrile - - Formic acid 0.1 % - 
79 21 Acetonitrile - - Acetic acid 1 % 4 
80 22 Acetonitrile Ammonium 
acetate 
0.2 mM - - - 
81 23 Acetonitrile -  Formic acid 0.1 % - 
82 32 Methanol Ammonium 
bicarbonate 
15 mM - - 10.
5 
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 Issue Article 
Organic 
Mobile Phase 
Salt Acid/Base 
 
83 34 Methanol Ammonium 
acetate 
5 mM Formic acid 0.1 % - 
84 35 Acetonitrile - - Formic acid 0.5 % - 
         
85 1 4 Acetonitrile - - Formic acid 0.1 % - 
86 5 Acetonitrile - - Formic acid 0.1 % - 
87 6 Methanol - - Formic acid 0.1 % - 
88 8B Acetonitrile Ammonium 
acetate 
1 % Acetic acid 0.035 
% 
- 
89 13C Acetonitrile Ammonium 
acetate 
10 % Formic acid  6.5 
90 18 Acetonitrile - - Formic acid 0.2 % - 
 
 
A : Including 10% methanol 
B : Including 0.002% trifluoracetic anhydride 
C : Including 4% isopropyl alcohol 
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Sample 
Calculated Concentration (ng/mL) % Recovery 
(human 
/mouse) 
%Difference 
Mouse Plasma 
Calibration 
Human Plasma 
Calibration 
1 24200 27700 114 14.5 
2 25800 29700 115 15.1 
3 8530 7490 87.8 -12.2 
4 1980 1790 90.4 -9.60 
5 1470 1410 95.9 -4.08 
6 1610 1490 92.5 -7.45 
7 795 634 79.7 -20.3 
8 1090 953 87.4 -12.6 
9 953 774 81.2 -18.8 
10 1090 950 87.2 -12.8 
11 593 443 74.7 -25.3 
12 907 860 94.8 -5.18 
13 690 610 88.4 -11.6 
14 791 641 81.0 -19.0 
15 752 549 73.0 -27.0 
16 121 103 85.1 -14.9 
17 118 101 85.6 -14.4 
18 80.9 71.4 88.3 -11.7 
19 11200 12700 113 13.4 
20 11300 11200 99.1 -0.88 
21 12000 11500 95.8 -4.17 
22 1330 961 72.3 -27.7 
23 2800 2640 94.3 -5.71 
24 2090 1770 84.7 -15.3 
25 1410 1260 89.4 -10.6 
26 1330 1290 97.0 -3.01 
27 1410 1370 97.2 -2.84 
28 901 730 81.0 -19.0 
29 835 768 92.0 -8.02 
30 703 592 84.2 -15.8 
31 765 700 91.5 -8.50 
32 906 843 93.0 -6.95 
33 828 727 87.8 -12.2 
34 46.5 44.9 96.6 -3.44 
35 58.0 51.5 88.8 -11.2 
36 80.0 74 92.5 -7.50 
37 29.7 25.2 84.8 -15.2 
38 37.0 28.8 77.8 -22.2 
 
Average 89.9 
 
 
Standard Deviation 9.91 
 
 
% Coefficient of Variation 11.0 
 
 
% Bias -10.1 
 
Appendix 2; Reproducibility of analysis of SARY in mouse plasma samples from dosed animals analysed using calibration 
samples prepared in mouse or human plasma. 
